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Xlll RÉSUMÉ 
La  contribution  à  la  croissance  économique  en  raison  des  secteurs  de  haute 
technologie, a fait que certains pays émergents ont tenté de développer des secteurs 
basés  sur  l'innovation  et  la  technologie,  incluant  la  biotechnologie.  Cependant, 
l'adoption  et  la  diffusion  des  biotechnologies  dans  ces  pays  ont  rencontré  des 
difficultés de nature institutionnelle et managériale. Malgré ces difficultés, quelques 
innovations  se  sont  produites,  et  quelques  entreprises  ont  réussi  à  incorporer  des 
biotechnologies  dans  leurs  procédés  de  production.  Ce  constat  nous  amène  au 
questionnement suivant : comment les entreprises dans des pays émergents adoptent-
elles  les  biotechnologies  modernes?  Sur la  base  de  trois  approches : management 
stratégique,  grappes  de  haute  technologie,  et  politiques  publiques,  Je  vms  me 
concentrer sur le cas du Mexique pour analyser cette problématique. 
Cette recherche  repose  sur différentes  sources  d'information : des  entrevues,  deux 
questionnaires,  des  bases de  données de  publications  et  de  brevets, et  des  rapports 
officiels et de consultation. Vingt cinq entrevues face-à-face ont été menées auprès de 
différents agents participants dans la biotechnologie au  centre du pays.  Les résultats 
de  cette  recherche  montrent  qu'au  Mexique,  les  entreprises  qui  utilisent  des 
biotechnologies,  spécialement  les  biotechnologies  modernes,  sont  nonnalement  de 
moyennes et grandes entreprises bien établies dans leurs marchés. Ces entreprises ont 
accumulé  différentes  capacités  à  travers  le  temps,  circonstance qui  leur permet  de 
mieux  comprendre  les  nouvelles  technologies  pour  améliorer  leurs  produits  et 
procédés, et par conséquence rester sur le  marché,  leur principal objectif. Ainsi, on 
peut argumenter que leur modèle d'affaires est de  caractère imitatif.  Également, ces 
entreprises  ont  besoin  d'établir  des  liens  avec  d'autres  agents  pour  accéder  aux 
nouvelles connaissances. Pour cette raison, elles ont établi des collaborations avec des 
agents  qui  peuvent  se  trouver  tant  au  pays  qu'à  1' étranger.  Pendant  la  dernière 
décennie,  le  gouvernement mexicain a essayé  de  mettre  en place des  politiques  de 
technologie  et  d'innovation,  mais  le  manque  de  vision  à  longue  haleine  et  les 
contraintes  budgétaires  font  que  les  résultats  soient maigres.  Donc,  les  entreprises 
désirant  adopter  des  biotechnologies  au  Mexique,  font  face  à  des  obstacles 
importants. 
Mots clés :biotechnologie, modèle d'affaire, grappes de haute technologie, politiques 
de science et technologie, pays émergents, Mexique. ABSTRACT 
The contribution to economie growth by high technology sectors has stimulated sorne 
emerging countries  to  establish policies in order to  encourage  the  development of 
those  sectors,  including  biotechnology.  However,  the  adoption  and  diffusion  of 
biotechnologies  in  emerging  countries  seem  to  face  several  institutional  and 
managerial obstacles. Nevertheless, sorne innovations have been developed and sorne 
local firms have incorporated modern biotechnologies into their production processes. 
Therefore,  a general question is  raised:  how  do  firms  in  emerging countries  adopt 
modem  biotechnologies?  In  order  to  analyze  this  subject,  I  use  three  different 
literature bodies -strategie management, high technology agglomerations, and public 
policies-, and I take the case of  Mexico. 
Different  sources  were  used  to  gather  information:  interviews,  questionnaires, 
publications and patent databases,  and institutional and  consulting reports.  Twenty-
five  face-to-face  interviews  were  carried  out  with  different  agents  in  the  central 
region  of  Mexico.  The  empirical  evidence  shows  that  enterprises  using 
biotechnologies,  especially  modem  biotechnologies,  in  Mexico  are  medium  and 
large, established enterprises. They have accumulated different capabilities that allow 
them to  improve their products and process in order to  remain on the market, their 
main objective. Therefore, it is  argued that they follow "imitation business models". 
They  have  established  collaboration  agreements  with  national  and  international 
agents  to  access  new knowledge.  In the  last decade,  the  Mexican government has 
started to implement innovation and technology policies, however, the lack of a long-
term  vision  and  the  reduced  budget  dedicated  to  this  end,  set  challenges  for  the 
adoption of  biotechnologies. 
Key words: Biotechnology, business models, high-technology agglomerations, 
science and technology policies, emerging countries, Mexico. INTRODUCTION 
High technologies play an important role in economie growth - biotechnology among 
them.  Biotechnology  involves  a  group  of technologies  (i.e.  genetic  engineering, 
bioleaching, bio pulping, bioinformatics, genomics, proteomics, and others) based on 
advances of science of the last sixty years (i.e.  biology, biochemistry, genetics) that 
are  used  in  different  industries.  This  wide  and  multidisciplinary  knowledge  base 
drives  biotechnology firms  to  complement their capabilities  in  order to  create new 
products.  The  empirical  evidence  in  developed  countries  shows  that  most 
biotechnology  enterprises  present  well-defined  characteristics:  close  relationships 
with knowledge-creating organizations, collaboration between different organizations 
and  institutions for  innovating,  and agglomeration in specifie regions  (Niosi et al., 
2005; Cooke, 2007). These characteristics have an impact on the way biotechnology 
firms create and capture economie value (Pisano, 2006; McKelvey, 2008). 
In  the  last  two  decades,  sorne  emerging and  developing  countries  have  promoted 
policies to  trigger the adoption of biotechnologies, especially modem biotechnology. 
Biotechnology is  seen as  an instrument to  overcome sorne of the  serious  problems 
faced by developing countries, such as  those related to health, food and environment 
(Nature  Biotechnology,  2004).  However,  the  adoption 
1  and  diffusion  of 
biotechnologies in sorne emerging and developing countries face shortage of financial 
resources, specialized workforce, and access to  sophisticated institutions; these facts 
have  implications  in  the  manner  enterprises  adopt  and  develop  biotechnologies, 
especially the more complex ones. Under these circumstances, attention tums toward 
questions  about  the  potential  to  create  and  consolidate  biotechnology  clusters  in 
emerging countries and the importance of govemment intervention to accomplish this 
task. 
Recently, the Mexican biotechnology landscape bas changed: sorne local firms have 
1 Adoption refers to use biotechnologies for manufacturing or developing products and services. 2 
started  to  adopt  new  biotechnologies,  collaboration  between  different  agents 
(university,  firms,  and  associations)  are  more  frequent,  and government  initiatives 
have been implemented to  promote the adaptation of new technologies. The general 
objective  of  this  research  is  to  understand  firms'  adoption  of  generic  high 
technologies
2  (that  can  be  used  in  different  industries)  th at  usually  require 
complementary  knowledge  from  other  agents,  in  an  institutional  environrnent  not 
well developed in terms  of knowledge production, financing and small govemment 
support.  I propose  to  analyze  this  situation with  the  case of Mexico, which is  an 
emerging country that recently has started to adopt biotechnologies. 
The questions of  this research are the following: 
•  What kinds ofbiotechnology users, actual or potential, exist in Mexico, and what 
kinds of  biotechnologies have been adopted? What business models are emerging 
in the Mexican-specific economie environment? 
•  Given that high technologies tend to agglomerate, does Mexico have the potential 
to create and support a biotechnology elus ter? What kinds of collaboration, if any, 
have emerged? 
•  How could the Mexican public policy framework be improved in order to support 
the adoption and diffusion of biotechnologies? 
Three closely related literature bodies are used to  analyze these questions:  strategie 
management, regional agglomerations, and science, technology and innovation (STI) 
policy literatures. 
Biotechnologies  are  based  on  scientific  discovery  and  involve  different  scientific 
2 Chapter 1 describe the characteristics and types of biotechnologies. 3 
disciplines. Therefore, the industrial application of biotechnologies calls for  a close 
relationship  between  scientific  and  managerial  capabilities,  which  implies  sorne 
difficulties given the different natures of both capabilities. The creation and capture 
of economie value is  related to  economie activities that are embedded in enterprises. 
When scientific researchers  look for  producing and  capturing economie value they 
face different obstacles that impede them to  translate their scientific knowledge into 
commercial  products.  In  this  sense,  the  strategie  management  literature  - which 
includes  business  models,  capabilities  and  collaboration  networks- is  useful  to 
analyze why and how agents, involved in  the creation and capture of scientific and 
economie value,  interact to  complement their capabilities, particularly in emerging 
economies where resources  are  scarce and  relationships  among different agents  are 
not well structured. 
High technology enterprises tend  to  agglomerate in specifie regions.  In  the case of 
biotechnology,  different organizations  are  involved in  the  processes  related  to  the 
creation,  development and commercialization of products -e.g. universities, public 
and private research labs, govemment agencies, enterprises, and associations. In order 
to  integrate the capabilities of such different organizations, collaboration is needed. 
This  collaboration  can vary  over  time.  In  this  sense,  regional  agglomerations  and 
innovation literatures provide the  framework to  analyze what variety of capabilities 
can be integrated and how the  agglomeration evolves  over time.  This  analysis  can 
improve  our  understanding  about  the  complex  relations  between  different  actors 
needed to foster high teclmology agglomerations in emerging countries. 
Govemment  intervention  plays  an  important  role  for  the  development  of high 
technology  industries.  In  the  case  of  biotechnology,  the  creation  of  scientific 
knowledge and the  translation of this  knowledge  into  commercial products require 
large  investments  in  infrastructure,  the  development  of scientific,  managerial,  and 4 
operational  capabilities,  and  market  support.  Governments  at  different  levels 
(national, regional and local)  often design and implement a variety of policies and 
programs  that  encourage  and  support  the  activities  involved  in  biotechnology,  to 
create an environment that allows the interaction between agents. In this sense, public 
policy literature focused  on science, technology and innovation is  useful to  analyze 
how governments are involved in the adoption and diffusion of biotechnologies. 
This document is  divided into two parts. Part I  includes the theoretical framework, 
the description of the Mexican institutional environment, and the methodology of this 
research.  Chapter I  presents  the  main characteristics  of biotechnologies  and  their 
implications for strategie management. In addition, this chapter shows an overview of 
the adoption of biotechnologies in emerging countries. The following three chapters 
present  the  different  literature  bodies  that  build  the  theoretical  framework  of this 
research: Chapter II deals with the concept of business model. Chapter III presents 
the concepts and dynamics of regional agglomerations, and Chapter IV presents the 
importance of public policies and  how they encourage and  support biotechnology. 
Chapter  V  presents  the  characteristics  of  the  Mexican  system  of  innovation. 
Chapter VI presents the integration of the concepts used in this research. In Chapter 
VII the  hypotheses and methodology are  presented.  Part II includes the  empirical 
results  and  conclusions  of this  thesis.  Chapter  VIII  presents  the  analysis  and 
discussion  of results.  Chapter  VIII  deals  with  the  STI  policies  implemented  in 
emerging countries, such China, India, Singapore, and Mexico. Finally, Conclusions 
of  this research are presented at the end. PARTI. THEORETICAL FRAMEWORK AND CONTEXT 
CHAPTERI 
BIOTECHNOLOGY IN EMERGING COUNTRIES: 
ANOVERVIEW 
The  objective  of  this  chapter  is  to  present  the  definition  and  evolution  of 
biotechnologies. This chapter is  organized as  follows:  in section 1.1  the definition of 
biotechnology and its  main characteristics are presented, section  1.2 deals with the 
characteristics of the adoption of biotechnology in developed countries, and section 
1.3 shows sorne evidence on how emerging countries have performed the process of 
catching up of modern biotechnologies. 
1.1 Biotechnology: definition, knowledge base and multidisciplinary nature 
Biotechnology  is  defined  as  "the  application  of science  and  technology  to  living 
organisms, as well as parts, products and models thereof, to alter living or non-living 
materials for the production of knowledge, goods and services" (OECD, 2005: 9). In 
addition,  biotechnology  encompasses  different kinds  of knowledge  embedded into 
new technologies to obtain and manipulate new molecules (Pisano, 2006). Given that 
"[rn  ]odern biotechnology depends on advances in different fields of medical science, 
natural  science  and engineering ...  Modern biotechnology is  more  than knowledge 
[about biotechnological mechanisms]- indeed its  impacts come about through the 
combination  of  increasing  knowledge  with  techniques  and  instrumentation" 
(McKelvey et al., 2004: 25). 
Sorne  authors  divide  the  historical  evolution  of  biotechnologies  into  three 
generations: the 'first generation or traditional biotechnology' is  charactefized by the 
empirical application of yeast and bacteria for food processing (  e.g. beer and yogurt), 
and selective animal breeding. It bas been in use for thousands of years. The 'second 
generation of biotechnology' dates from  the  early twenty century. It was seen as  an 6 
industrial tool:  "[they] become a tool in the hands of engineers when biotechnology 
based production process became industrialized  . . .  [  e.g.]  bioprocessing in arder to 
make  biopharmaceuticals  and  fine  chemicals  such  as  penicillin  and  citric  acid 
respectively"  (McKelvey  et  al.,  2004:  24).  The  'third  generation  or  modern 
biotechnology'  started  in  the  1950s  with  the  work  of Watson  and  Crick,  who 
described the structure of DNA as  a double helix, these scientists set the foundation 
for the development of the science of molecular biotechnology (Powell et al.,  1996). 
Then,  in  the  1970s,  there  were  three  main events  that  changed the  way  to  obtain 
molecules:  "Cohen and Boyer' s  1973  breakthrough in genetic engineering methods 
enable  gene  reproduction  in  bacteria  and  heralded  the  arrivai  a  new  era.  Cesar 
Milstein  and  Georges  Kahler  produced  monoclonal  antibodies  using  hybridoma 
technology  in  1975,  and  in  1976,  DNA sequencing  was  discovered  and  the  first 
working synthetic gene developed" (Shan et al.,  1994:  388). The most remarkable 
characteristic of the third generation is its closeness with scientific discovery: "[t]he 
third generation is  explicitly based on underlying scientific progress whereas the first 
and  second  generation  were  more  technological  applications,  without  a  solid 
scientific understanding of  the underlying biological process" (McKelvey et al., 2004: 
24). 
Accordingly, modem biotechnology encompasses a range of  different techniques. 
The OECD (2005, 2009: 9) suggests a list ofbiotechnology techniques: 
•  DNA/RNA:  Genomics,  pharmaco-genomics,  gene  probes,  genetic 
engineering, DNA/RNA sequencing/synthesis/amplification, gene expression 
pro  fi ling, and use of antisense technology. 
•  Proteins  and  other molecules: Sequencing/synthesis/engineering of proteins 
and  peptides  (including  large  molecule  hormones);  improved  delivery 
methods  for  large  molecule  drugs;  proteomics,  protein  isolation  and 
purification, signalling, identification of  cell receptors. 7 
•  Cell and tissue culture and engineering: Cell/tissue culture, tissue engineering 
(including  tissue  scaffolds  and  biomedical  engineering),  cellular  fusion, 
vaccine/immune stimulants, embryo manipulation. 
•  Process  biotechnology  techniques:  Fermentation 
bioprocessing,  bioleaching,  biopulping,  biobleaching, 
bioremediation, biofiltration and phytoremediation. 
•  Gene and RNA vectors: Gene therapy, viral vectors. 
using  bioreactors, 
biodesulphurisation, 
•  Bioinformatics:  Construction  of databases  on  genomes,  protein  sequences; 
modelling complex biological processes, including systems biology. 
•  Nanobiotechnology: Applies the tools and processes of nano/microfabrication 
to  build deviees  for  studying biosystems  and  applications  in  drug delivery, 
diagnostics, etc. 
Although these techniques can be applied to different industrial fields and sectors, the 
most dynamic  sectors  are  those  related  to  human  health  and  agriculture  (Kenney, 
1986). 
1.2 Commercial applications of  modem biotechnologies 
Modem  biotechnology commercialization began  in  the  1970s  in  Califomia,  USA. 
Two enterprises are associated to  the  origin of the  industrial use of biotechnology: 
Cetus and Genentech.  Cetus Corporation was  established in 1972  and founded by a 
group of scientists (P.  Farley, a physician; R.  Cape, a biochemist; D.  Glaser, a Nobel 
Laureate  physicist;  and  severa!  others)  for  commercializing  recombinant  DNA 
technology  (Demain,  2004).  Genentech  was  established  in  1976  and  founded  by 
Herbert  Boyer  (a  biochemist)  and  Robert  A.  Swanson  (a  venture  capitalist)  for 
exploiting the  commercial potential of genetic engineering science (Pisano,  2006)
3
. 
During the late 1970s and early 1980s, severa! scientists from prestigious universities 
3  Cetus  was  sold to  Chiron Corporation in  1991,  which was  acquired by Novartis in 2006.  In 2009, 
Genentech was acquired by a large pharmaceutical, Roche Group. 8 
founded  biotechnology  enterprises  in  developed  countries  (  e.g.  Amgen,  Biogen, 
Chiron,  Genetics  Institute,  Genzyme).  These  events  revealed  the  strong  relation 
between biotechnology scientific discoveries  and industrial applications.  Therefore, 
enterprises  looking  for  commercializing  biotechnology  products  have  to  have 
scientific  background,  which  generates  a  particular  challenge.  In  Pisano's  words, 
biotechnology  enterprises  are  science-based businesses,  which  means  "commercial 
enterprises  that attempt to  both, create science and capture  value  from  it" (Pisano, 
2006: 2). 
What have been the implications of this scientific base for enterprises developing and 
using biotechnologies?  The scientific base of biotechnologies has  implications  that 
affect  the  dynamics  and  organizational  designs  of  the  following  organizations: 
universities and research centres, and new firms and large established companies. 
Severa! authors have emphasized the importance of universities and research centres 
in  the  invention  and  development  of biotechnologies,  particularly  in  knowledge 
advancement and the formation and training of specialized workforce (Cooke, 2007; 
Cockbum and  Stem,  2010).  Since  the  beginning  of the  industrial  applications  of 
modem biotechnologies in the late  1970s, the  creation of new enterprises dedicated 
almost exclusively to R&D activities is related with the presence of star scientists in 
academie  and  research  environments.  As  university  scientists  realize  that  their 
intellectual knowledge could be translated into a product, they occasionally think of 
establishing an enterprise or spin-off in order to appropriate its economie value. 
They often  keep  contact with  their  colleagues  at  universities  and  research  labs  m 
order to  obtain information of new scientific advances, and to  recruit new scientists 
who are  trained in state-of-the-art techniques and methodologies (Audretsch, 2001). 
The recruitment of young scientists is important since "biotechnology is characterized 9 
by high degrees of natural excludability, i.e.  the  techniques for their replication are 
not widely known and anyone  who wishes  to  build  on new knowledge must gain 
access  to  the  research  team  of the  laboratory  setting  that  know-how"  (Fuchs  and 
Krauss,  2003:  4).  In other  words,  science  is  the  critical  input  for  creating  new 
biotechnology products (Audretsch, 2001; Pisano, 2006). 
While the  process of creation of new scientific knowledge is  clearly carried out by 
scientists  in  universities  and  research  centres,  the  translation  of  that  scientific 
knowledge  into  commercial  products  is  accomplished,  most  of  the  time,  by 
enterprises.  In  this  regard,  sorne  authors  have  suggested the  existence of a  'close' 
relationship  between  the  science  and  the  market.  For  example,  Arora  and 
Gambardella  (1990:  363)  mention  that  "in  biotechnology  the  distance  between 
scientific advances and commercial application is  relatively short;  in  many cases a 
new  scientific  discovery  is  almost  a  new  product".  These  authors  showed  a  very 
optimistic vision of the translation from  science to  market.  Other authors  are more 
skeptical  and  suggest  that  the  translation  from  the  knowledge  generated  in 
laboratories to  its  application and development into a commercial product is  neither 
easy  nor  immediate.
4  For  example,  Pisano's  (2006)  analysis  of  the  economie 
performance  of R&D-driven biotechnology enterprises  in  the  human health  sector 
over the last thirty years points out the particular obstacles these enterprises face: "a 
science-based  business  entails  unique  challenges  that  require  different  kinds  of 
organizational  and  institutional  arrangements  and  different  approaches  to 
management" (p. 4). 
The  applications  of biotechnologies  are  m  constant  change,  g1ven  the  scientific 
progress; therefore, several biotechnology applications are not yet standardized (Pyka 
4  For example,  monoclonal  antibodies  were  invented  in  1975, 35 years  later,  they coming  to  new 
drugs. Genetic engineering has over 40 years. Y  et, genomic therapy is still in its infancy. 10 
and  Saviotti,  2002; Pisano, 2006),  and  this  can be seen as  an  opportunity for  the 
creation of new enterprises. Therefore, countries that are concerned with the adoption 
and  diffusion  of modern  biotechnologies  into  the  industries  have  to  consider  the 
implications of this complex science-industry relationship. In sum, universities and 
research centres play an important role for creating new scientific knowledge, but the 
translation of that knowledge into  commercial products require  several  managerial 
and institutional interventions. 
Biotechnology enterprises are defined as those that apply biotechnology techniques in 
order to  produce products  or services
5
.  There  are  two  subgroups of biotechnology 
enterprises that are related to  modern biotechnology (Beuzekom and Arundel, 2009: 
10, see Figure 1.1): 
"Dedicated biotechnology  firms:  defined  as  biotechnology firms  whose 
predominant activity involves the application of biotechnology techniques 
to produce goods and service and/orto perform biotechnology R&D. 
Biotechnology R&D firms:  defined as biotechnology firn1s that perform 
biotechnology R&D. Dedicated biotech R&D firms devote 75% or more 
of their total R&D budget to biotechnology R&D." 
In addition  to  these  types  of biotechnology  enterprises,  pre-existing  industrial  or 
commercial  compames  (such  as  veterinary  product  firms,  pharmaceutical 
manufacturers,  food  additives  producers  or grain  traders)  can  adopt  biotechnology 
and  develop  new  products  on  the  basis  of  biotechnology;  they  thus  become 
biotechnology users or biotechnology adopters. 
5 The OECD (2005: 9-10) defines biotechnology active finn as a "finn engaged in key biotechnology 
activities such as  the application of at !east one  biotechnology technique [e.g.  DNA/RNA sequence, 
proteins  and  other  molecules,  cell  and  tissue  culture  and  engineering,  process  biotechnology 
techniques,  gene  and  RNA  vectors,  bioinformatics,  and  nanobiotechnology]  to  produce  goods  or 
services and/or the performance ofbiotechnology R&D". r- ---
11 
Figure 1.1 
Types of biotechnology enterprises 
Source: Beuzekom and Arundel (2009: 1  0) 
Since the  1970s, thousands of new and established enterprises in different countries 
have adopted biotechnologies. Table 1.1  shows that the United States have the largest 
number ofbiotechnology adopters (6,213) followed by Australia, Canada, Germany, 
Korea, Japan, France, and Spain, which have more than 500 biotechnology adopters 
each, while the rest of the countries have less than 200 biotechnology enterprises. 12 
Table 1.1 
Number ofbiotechnology enterprises in OECD countries 
Biotechnology 
Dedicated 
Country  biotechnology  Year 
adopters 
firms 
United States  6 213  2 370  2009 
Spain  1095  399  2009 
France  1067  676  2008 
Japan  925  ND  2008 
Korea  833  358  2008 
German  y  663  538  2010 
Canada*  583  2011 
Australia  527  384  2006 
United Kingdom  487  ND  2010 
Switzerland  288  184  2008 
Netherlands  206  72  2008 
Ital  y  197  117  2008 
New Zealand  186  93  2009 
Norway  173  ND  2009 
Ire  land  167  71  2009 
Denmark  157  66  2009 
Belgium  145  122  2006 
Finland  141  77  2007 
A  us tria  121  111  2006 
Portugal  105  43  2009 
Sweden  100  58  2009 
Czech Republic  93  69  2009 
South Africa  78  38  2006 
Estonia  38  31  2009 
Po land  37  16  2009 
Slovenia  17  9  2009 
Slovak Republic  11  8  2009 
*Data from BIOTECanada: www.biotech.ca/en/resource-centre/overview.aspx 
(Accessed on 13 February 2012) 
ND: No determined. 
Source: OECD (20 11) 13 
Several au thors have emphasized the importance of public policies to  create adequate 
organizations  and  institutional  frameworks  able  to  foster  new  business.  Building 
these  institutions  and  organization  is  not  an  easy  task:  emerging  and  developing 
countries have struggled to adopt and support biotechnologies. 
1.3 Catching up of biotechnologies in emerging countries 
According to  Singh (2010:  1), "An emerging market refers  to  a developing market 
economy with low-to-middle per capita income. Countries in this category are usually 
undertaking a process of economie development and reform ...  they are in the process 
of moving from closed economies to  more open economies.. . they experience rapid 
growth  in  both  local  and  foreign  investment".  Therefore,  the  label  "emerging 
countries"  includes  a  wide  range  of countries  with  a  variety  of socio-economic 
characteristics.  For  example,  Brazil,  Russia,  India  and  China  are  weil  known 
"emerging countries" but several agencies have built lists that include countries with 
very different economie growth (see AnnexA). 
The adoption and diffusion of biotechnologies in emerging countries vary according 
to the different socio-economic contexts and govemment intervention. Emerging and 
developing  countries  face,  at  different  levels,  scarcity  in  financial  resources, 
specialized human resources and access to  sophisticated institutions, machinery and 
instruments.  These  facts  have  implications  in  the  local  scientific  progress  of 
biotechnology areas  and in the manner enterprises adopt and develop  technologies, 
especially the more complex biotechnologies. 
Emerging  countries  like  China,  India,  and  Brazil  seem  to  have  the  potential  to 
become important players in  the creation and development of biotechnology-related 
products.  Their  govemments  have  been  actively  involved  in  the  creation  of a 
favourable  environment  to  adopt  biotechnologies  - from  improving  education, 14 
training and infrastructure, passing through modemization of local industries to  the 
creation of venture capital industries (Nature, 2005; Niosi and Reid, 2007; Prevezer, 
2008).  Govemments  and  companies  in  other  countries  have  attempted  to  develop 
biotechnology  products  and  services.  For  instance,  sorne  efforts  have  been 
documented  in  Argentina,  Brazil,  Chile,  Mexico,  South  Africa,  South  Korea,  and 
Turkey (Bolivar  et  al.,  2002;  Nature  Biotechnology,  2004;  Buckley et  al.,  2006). 
However, the  large investments and complexity of modern biotechnologies seem to 
set barriers for their adoption and diffusion (Niosi and Reid, 2007). 
Among the emerging economies, two countries seem to  be in  an accelerated process 
of catching-up of modern and complex biotechnologies:  China and  lndia. The  two 
countries  have  followed  different  strategies  to  adopt  biotechnologies:  ln  both 
countries,  govemment  has  played  an  important  role  for  improving  scientific  and 
technological  capabilities,  promoting  the  linkages  between  science  and  business 
sectors,  and  fostering innovation activities based on extemal sources  and domestic 
efforts  (Fan,  2011;  Frew  et al.,  2008)
6
.  The  adoption  of modern  biotechnologies, 
particularly in the biopharmaceutical industry, has  followed different patterns given 
the  specifie characteristics of each country.  On the one hand, Indian biotechnology 
has  been  developed  by  the  combination of scientific  research  capabilities  (Mani, 
2004)  and  legal  frameworks  that  facilitate  the  adoption  of  biotechnologies  in 
pharmaceutical processes (Ramani, 2002). Large and medium enterprises started  to 
incorporate bioteclmology as a strategy to  maintain their position in the local market. 
On the  other hand, China has attempted to  imitate developed countries, particularly 
the  United  States,  establishing  several  bioteclmology  start-ups  and  generating  an 
institutional environment to develop modem biotechnologies (Prevezer, 2008). Then, 
large phannaceuticals acquired innovative biotech start-ups as  a strategy to  maintain 
6 See Chapter IX for details of government intervention for supporting adoption and diffusion of 
biotechnologies. 15 
their  position in  the  market.  In  addition,  China has  based its  growth  on the  large 
internai  market  (Frew  et  al.,  2008)  while  India  has  based  its  biopharmaceutical 
manufacturing  industry  upon  exports  (Fan  and  Watanabe,  2008).  Given  the 
complexity  of  biotechnologies,  these  countries  still  face  institutional  and 
organizational  obstacles  (Fan,  2011;  Thomas,  2008).  It seems  that  the  patterns 
followed  by developed countries  to  adopt and  diffuse  modern biotechnologies are 
difficult to implement in emerging and developing countries. 
The  following  chapters  II-IV  discuss  three  bodies  of literature  that  are  useful  to 
understand the  specifie institutional and organizational dynamic of the  adoption of 
modern biotechnologies in emerging and developing countries. Figure 1.2 depicts the 
relation between the three theoretical bodies used in this research. Scdoril 
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Figure 1.2 
Relation between the theoretical bodies used in this research 
F.nvironment: policies, rel:ulaticms, s.:ientifie inJ'm<lructure 
at national,  re~;, ~ orta l anù local leve! 
{
Relation~hip  b~lW&'m tlle enlerprise} 
tmd · the ms!iluMna! fhlmework 
~ 
1 
1 
1  1 
L  __  !~!~~!:.'~'!;;.~t~':!"!  ~J!u.:;:_:a~:_  ~~~~~·-__ J 
Natiunal  market 
Ch.apter rn 
Ge.og:raphic~l 
agglom~-rations 
ChaplériV 
STI policios 
nu~iness modds CHAPTERII 
BUSINESS MODELS AND BIOTECHNOLOGY ENTERPRISES 
The  objective  of this  chapter  is  to  analyze,  through  the  lenses  of management 
literature,  how  high-technology  firms,  particularly  biotechnology  firms,  deal  with 
scientific advancement and multidisciplinary nature to  create and  capture economie 
value.  The  chapter  is  divided  as  follows:  section  2.1  presents  the  definition  of 
business mode! and the importance of this concept in strate  gy and innovation. Section 
2.2 presents the different business models that have been identified in biotechnology 
enterprises. 
2.1  Definition of  business models 
In the  last century,  technological changes and the emergence of new markets have 
influenced the  processes by which firms  produce goods  and services as  well as  the 
ways  customers  fulfill  their  needs.  Consequently,  management  literature  has 
developed different strategy approaches 
7 that include a variety of concepts and tools 
for helping managers  to  deal  with changes in demand (  e.g.  eus tomer needs, market 
scope  ),  institutional  environments  (  e.g.  regulations  and  poli ci es)  and  technologies 
(e.g.  information and communication technologies)  (see  Annex B).  Since the  mid-
1990s, the term 'business model' has gained relevance as  a platming tool to  identify 
the processes involved in the creation and capture of economie value. However, this 
term has severa! definitions and few theoretical efforts have been made to  define its 
components: "a business model has been referred as  to  a statement, a description, a 
representation,  an  architecture,  a conceptual tool  or  model, a structural  template,  a 
method, a framework, a pattern, and a set" (Zott et al., 2011 : 1022) (see Table 2.1). A 
general definition includes:  the  value creation process that encompasses a "series of 
7  Strategy  is  "a plan that  aims  to  give  the  enterprise  a  competitive  advantage  over  rivals  through 
differentiation. Strategy is  about  understanding what  you do,  what you  want  to  become,  and  most 
importantly - focusing on how you plan to get there" (Harvard Business Review, 2005: xiv). 18 
activities that will yield a new product or service, with value being added through the 
various activities", and the value capture process, which "requires the establishment 
of  a unique resource, asset or position within the series of activities in which the firm 
enjoys a competitive advantage" (Chesbrough, 2007b: 22). 
Table 2.1 
Definitions of  business models 
Author(s) Year  Definition 
Tirnmers, 1998  The business mode! is "an architecture of  the product, service and 
information flows, including a description of  the various business 
actors and their roles; a description of  the potential benefits for the 
various business ac tors; a description of the sources of  revenues" 
(p. 2) 
Amit & Zott, 2001;  The business mode! depicts "the content, structure, and 
Zott 8ç- Amit, 2010  govemance of  transactions designed so as to create value tlu·ough 
the exploitation of  business oppmiunities" (200 1: 511). 
Based on the fact that transactions connect activities, the authors 
further evolved this definition to conceptualize a finn's business 
modelas "a system of  interdependent activities tbat transcends the 
focal finn and spans its boundaries" (2010: 216). 
Chesbrough &  The business mode! is "the heuristic logic that connects technical 
Rosenbloom, 2002  potential with the realization of  economie value" (p. 529). 
Magretta, 2002  Business models are "stories that explain how enterprises work. A 
good business mode! answers Peter Drucker's questions: Who is 
the customer? And what does the customer value? lt also answers 
the fundamental questions every manager must ask: How do we 
make money in this business? What is the underlying economie 
logic tbat explains how we can deliver value to customers at an 
appropriate cost?" (p. 4). 
Monis et al., 2005  A business mode! is a "concise representation of  how an 
interrelated set of decision variables in the areas of  venture 
strategy, architecture, and economies are addressed to create 
sustainable competitive advantage in defined markets" (p. 727). lt 
has six fundamental components: Value proposition, customer, 
intemal processes/competencies, extemal positioning, economie 
model, and personallinvestor factors. 
Johnson,  Business models "consist of  four interlocking elements, th at, 
Christensen,  taken together, create and deliver value" (p. 52). These are 
& Kagermann, 2008  customer value proposition, profit fonnula, key resources, and key 19 
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Casadesus-Masanell  "A business mode! is .  . a reflection of the firm' s realized 
& Ricart, 2010  strategy" (p.  195). 
Teece, 2010  "A business mode! articulates the logic, the data and other 
evidence that support a value proposition for the customer, and a 
viable structure of  revenues and costs for the enterprise delivering 
that value" (p. 179) 
Source: Zott et al. (2011:  1024) 
Given the  diversity of business  model definitions,  different contents  and  elements 
have been identified as  part of business models.  For example, Shafer et al.  (2005) 
present  the  following  elements:  strategie  choices,  value  creation  and  capture,  and 
value networks. While Onetti et al. (20 1  0)  assert that a business model has elements 
related  to  the  firm's  objectives/mission,  strategy,  and  financial  aspects,  they 
emphasize  the  importance  of the  allocation  of resources,  the  kind  of activities 
performed by the firm,  and the location of activities in the definition of a business 
model: 
"[T]he way a  company structures  its  own activities  in  determining  the 
focus,  locus,  and modus  of its  business ...  Focus decisions  concem the 
allocation of company resources to different activities ... Locus decisions 
refer to where the  different activities of the company are located ...  this 
decision  has  to  be made for  each  activity the  company has  chosen to 
focus ... The modus decisions of the business model designs  the  way a 
company  operates  in  selecting  the  management  methods  for  each 
activity...  which  activities  to  manage  in-house  and  which  ones  to 
outsource" (Onetti et al., 2010: 32). 
Therefore,  this  concept  seems  to  integrate  firm's  capabilities  with  the  strategie 
decisions about activities' location and relationship with partners. In addition to these 
elements,  sorne authors have mentioned the  dynamic character of business models. 
Given that a business model encompasses aspects of  the strate  gy and decision making 
processes,  this  implies  evolution  and  adaptation  over  time:  "an  organization's 20 
business  model  is  never  complete  as  the  process  of making  choices  and  testing 
business models should be ongoing and  iterative" (Shafer et al.,  2005: 207; Francis 
and  Bessant,  2005;  Chesbrough,  2007a).  Actually,  the  dynamism  of the  business 
model can become an important element for value sustainability: füms have to renew 
their  business  mode!  to  maintain  their  competitiveness  (Davenport  et  al.,  2006; 
McKelvey, 2008; Teece, 2010). Over time, firms face  internat and externat changes 
that  push  them  to  modify  and  improve  their  products  and  processes  to  reach  and 
maintain  competitive  positions.  Internai  changes  can  be  generated  by  the 
recombination or acquisition of new assets or capabilities (Helfat and Peteraf, 2003) 
while externat changes caused by economical and institutional environments provoke 
the firm  to  respond (McKelvey, 2008). In both cases, the firm's capabilities will be 
affected,  and  business  models  would  be  modified  in  a  reaction  to  business 
opportunities such as  penetration of existing markets, expanding markets, or creating 
new markets (Francis and Bessant, 2005). 
There  are  at  least  four  relevant  externat  factors  that  influence  a  business  model 
(Mckelvey, 2008): 
•  Technological advances:  they help  to  open up  'technological opportunities'; 
in turn they will become market opportunities, 
•  Public  and  private  interfaces:  collaboration  between  public  and  private 
organizations could be difficult to manage, 
•  Public policy, institutions  and regulations:  how and why institutions set the 
framework of  competition, 
•  Demand and consumer: the way in which demand can be expressed. 
Firms could respond to  extemal changes, but also they could be part of that change 
through  experimentation,  by modifying  their  internai resources:  "As soon as  they 21 
[firms] run into problems or see new business opportunities, most firms are willing to 
experiment. Thus they will change their internai resources ... in order to  respond to 
new  business  opportunities  and  to  solve  political  and  technological  challenges" 
(McKelvey, 2008:14). 
Here it is  important to  mention the difference between strategy and business model. 
These concepts are  closely related but they have different purposes: "while strategy 
provides differentiation and competitive advantage, the business model explains the 
economies  of how  the  business  works  and  makes  money"  (HBR,  2005:  vxi). 
According to Davenport et al.  (2006: 182) 
"a business  model  is  concemed  with  creating  value  for  the  customer, 
therefore,  it  underlies  the  rational  for  being  in  business  and  seeks  to 
obtain innovative knowledge from  outside stakeholders (networking).  A 
strategy is  concerned with  competition,  therefore  it  develops  a plan of 
how to put a business model (differentially) into action, and consequently, 
strate  gy in  volves the internalization of  re-shaping of  knowledge". 
In other words, business models are  'more generic' than a business strategy (Teece, 
2010: 180).
8 
The  relevance  of  business  model  in  innovation  relies  on  the  fact  that  global 
competition and technological innovation urge firms  to  look for new organizational 
setups  and new ways  to  interact with  their institutional environment. In this  sense, 
business  models  can  be  seen  as  tools  to  ensure  firm's  competitive  advantage 
(Davenport et al., 2006; Teece, 2010). 
"A good business model will provide considerable value to the customer 
8  Internet  version of newspapers  can  help  to  illustrate  the  difference  between  business  mode!  and 
strategy. The business mode! of these companies is  simple: to  put information on Internet and  ob tain 
revenue  for  advertising.  There  are  at  !east  two  different  business  models  for  newspapers:  having 
complete  access  (e.g.  La  Presse  Montreal)  or  having  a  limited  access  (e.g.  Le  Devoir).  Many 
newspapers have adopted one of these business models, however no all of them have the same market 
success. The competitive advantage ofthese newspapers relies on their strategies, for example, kind of 
contents, reputation of  the columnists, and supplements, which are more difficult to imitate. and  collect  a  viable  portion  of this  in  revenues.  But  developing  a 
successful business model (no matter how novel) is  insufficient in and of 
itself  to  assure  competitive  advantage.  Once  implemented,  the  gross 
elements of business models are often qui te transparent and (in principal) 
easy  to  imitate  -indeed,  it  is  usually  a  matter of a  few  years  - if not 
months- before  an  evidently  successful  new  business  model  elicits 
imitative  efforts.  In  practice,  successful  business  models  very  often 
become, to sorne degree, 'shared' by multiple competitors" (Teece, 2010: 
179). 
22 
Here it is important to mention that even when the 'gross elements' are transparent, in 
the case of biotechnology, it seems that there are sorne business models that are not 
easy  to  replicate  (see  section  2.2).  Therefore,  the  business  models  become  a 
competitive advantage: "if not easily replicated by competitors, they can provide an 
opportunity to generate higher retums to the pioneer, at least until their novel features 
are copied" (Teece, 2010: 181). 
2.1.1 Components ofbusiness models: capabilities and collaborations 
Summarizing  the  definitions  presented in  the  previous  section,  a  business  models 
encompasses aspects of mission, strategy, allocation of resources, relationships with 
other agents, location of activities, and financial aspects (see Figure 2.1 ). Figure 2.1 
Components of  business models 
Value creation 
Innovation 
Corporatc idcntity/reputation!culture 
Competitors /competitive environment 
Differcntiation! target market 
Processes/activities/value chain 
Resources/assets 
Competencies/capabilities 
Partners/value networkslalliances 
Customer relationship/interface 
Information flow 
Functionali  tics/  supporting processcs 
Transaction (content, govemance, costs) 
Infrastructure/infrastructure management 
Techno1ogy 
Location 
Revenue 
Costs 
Profit 
Financial aspects 
Source: Onetti et al. (20 1  0); Teece (20 1  0) 
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Business model 
In  this  research,  only  two  components  of business  models  are  analyzed,  namely 
capabilities  and  collaborations,  since  the  focus  is  on  the  importance  of scientific 
discoveries  and  the  interaction  of different  actors  in  the  development  of high 
technology products. 
Capabilities and innovation 24 
The strategie management literature has emphasized the heterogeneity of firms.  This 
heterogeneity is  based on the creation and development of competences and dynamic 
capabilities, which are key elements to  achieve and maintain a strategie position in 
the  market.  Resources per se do  not contribute to  the  competitiveness of the  firm. 
The  ir  combination is  wh at  makes  them  useful  to  improve  the  firms'  performance 
(Penrose,  1995). Depending on their contributions, sorne specifie resources become 
valuable assets to the firm, and therefore, they are the main components of the firm's 
competences  (Foss,  1996;  Teece  et  al.,  1997).  Competences  can  be  found  at 
individual and organizationallevels. Foss (1996: 1) defines a competence as "a typical 
idiosyncratic  knowledge  capital  that  allows  its  holder  to  perform  activities  - in 
particular to  solve problems- in certain ways, and typically do  this  more efficiently 
than others". Therefore, knowledge becomes an important asset to  the firm,  which is 
built through a continuous repetition of activities and remains in the firm's memory 
as  routines  (Nelson  and  Win  ter,  1982).  These  particular  routines  are  'distinctive 
activities' well performed by the firm (Teece et al., 1997). Firms can have a variety of 
competences,  sorne of these competences are  'core  competences', which allow  the 
firm  to  develop core products:  "core competences are  the  collective  learning in  the 
organization,  specially  how  to  coordinate  diverse  production  skills  and  integrate 
multiple streams of  technologies" (Prahalad and Hamel, 1990: 82). 
In addition,  firm's  competences  are  not  limited  to  the  firm's  boundaries.  Firms 
interact with other organizations, especially in environments in constant change such 
as  those of high technologies;  therefore firms  have to  develop  abilities to  integrate, 
build,  and  reconfigure  internai  and  externat  competences  (Cohen  and  Levinthal, 
1990; Teece et al., 1997: 516; Helfat and Peteraf, 2003). 
Collaboration and innovation 25 
Different  approaches  have  been  developed  to  explain  industrial  organization. 
According  to  economie  theory,  markets  and  hierarchies  were  considered  to  be 
efficient forms of organization, and other forms were expected to  be temporary (  e.g. 
collaboration networks, alliances). Nevertheless, in the last decades, the development 
of complex  technologies  and  products  has  required  the  participation  of different 
organizations (firm and non-firm) on a more permanent basis. Basically, the objective 
of collaboration is to access specifie assets that can contribute to the firm's economie 
success.  This  subsection  presents  two  approaches  that  deal  with  temporary 
collaborations  and  its  relevance  for  innovating:  transaction  costs  and  networks  of 
leaming. 
Transaction cost approach 
Markets for  specialized assets rely on the  assumption of a clear division of labour 
according  to  the  value  chain,  in  which  each  firm  has  specifie  capabilities/assets. 
However,  this  market of specialized assets  involves  information asymmetries,  tacit 
knowledge, and intellectual property uncertainty that could generate transaction costs 
(Williamson,  1979;  Pisano,  1991).  The  transaction  costs  approach  suggests  that 
vertical integration helps avoid uncertainty and opportunism from other agents in the 
market.  However,  in  sorne  high-tech industries  the  collaboration between different 
agents  seems mandatory to  survive in  the market (  e.g.  the collaboration between a 
dedicated  biotechnology  firm  (DBF)  and  a  large  pharmaceutical  company).  High 
technologies are closely related to  scientific knowledge, and these - particularly in 
biology and related disciplines - have a rapidly moving frontier; therefore incumbent 
firms  may not have  the  sufficient  absorptive  capabilities  to  intemalize  such large 
amounts of  new knowledge (Cohen and Levinthal, 1990; Pisano, 1991). 
N etworks of  leaming approach 26 
Another approach that has contributed to the understanding of collaborations between 
firms  is  networks of learning (Powell,  1990; Powell et al.,  1996). This approach is 
based on the social character of knowledge and its accumulation over time (Nelson 
and Winter, 1982; Nonaka, 1994). 
A  network is  a form of coordinating economie activity,  a forrn  of governance that 
allow collaboration among different actors facilitating the exchange of information, 
the access to  valuable assets  (e.g.  knowledge, know-how), the production of goods 
and services, and the sharing of  risks (Powell, 1990). The concept of  network is based 
on the socialization of individuals and it involves the mutual support among parts 
(Powell,  1990).  As  the  network  evolves,  the  actors'  interdependence  increases, 
therefore,  they  often  prefer to  remain  iri  the  network rather  than  to  exit (Powell, 
1990). Networks vary according to their structure,  governance, and industry. These 
elements are the result of historical events (Powell,  1990; Smith-Doerr and Powell, 
2005). 
How do networks impact learning and innovation processes? According to  Powell et 
al.  (1996), the  locus of innovation is  found  in networks  of learning rather than in 
individual firms. The main argument of this approach is that since no single fitm can 
have  aU  the  resources  needed  for  the  creation,  production,  and  market  of new 
products,  and  since  the  amount  of  available  useful  new  knowledge  increases 
exponentially,  firms  often  collaborate  with  other  organizations  (  e.g.  universities, 
government agencies, and other firms) in order to obtain complementary knowledge, 
resources  and  capabilities  (Powell  et  al.,  1996).  For example,  collaborative R&D 
allows individuals to  expand their sources of knowledge (Powell et al., 1996; Oliver, 
2001).  This  argument  fits  well  with  the  process  of R&D  in  complex  (high) 
technologies because  they involve many resources  such as  specialized knowledge, 
technological and managerial capabilities, and funds. 27 
Knowledge is  the main input for the Ïlmovation process (Nelson and Winter, 1982). 
Nonaka (1994) mentions that there are two main types ofknowledge: tacit knowledge 
that is  difficult to  transfer, deeply rooted in action, commitment, and involved in a 
specifie context (know-how, crafts, skills); and explicit or codified knowledge that is 
discrete and is captured in blueprints, documents, manuals and models.  Knowledge is 
based on the  interaction among individuals; therefore, organizational knowledge can 
be understood in terms of a process that "organizationally" amplifies the knowledge 
created by individuals, and crystallizes it  as  a part of the knowledge network of an 
organization  (Nonaka,  1994).  In addition  to  interna! knowledge,  firms  can benefit 
from external sources to  increase their competences: "a firm's value and ability as a 
collaborator is related to its interna! assets, but at the same time, collaboration further 
develops and strengthens those interna! competencies" (Powell et al.,  1996: 119). In 
other words,  the  collaboration  among  different  organizations  allows  people  to  be 
aware  of other  activities  or  other projects  that  could  improve  their  performance. 
Therefore, the external sources of  knowledge are relevant for innovation; but the finn 
should  have  absorptive  capacity  to  benefit  from  external  knowledge  (Cohen  and 
Levinthal,  1990). In words of Oliver (2001):  "the evaluation and utilization of this 
[  external] knowledge is  a function of prior related knowledge which includes basic 
skills  such  as  shared language  and  knowledge  of the  technological  and  scientific 
developments  in  the  field"  (p.  468).  Consequently,  networks  of learning  make 
possible the  diffusion of knowledge,  the  inter-firm learning and the exploration of 
complementarities  among firms,  which  is  crucial  in  high  technologies  given  their 
complexity and multidisciplinary nature (Pyka and Saviotti, 2000: 15). 
In sum, although the transaction costs approach suggests that firms  with specialized 
assets (e.g.  scientific knowledge or regulatory capabilities) should attempt a vertical 
integration strategy to  acquire  capabilities  and reach  a  competitive position in the 
market,  the  increased  complexity  of  high  technologies  calls  for  collaboration 28 
networks  between  different  actors  that  allows  firms  to  explore  and  complement 
capabilities to become a competitive agent. 
2.2 Business models in biotechnology 
The creation, adoption and commercialization of biotechnology-related products rely 
on  collaboration  networks  that  involve  different  actors.  Prominent  actors  are 
dedicated biotechnology firms (DBF), which have been under the spotlight in the last 
three  decades  because of their  role  as  a  mechanism of translation  from  scientific 
results  to  high  quality  products,  particularly  in  the  human  health  and  agriculture 
sectors  of developed  countries.  However,  in  recent  years,  sorne  authors  have 
questioned  the  performance  of DBFs  as  a  mechanism  to  generate  and  capture 
economie value (Pisano, 2006). In addition, the financial crises of 2000-1  and 2008-
10  have  reduced  considerably  the  availability  of  venture  capital  (Nature 
Biotechnology,  2010),  which  has  affected  the  establishment  and  survival  of 
biotechnology  start-ups.  This  section  seeks  to  describe  how  firms  generating  and 
adopting  biotechnologies  create  and  capture  economie  value.  These  elements  will 
allow setting the basis to discuss the implications for the adoption of biotechnologies 
in  countries,  like  Mexico,  which  has  underdeveloped  organizations  to  support the 
adoption of  complex biotechnologies. 
Firms vary according to the combination of their capabilities, strategies, their reaction 
to  externat  environments  (e.g.  institutions)  (Nelson,  1991;  McKelvey,  2008),  and 
their  kinds  of collaboration  networks  in  which  they  participate.  In  the  case  of 
biotechnology enterprises,  scientific discoveries  in different disciplines  imply more 
complexity and diversity. This scientific advance has  two  main implications:  1)  the 
population  of enterprises  remains  heterogeneous  because  the  different  industrial 
applications;  and  2)  the  number  of organizations  involved  in  the  discovery  and 
-29 
commercialization processes to  achieve new products seems to  increase (McKelvey, 
2004; McMeekin et al.,  2004).  Consequently, biotechnology enterprises vary in the 
way they create and capture economie value. 
2.2 Definition of  a business madel for biotechnology enterprises 
Since the early 1980s, several scholars and practitioners have analyzed the  creation 
and growth of firms  using biotechnologies.  In the  last  decade,  sorne  authors  have 
started to  focus  on  'biotechnology business models';  i.e.  how firms  do  business in 
biotechnology. 
There is  not a specifie concept of business madel for biotechnology. However, sorne 
authors  have  used  a  general  concept  that  includes  'a detailed  description  of the 
activities  carried out by the  biotechnology firms'  (see Table 2.2).  As  mentioned in 
Chapter I,  the earl y adoptions of biotechnologies for indus trial products were carried 
out in developed  countries  and  particularly in  the  pharmaceutical  and  agricultural 
sectors.  Based  on  these  experiences,  authors  have  identified  two  well-defined 
business models in  biotechnology firms:  classic dedicated biotechnology model and 
large, vertically integrated company business model. 
"In  the  classical  biotechnology  madel,  scientific  discoveries  and 
technological  inventions  have  been  quickly  developed  within 
entrepreneurial firms,  usually based upon venture capital. They compete 
through  their  specialized  scientific  knowledge,  often  sold  to  large 
companies,  and  also  compete  through  their  flexibility  such  as  quick 
commercialization, alliances, and keeping up  to  date with scientific and 
technological breakthroughs. These firms  invest heavily in research and 
development (R&D) - but often have difficulties making money off their 
internai knowledge resources ... 
"In the large, vertical integrated company business model, economies of 
scale and the use of integrated resources have been characteristic. These 
firms  have integrated everything from research and development (R&D) to  production  to  marketing  and  after  sales  monitoring.  They  have 
competed through finding the next 'blockbuster drug' in pharmaceuticals 
and through having large segments of the market in other industries like 
medical deviees." (McKelvey, 2008: 9, bolds added) 
30 
Although human health and agriculture are the main areas in which biotechnologies 
have  been  applied,  indus trial  applications  of  biotechnologies  (  e.g.  enzymes, 
biopolymers, plastics) are becoming more prevalent (BIO,  2010):  "modern biotech 
firms  do  many different things,  and bence  there  are  not  a  traditional sector in the 
sense  of selling  more  or  less  homogeneous  and  competing  products"  (McKelvey, 
2008:  16;  McMeekin  et  al.,  2004).  Therefore,  a  range  of biotechnology  business 
models  has  emerged  between  the  'classical  biotech  firm',  and  the  'full  vertically 
integrated' or 'Genentech model' (see Figure 2.2 and Table 2.2). New entrant  } 
thal necds to 
collaboratc 
with othcr 
organizations 
New entrant 
that integrales  ) 
ali processcs to 
crcate and sel! 
aproduct ~ 
'Oztztffiçj) mode!' 
Incumbent 
e.g.~ 
agriculture, 
animal health  ) 
Scicntific 
discovcry 
Figure 2.2 
Range of biotechnology business models 
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Generally, the image of a biotechnology enterprise is related to  the classical business 
rnodel (srnall enterprises almost entirely dedicated to  R&D activities),  and actually, 
severa! countries are attempting to  generate and support this kind of enterprises (see 
Table  1.1  in  Chapter  1).  However,  there  are  very  few  successful  cases  of large, 
vertical  integrated  models  like  Genentech  and  Genzyme, which initiated  from  the 
classical business model. For instance, in 2010 only 16  biotechnology enterprises in 32 
the United States were considered 'commercial leaders' (firms with revenues greater 
than USD 500  million) (Ernst & Young, 2011:  43).
9  The large-scale mode1  implies 
high risk given the huge investments in clinicat assays, drug approval, manufacturing 
and marketing. Additionally, two factors have affected the possibilities for small and 
medium DBFs to become large integrated firms:  international financial crises and the 
incorporation of biotechnologies into the R&D labs of large, established firms.  The 
financial  crises  of 2000-1,  and  2008-10  have  reduced  the  availability  of venture 
capital, as  the stock market exit became very difficult (Nature Biotechnology, 2010). 
In addition, established companies in pharmaceutica1, food and chemical industries as 
well  as  seed  traders  have  invested  in  establishing  their  own  biotechnology  R&D 
facilities  in order to  acquire and develop state-of-the-art biotechnologies capabilities 
that  allow  them  to  vertically  integrate  themselves,  improve  their  processes  and 
develop new products (Nature Biotechnology, 2010). Thus, the  large-scale model-
the Genentech model- that of a DBF growing to become a large corporation, is almost 
entirely precluded.  The integration of biotechnology in  large  established  industrial 
firms  is  taking  place  through  two  different  processes:  the  acquisition  of existing 
DBFs,  and  the  creation of new biotechnology R&D  labs  within  the  corporations. 
While this convergence process takes place in advanced OECD countries, the number 
of large  industrial and commercial firms  able  to  adopt biotechnology is  reduced in 
developing and emerging countries. 
So far the analysis of biotechnology enterprises' business models has been focused on 
the  human health  sector  in  developed countries.  These studies  reveal  a  variety of 
business  models,  and  also  show  evidence  of the  different elements  that  influence 
those models  (Table 2.2).  For example, Fisken and Rotherford (2002)  analyze  the 
development of capabilities and risk management of  biotechnology firms and identify 
9 This  list does  not include Genentech, which was acquired by Roche Group in 2009. And Genzyme 
appears in the list but Sanofi acquired it in 201 1. 33 
four business models: full integrated, product, platforrn!tool, and hybrid (product and 
platform). Mangematin et al.  (2003) propose two different business models according 
to the biotechnology firms' market scope and its influence on the growth path:  firms 
that  target  niches  within  local  markets;  and  firms  that  target  larger  national  and 
international markets. Nosella et al.  (2005) mention five business models evaluating 
the different position firms have in the value chain: "new biotechnology firms (NBF), 
integrated companies,  involved in the  process  from  research  to  comrnercialization, 
integrated  companies  which  sell  products  to  other  companies,  manufacturing 
companies  (which  carry  out  the  final  stage  of  ümovation,  from  industrial 
development  to  production  and  comrnercialization),  and  services  companies"  (p. 
854).  McKelvey (2008) suggests ten different business models  in  the  human health 
sector according to  two dimensions:  emphasis on the internai or external capabilities 
and the focus  on market or technology competition.  According to  the  objectives of 
collaboration, Greiner and Ang (2010) suggest that hybrid business models perform 
more  exploration  activities  than  product  focused  business  models  and  technology 
platform business models, which carry out more exploitation activities. Therefore, the 
elements  involved  in  biotechnology firms'  business  model  can  be  summarized  in 
capabilities, collaborations, and competitive environments or market. 1
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Capabilities in biotechnology enterprises 
As mentioned above, firms need different capabilities to  generate new products and 
react to environments. In general, these capabilities can be categorized, for example, 
in technological, operational, and managerial capabilities. However, in the particular 
case  of biotechnology,  scientific  capabilities  are  crucial  to  understand  complex 
biology  systems,  in  which  other  disciplines  have  been joined  for  analyzing  and 
discovering  -for  example  mathematics,  neuroinformatics,  bioinformatics,  and 
molecular genetics (Hayden, 2010; Abbott, 2010). 
In  addition  to  scientific  capabilities,  technological  and  managerial  capabilities  are 
needed to  develop,  manufacture and commercialize biotechnology-related products. 
Technological capabilities are those capabilities that firms perform to  produce goods 
and services. They allow firms to identify, use, and modify technologies (Kim, 1997). 
Managerial capabilities allow the firm to organize its activities and its relations with 
other  organizations  (Fisken  and  Rutherford,  2002)  to  obtain  complementary 
capabilities or assets  (Teece,  1986).  Therefore,  the  establishment of collaborations 
between  biotechnology  enterprises  with  other  organizations  (  e.g.  venture  capital 
firms,  government agencies,  universities  and research  centres)  becomes  critical for 
the performance of these enterprises. 
These capabilities are required to  explore new products and processes,  but are  not 
enough  to  manage  a  successful  dedicated  biotechnology  firm  (DBF).  Other 
capabilities  are  needed  to  evaluate  information  about  markets  and  environments. 
These other capabilities include those of assessing markets and future income flows 
from  those  markets,  devising  a  financial  strategy  by  understanding  the  different 
sources  of  finance  (venture  and  angel  capital,  bank  loans,  capital  markets, 
government subsidies, tax credits, reimbursable loans and other public funds, as well 
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as  foundations  such as  the Wellcome Trust,  the  Gates Foundation and hundreds of 
others). Also, DBFs need to  acquire legal competencies required to  patent, transfer 
technology (in and out)  and obtain the necessary national approvals for  new drugs 
(  e.g. FDA in the United States, the European Medicines Agency, Health Canada) or 
the use of biotechnologies without affecting crops and environment.  And of course, 
DBFs managers  need to  understand sorne  industrial economies  to  decide  the  types 
and quantities  of their production, potential  markets  and  market  share,  number of 
actual and future competitors, pricing policies and the like. DBFs are born with a very 
restricted set of competencies.  Successful firms  are  those  that  arrive to  incorporate 
these  other complementary competencies  during  the  first  years  of their  existence. 
Often, venture capital firms  help biotech firms  to  incorporate these complementary 
competences (Hollway, 201 0). 
Collaborations in biotechnology 
Biotechnologies involve a mix of codified and  tacit knowledge (McKelvey,  1998). 
This knowledge is  embedded in  few  scientists who have the  ability to  acquire  and 
create this knowledge and.  "the information about the potential commercial market for 
viable  products  resulting  from  that knowledge"  (Audretsch,  2001:  40).  In  the  last 
decades,  other  scientific  disciplines  have  been  added  to  the  creation  of  new 
biotechnology techniques.  This  has  two  implications for  biotechnology innovation: 
on one hand, "the rapid development of different research fronts makes it difficult for 
large firms  to  joint multiple research decisions"  (Oliver,  2001:  472),  it means  that 
small  and  medium  DBFs  have  an  advantage  derived  from  their  unique  scientific 
knowledge; on the other hand, biotechnologies imply a specifie challenge; because as 
the frontiers of science move forward, new techniques are discovered, and knowledge 
becomes  more  complex  and  di ffi cult  to  manage  (Oliver,  2001;  Pisano,  2006). 
Therefore,  a  network of different actors  is  necessary to  create  and  commercialize 38 
biotechnology-products.  This  network  includes  universities,  public  research  labs, 
venture capital firrns  and other sources of funds, DBF, large, established companies, 
govemment agencies. 
What are  the  organizations  and institutions  that shape  a  'biotechnology network'? 
Since the beginning of the adoption for commercialization of bioteclmologies in the 
1970s, the relationship between firrns -developing or adopting biotechnologies- and 
knowledge-creating organizations has  played an  important role for the diffusion of 
biotechnologies.  N evertheless,  sorne  other  organizations  and  institutions  are 
necessary  to  nurture  and  support  the  development  and  commercialization  of 
biotechnology-related  products.  These  organizations  are  embedded  in  institutional 
frameworks,  which  in  tum,  influence  the  way  firms  adopt  business  models  (see 
Figure  1.2  in  Chapter I).  The  institutional  framework promotes  and  facilitates  the 
experimentation of different business modes and the evolution of those according to 
the  characteristics  of the  adoption  of biotechnologies:  scientific  knowledge  base, 
multidisciplinary, and large investments (Pisano, 2006;  Cockbum and Stem, 2010). 
Therefore,  the  increasingly multidisciplinary of biotechnologies,  the  complexity of 
living organisms,  and  the  changes  in  demand  and  institutional  context (e.g.  laws) 
make  possible  a  diversity  of business  models  away  from  the  classical  dichotomy 
(McKelvey, 2008). CHAPTER III 
GEOGRAPHICAL AGGLOMERATIONS 
Empirical research has demonstrated that high-teclmology firms  tend to  agglomerate 
in  specifie  geographical  areas  (Saxenian,  1994;  Swann  et  al.,  1998, Niosi  et  al., 
2005). Firms tend to agglomerate given the positive extemalities that they can obtain 
within  specifie  areas:  knowledge  spillovers,  pools  of qualified  human  resources, 
specialized services and access to funding among others (Braunerhjelm and Feldman, 
2006).  This  chapter  deals  with  the  following  questions:  how  do  biotechnology 
agglomerations  emerge?  What  are  the  elements  and  factors  that  allow  the 
development of such agglomerations over time? In order to  answer these questions, 
section  3.1  presents  three  different  concepts  of agglomerations.  The  dynamics  of 
agglomerations  are  presented  in  the  section  3.2,  and  section  3.3  describes  the 
dynamics ofbiotechnology agglomerations. 
3.1  Concepts of  agglomerations 
Different concepts  have  been  developed  to  analyze  the  agglomeration of firms  in 
specifie  geographie  areas.  At  least  three  concepts  have  dealt  with  the  study  of 
biotechnology agglomerations:  The  most popular is  the  concept of cluster (Porter, 
2000);  this  concept  emphasizes  the  participation  of different  actors  in  a  related 
industry within a geographical area.  The concept of regional system of  innovation 
focuses on the analysis of relationships between different agents in a specifie region 
(Cooke  and  Morgan,  1998).  In the  last  years,  the  concept  of anchor tenant has 
emerged  in  regional  agglomeration  and  innovation  literatures  (Agrawal  and 
Cockbum, 2003; Feldman, 2003). This concept helps to identify the main attractor(s) 
to the agglomeration. The definitions of these concepts are presented in the following 
paragraphs. Cl us ter 
Porter (2000) defines a cluster as follows: 
"[A] geographically proximate group of inter-connected companies and 
associated institutions in a particular field, linked by commonalities and 
complementarities.  The geographical scope of cluster can range from  a 
single city or state to a country or even a group of  neighbouring countries. 
Clusters take varying forms  depending on their depth and sophistication 
but  most  include  end-product  or  service  companies;  suppliers  of 
specialized  inputs,  components,  machinery,  and  services;  financial 
institutions; and firms  in related industries. Clusters also often involve a 
number  of  institutions,  governmental  of  otherwise,  that  provide 
specialized  training,  education,  information,  research  and  technical 
support (such as  universities, think tanks, vocational training providers); 
and standards-setting agencies. Governments departments and regulatory 
agencies that significantly influence a elus ter can be considered part of it. 
Finally,  many  clusters  include  trade  associations  and  other  collective 
private sector bodies that support cluster members" (p. 254, bolds added). 
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This  definition  attempts  to  encompass  the  extensive  range  of participants  that 
agglomerate in a determined geographical area, however, this concept does not deal 
with  the  dynamics  followed  by  the  group  of different  organizations  in  order  to 
understand why and how they  agglomerate,  what  are  the  forces  of attraction  and 
whether  the  attraction  process  is  11mited  in  time  and  geography  or  through  the 
saturation of organizations (Martin and Sunley, 2003).  Moreover, the  concept does 
not deal  with  the  precise  types  of organizations  and institutions  involved  in  these 
dynamics,  the  geographical  limitation  of  the  cluster,  and  the  kinds  of 
complementarities that are needed and produced. For example, sorne authors consider 
clusters  of enterprises wh ile others  consider clusters of industries  (Prevezer,  1997; 
Porter, 2003). 
Feldman and Braunerhjelm (2006:  3-4) underline that cluster formation  follows  an 
evolutionary  process  based  on  endogenous  resources:  at  the  beginning,  sorne 41 
triggering (historical-social-political) and entrepreneurial events spark the emergence 
of a clusters;  then the  creation of competitive advantages  and the  establishment of 
adequate  institutions  create  agglomeration  forces  - like  labour  market  pooling, 
supplier specialization, knowledge spillovers, entrepreneurship, local demand- which 
in  turn,  influence  internai  socio-economic  dynamics;  finally,  the  evolution of the 
industry and local competition defines the future of the elus ter:  either to  become 'the 
place to be' orto accept the stagnation or decay. Although a random event can trigger 
the emergence of clusters, the most important issue is what happens later and how to 
support the  development of that cluster (Feldman and Braunerhjelm, 2006).  In this 
sense,  sorne  authors  have emphasized the  role of government intervention through 
public policies  to  promote and  support the  development and  growth of the  cluster 
(Carlsson, 2006) (see Chapter IV). 
Regional systems of innovation 
Innovation  is  a  complex  process  that  involves  knowledge  as  the  main  input  and 
learning process as  the strategie activity for competitiveness (Lundvall, 1992; Asheim 
and  Coenen,  2005).  The  concept of national  system of innovation emphasizes  the 
roles of knowledge, learning and networks in the innovation process at the national 
level. Since the 1980s, scholars have underlined the special characteristics of regions 
in  terms of industries, institutions, resources,  and human capital:  "within industrial 
and industrializing countries, innovation takes place in a few metropolitan areas and 
regions"  (Niosi  et  al.,  2005:  4).  Thus,  the  regional  system  of innovation  (RSI) 
approach  highlights  the  importance  of an  institutional  environment  that  enables 
systemic linkages to encourages innovation within the region: 
"Regions which passes the fully panoply of innovation organizations set 
in  an  institutional  milieu  where  systemic  linkage  and  interactive 
communication  among  the  innovation  actors  is  normal,  approach  the designation of regional innovation systems.  These organizations can be 
expected  to  consist of universities,  basic  research  laboratories,  applied 
research  laboratories,  technical  transfer  agencies,  regional  public  and 
private  (e.g.  trade  associations,  chambers  of commerce)  governance 
organizations,  vocational  training  organizations,  banks,  venture 
capitalists,  and  interacting  large  and small  firm.  Moreover they should 
demonstrate systemic linkages trough concertation programmes, research 
partnerships,  value-adding  information  flows,  and  policy  action  lines 
from  the  governance organizations.  This  system combine learning with 
upstream  and  downstream  innovation  capability,  and  thus  warrant  the 
designation regional innovation systems." (Cooke and Morgan, 1998: 71). 
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Given  the  importance  of knowledge  in  the  innovation  process,  Cooke  (2004:  3) 
defines  the  RSI as  "interacting knowledge generation and exploitation sub-systems 
linked  to  global,  national  and  other  regional  systems  for  commercializing  new 
knowledge".  The  knowledge  generation  subsystem  involves  public  and  private 
research laboratories, universities and colleges, and technology transfer agencies. The 
knowledge  exploitation subsystem  involves  mainly firms.  The  interaction  between 
the  two  sub-systems allows the  creation, use and diffusion of knowledge as  well as 
defines,  through  time,  the  patterns  of behaviour (e.g.  norms  and  laws)  among  the 
actors in the regional institutions. In turn, these  institutions affect the way in which 
the innovation takes place (Asheim and Coenen, 2005; Niosi et al., 2005). 
Cooke (2002:  143) underlines that "the regional and,  more particularly, locallevels 
become most important for the  evolution of clusters, including the  concentration of 
cri  ti cal research mass, the formation of networks, development of elus ter interactions 
and even the commercialisation of products". In addition to  regional conditions, the 
national and internationallevels also play a role. For example, the regulatory regime 
is  implemented  at  the  national  levet,  while  commercialisation,  links  to  large 
companies, customers, and even venture capital, are frequently global (Cooke, 2002). 
Anchor tenant 43 
Agrawal and Cockburn (2003) developed the  anchor tenant
10  concept to  explain the 
relationship between university research and industrial R&D in  a regional, high-tech 
context. An anchor tenant (AT) organization is defined as follows: 
"[A]  large,  locally present firm  that is:  (1)  heavily engaged in R&D  in 
general  and  (2)  has  at  least  minor  absorptive  capacity  in  a  particular 
technological area [ ...  ] the presence of  an anchor tenant firm enhances the 
regional  innovation  system  such  that  local  university  research  is  more 
likely to  be absorbed by and to  stimulate local industry R&D" (Agrawal 
and Cockburn, 2003: 1229). 
According  to  these  au thors,  the  mam  attribute  of the  AT  is  th at  it  can  crea  te 
knowledge  and  participate  in  technology markets  within  the  region.  The  AT  also 
facilitates  the process of technology transfer from university research into industrial 
R&D, for example, if a large, established firm (AT) is engaged in R&D activities in a 
particular technological area, this fif!ll  create demand for scientific research services 
from  the  local university;  at the  same time  the  AT  firm  must have  the  absorptive 
capacity to  internalize the scientific knowledge created in the universities or public 
research labs. 
Feldman  (2003)  adopts  the  concept of anchor  tenant  to  explain  the  location  and 
specialization of firms  using  and  developing  biotechnologies  in  a  specifie  region. 
Sorne  authors  have underlined that biotechnology "is developing differentiated and 
unique capabilities in specifie location" (Feldman, 2003:  316; Niosi and Bas, 2001; 
Cooke,  2007).  Feldman  (2003)  suggests  that  a  possible  reason  of this  'unique 
capabilities'  is  the  role  played  by anchor  tenant  organizations.  She  enhanced  the 
concept of AT and proposed that regional anchors may include knowledge-creating 
organizations and established firms: 
10  "The  classic  'anchor  tenant'  is the  large  department  store  in a  retail  shopping  mali  that creates 
demand  externalities  for  the other shops. Large  department  stores  with a recognized name generate 
mali traffic that indirectly increases the sales of lesser-known stores" (Agrawal and  Cockburn, 2003: 
1229) "Established firms  may  provide  expertise  and knowledge  about  specifie 
applications, product markets,  and  technical development trajectories  that 
move  generic  scientific  innovations  in  a particular direction, which  over 
time, may distinguish the specialization of the industrial cluster [  ...  ] Once 
the region is  noted to  have developed an expertise, others that work on the 
application or in the product market may be encouraged to start firms in the 
region. Over time, a cluster may develop around that specialized expertise" 
(Feldman, 2003: 312). 
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Feldman (2003)  argues  that although research universities have been the  source of 
knowledge spillovers in biotechnology, a "university atone may not be  sufficient to 
anchor a developing industry in a location" (p. 321). She mentions that the difference 
between science and technology affects the location dynamics: 
"Science, as the pursuit of new knowledge, is  originated in universities .. . 
technology  develops  ideas  from  science  to  commercial  applications .. . 
[Therefore] we expect th at as industry develops and science is  translated 
into  commercial  applications,  the  locational  dynamics  may  change  to 
emphasize industrial and technological attributes" (Feldman, 2003: 321). 
In other words, she proposes that in the earl  y stages of biotechnology agglomerations, 
universities  play  an  important  role  in  creating  scientific  knowledge  and  defining 
technological capabilities of the location (concentration and specialization); then, as 
industry evolves, other assets  and capabilities are needed and other agents, such as 
small and large firms, may become more important. 
These  three  concepts  -cluster,  regional  system  of innovation  and  anchor  tenant-
analyze  different issues  in the  agglomeration phenomenon.  The  concept of cluster 
focuses on identifying the main ac tors in the agglomeration. The concept of regional 
system of innovation also identifies the different actors within the agglomeration but 
also underlines the interactions between those actors and the institutional context. The 
concept of anchor tenant focuses on the organizations that are main attractors to the 
agglomeration. In the  following  sections,  these  concepts  are  used  to  describe  and 45 
analyze the dynamics taking place in bioteclmology agglomerations. 
3.2 Dynamics of  agglomerations 
Empirical research has shown that firms within agglomerations are better performers 
than non-agglomerated fîrms, and they develop competitive advantages in production 
and innovation terms (Saxenian, 1994; Swann et al., 1998). Agglomerations seem to 
follow  a  life  cycle  pattern  that  could  be  represented  by  different  stages:  birth  or 
creation,  development or growth,  sustaining, and dead  or saturation (Feldman  and 
Braunerhjelm, 2006; Menzel and Fomahl, 2009). 
3 .2.1. Specialization versus diversification 
The development of high technology industries relies heavily on scientific discovery, 
which  involves  face-to-face  communication  and  interaction  in  order  to  facilitate 
content transmission. In general, the transmission of this  type of knowledge and its 
effects on the agglomeration process and economie growth have been associated with 
at least two  types  of extemalities (Glaeser,  1992): the  first  one  is  Marshall-Arrow-
Romer (MAR) extemalities, in which cluster specialization in a specifie industry is  a 
key element to  ens ure economie growth.  The second one  is  the  Jacobs-Rosenberg-
Bairoch (JRB)  extemalities, in which the role  of diversity of knowledge  and ideas 
across industries within clusters encourage and foster economie growth, especially in 
large cities. 
On one hand, the MAR extemalities suggest that knowledge spillovers occur among 
fîrms  in  the  same  or similar industry,  and  they  benefît from  the  concentration  of 
skilled  workers,  source  of ideas  and  sharing  the  use  of  expensive  machinery 
(Marshall,  1947).  On  the  other  hand,  JRB  extemalities  suggest  that  knowledge 
spillovers  occur  more  frequently  in  cities  where  people  from  different  industries 46 
interact and help to  generate new ideas and innovation. Solving problems allow new 
work 'to be added directly onto older .work' (Jacobs, 1969: 55). 
Scholars  have  analyzed  the  impact  of specialization  and  diversification  on  the 
development  of regions  and  agglomerations.  These  studies  underline  that  both 
extemalities  are  important  for  economie  growth,  especially  in  high  technology 
industries  (Feldman  and  Audrestch,  1999;  Beaudry  and  Schiffauerova,  2009). 
However,  the  importance  of each  type  of extemalities  differs  along  the  industry 
lifecycle  (Feldman  et  al.,  2005;  Beaudry  and  Schiffauerova,  2009;  Merzel  and 
Fomahl, 2009): 
"In the initial stage of the innovative process an increased diversity and 
variety propels the creation of novelty, inventive ideas, creative concepts 
and radically new designs.  When the  industry matures  and the design 
reaches a critical mass on the market, the product becomes standardized 
and  the  knowledge  involved  in  the  innovation  process  highly 
specialized.  Firms  then  may  greatly  benefit  from  leaming  from  the 
solutions and mistakes of  other firms in the same industry in a region with 
high  concentration  of  their  own  industry.  Finally,  it  is  the  high 
concentration of the mature industry, which decreases the region's ability 
to  innovate,  rejuvenate  and restructure,  and  which inevitably  leads  the 
region  into  a  lock-in."  (Beaudry  and  Schiffauerova,  2009:  325,  bolds 
added) 
Therefore,  inter-industry  extemalities  are  important  at  the  initial  stages,  later 
specialization may become more important. However, if the agglomeration becomes 
too  much specialized it may decline along with its  engine industry. Thus, it seems 
that high technology enterprises prefer diversified agglomerations, where they have 
access to different sources of  ideas and knowledge. 
3.2.2 Agglomeration lifecycle 
Menzel  and  Fomahl  (2009)  identify  two  dimensions  111  agglomeration  lifecycles: -------------------------------------------------
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quantitative and qualitative (Figure 3.1). According to  these authors, the quantitative 
dimension  refers  to  the  number  of enterprises  and  employees  comprised  in  an 
agglomeration,  while  the  qualitative  dimension  is  related  to  the  heterogeneity  of 
knowledge within an agglomeration. 
Considering  the  quantitative  dimension,  the  lifecycle  of agglomerations  can  be 
characterized  as  follows  (Menzel  and  Fornahl,  2009:  218):  in  the  first  stage, 
emergence, socio-economic events trigger the establishment of  few enterprises. In the 
growth  stage,  the  successful  experience  of the  early  entrepreneurs  encourages  the 
establishment of a second generation of enterprises, and employment increases. Then, 
in the third stage, sustain, the agglomeration maintains the employment on a high and 
constant level.  Finally, in  the decline stage, the  agglomeration cannat generate new 
employment and the establishment of  new enterprises is rare. 
When considering the qualitative dimension, Menzel and Fornahl (2009) suggest that 
the heterogeneity ofknowledge may evolve over time as follows: 
"As  a  elus ter  emerges...  the  heterogeneity  increases  strongly  because 
every new company ventures into new technological areas of the cluster. 
In  the  growth  phase,  the  technological  path  becomes  increasingly 
focused.  The heterogeneity decreases until  the  cluster has matured and a 
distinct  development  path  has  taken  shape.  However  if the  cluster  is 
focused  too  narrowly,  it  loses  its  capacity for  renewal  and  decline"  (p. 
218). 
This  scenario  is  focused  on the  agglomeration  of firms  in one  industry  or related 
industries, thus, this scenario is one among severa! possible others. An agglomeration 
can adopt other technologies to  avoid specialization, for example, agglomerations in 
large  cities  (e.g.  Mexico, San Paolo, Buenos Aires), which host several industries, 
may  not  become  more  specialized  over  time.  Therefore,  the  heterogeneity  of the 
knowledge is closely related to  the two types of externalities presented in the above 48 
section (MAR and JRB  extemalities).  Industrial  agglomerations  are  not generated 
spontaneously;  socio-economical  conditions  trigger  their  establishment  in  specifie 
geographical areas, often in large cities where cross-fertilization of knowledge and 
ideas  facilitate  innovation (Jacobs,  1969).  Particularly, high technology enterprises 
may prefer large  cities  where knowledge externalities  across  industries  can occur, 
which is crucial for these industries (Beaudry and Schiffauerova, 2009). 
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Figure 3.1 
Dimensions of  an agglomeration 
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Source: Own elaboration based on Menzel and Fornahl (2009: 218) 
Maturity 
In  addition  to  the  triggering  events,  an  important  issue  is  how  to  create  an 
environment  that  supports  the  establishment  of  start-ups  and  attracts  new 
complementary agents for the agglomeration's development. It seems that two other 
stages can be added to the traditional ones -emergence, growth, sustainment, decline: 49 
transition and new opportunities  (see Table 3.1  and Figure 3.1). These new stages 
suggest  an active role  of the  government  in  generating  conditions  to  increase  the 
business opportunities and the heterogeneity ofknowledge (see Chapter IV). 
Consequently, the agglomeration lifecycle may evolve in the following way: when an 
agglomeration  emerges,  the  heterogeneity  of knowledge  is  high,  and  different 
technological approaches are adopted. In addition, only few start-ups are founded and 
there is not collaboration with other organizations. In this stage, government may not 
be  involved  for  supporting  agglomeration.  Later,  at  the  'transition'  stage,  from 
emergence to growth, the number of  start-ups increases at the same time that a critical 
mass  arises  and defines  the  technology profile  of the  agglomeration  (Menzel and 
Fomahl,  2009).  Sorne  start-ups  that  spin-off from  other  organizations  begin  to 
generate  synergies.  At  this  point,  the  creation  or  improvement of an  institutional 
environment plays  an  important role  to  shape  the  future  collaborations  that  could 
bring complementary resources and capabilities to enterprises (Feldman et al., 2005). 
At the growth stage, a second wave of new start-ups appears adopting the defined 
technological profile, and enterprises and potential partners within the agglomeration 
start to collaborate. The sustainment stage is  reached when the number of enterprises 
is  stable  and  enterprises  have  established  dense  networks  of collaborations  with 
partners  inside  and  outside  the  agglomerations.  After  the  sustainment  stage, 
agglomerations have to  be ready to undertake new opportunities of development and 
avoid declining. Menzel and Fomahl (2009)  mention that  there  are  three different 
ways in which an agglomeration can rejuvenate:  1)  by the  adoption of incrementai 
changes  in  the  technological  path,  2)  renewal  through  the  integration  of new 
technologies  into  the  agglomeration,  and  3)  transformation,  in  which  the 
agglomeration moves into a completely new technological field (p.  219). In order to 
benefit  from  these  new  opportunities,  it  is  necessary,  in  all  cases,  that  the 
agglomeration does not have a total technological specialization or lock-in, if this is 50 
the  case,  enterprises  m  the  agglomeration  will  not  be  able  to  incorporate  new 
knowledge and technologies, and innovate (Wolf and Gertler, 2006). Therefore, in the 
'new  opportunities'  stage,  governrnents  play  an  important  role  implementing 
programs  that  support  the  creation,  adoption  and  the  commercialization  of new 
technologies; otherwise, the agglomeration will decline. 5
1
 
T
a
b
l
e
3
.
1
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
a
n
 
a
g
g
l
o
m
e
r
a
t
i
o
n
'
s
 
l
i
f
e
c
y
c
l
e
 
s
t
a
g
e
s
 
S
 
E
n
t
r
e
p
r
e
n
e
u
r
i
a
l
 
E
x
p
e
r
i
e
n
c
e
/
 
1
 
T
e
c
h
n
o
l
o
g
i
c
a
l
 
C
 
1
1
 
b
 
f
 
1
 
G
o
v
e
r
n
m
e
n
t
 
t
a
g
e
s
 
.
.
.
 
•
 
1
 
•
 
o
 
a
 
o
r
a
 
w
n
s
 
1
 
i
n
v
o
l
v
e
m
e
n
t
 
a
c
t
l
v
i
t
l
e
s
 
L
e
a
m
m
g
 
1
 
d
i
s
t
a
n
c
e
 
·
 
E
m
e
r
g
e
n
c
e
 
F
e
w
 
s
t
a
r
t
-
u
p
s
 
L
i
t
t
l
e
 
!
 
W
i
d
e
 
t
e
c
h
n
o
l
o
g
i
c
a
l
 
N
 
1
1
 
b
 
f
 
•
 
1
 
.
 
o
 
c
o
 
a
 
o
r
a
 
1
0
n
s
 
·
-
-
·
-
-
·
·
·
·
·
·
·
-
·
-
·
-
·
·
·
·
-
·
·
-
·
 
-
·
·
-
-
·
·
-
-
-
-
-
-
-
-
-
·
-
·
-
-
-
·
·
·
·
·
·
-
-
·
 
~
x
p
e
J
2
~
n
~
~
-
-
-
-
-
-
+
i
~
.
s
t
a
n
c
e
 
_
 
-
·
·
 
_
_
 
·
-
-
·
·
·
-
-
-
-
-
1
 
S
y
n
e
r
g
i
e
s
 
o
n
l
y
 
T
r
a
n
s
i
t
i
o
n
 
l
n
c
r
e
a
s
i
n
g
 
n
u
m
b
e
r
 
L
e
v
e
r
i
n
g
 
1
 
S
t
a
r
t
 
t
o
 
d
e
f
i
n
e
 
a
 
b
e
t
w
e
e
n
 
s
p
i
n
-
o
f
f
s
 
o
f
 
s
t
a
r
t
-
u
p
s
 
l
e
a
r
n
i
n
g
 
,
 
t
e
c
h
n
o
l
o
g
i
c
a
l
 
p
a
t
h
 
l
 
a
n
d
 
p
a
r
e
n
t
 
o
r
g
a
n
i
z
a
t
i
o
n
s
 
S
e
c
o
n
d
 
g
e
n
e
r
a
t
i
o
n
 
o
f
 
1
 
N
e
w
 
p
o
t
e
n
t
i
a
l
 
I
m
p
r
o
v
e
m
e
n
t
 
G
r
o
w
t
h
 
o
f
 
s
u
p
p
o
r
t
i
n
g
 
e
n
t
r
e
p
r
e
n
e
u
r
s
 
F
i
r
m
s
 
m
o
v
e
 
i
n
 
D
i
r
n
i
n
i
s
h
 
p
a
r
t
n
e
r
s
 
i
n
f
r
a
s
t
r
u
c
t
u
r
e
 
N
e
i
t
h
e
r
 
h
i
g
h
 
g
r
o
w
t
h
 
t
h
e
 
s
a
m
e
 
.
 
t
e
c
h
n
o
l
o
g
y
 
1
 
D
e
n
s
e
 
c
o
l
l
a
b
o
r
a
t
i
o
n
s
 
n
o
r
 
r
e
m
a
r
k
a
b
l
e
 
d
i
r
e
c
t
i
o
n
 
d
i
s
t
a
n
c
e
,
 
m
o
r
e
 
S
u
s
 
t
a
i
n
 
d
e
c
r
e
a
s
e
 
i
n
 
t
h
e
 
f
o
c
u
s
e
d
 
o
r
i
e
n
t
a
t
i
o
n
 
i
n
s
i
d
e
 
a
n
d
 
o
u
t
s
i
d
e
 
o
f
 
n
u
m
b
e
r
 
o
f
 
c
o
m
p
a
n
i
e
s
 
t
h
e
 
a
g
g
l
o
m
e
r
a
t
i
o
n
 
G
e
n
e
r
a
t
e
 
n
e
w
 
S
u
p
p
o
r
t
 
t
o
 
N
e
w
 
I
n
c
o
r
p
o
r
a
t
i
n
g
 
n
e
w
 
A
d
a
p
t
a
t
i
o
n
,
 
k
n
o
w
l
e
d
g
e
 
a
n
d
/
o
r
 
a
d
o
p
t
 
n
e
w
 
o
p
p
o
r
t
u
n
i
t
i
e
s
 
k
n
o
w
l
e
d
g
e
 
R
e
n
e
w
a
l
,
 
b
r
i
n
g
 
i
t
 
f
r
o
m
 
t
e
c
h
n
o
l
o
g
i
e
s
 
T
r
a
n
s
f
o
r
m
a
t
i
o
n
.
 
o
u
t
s
i
d
e
r
 
p
a
r
t
n
e
r
s
 
a
n
d
 
g
e
n
e
r
a
t
e
 
n
e
w
 
m
a
r
k
e
t
s
 
1
 
C
o
m
p
e
t
e
n
c
e
s
 
1
 
C
l
o
s
e
d
 
a
n
d
 
D
e
c
l
i
n
e
 
S
t
a
i
t
-
u
p
s
 
a
r
e
 
r
a
r
e
 
a
r
e
 
c
o
n
t
a
i
n
e
d
 
L
i
t
t
l
e
 
t
e
c
h
n
o
l
o
g
i
c
a
l
 
h
o
m
o
g
e
n
e
o
u
s
 
i
n
 
f
e
w
 
d
i
s
t
a
n
c
e
 
(
l
o
c
k
-
i
n
)
 
1
 
c
o
l
l
a
b
o
r
a
t
i
o
n
 
1
 
c
o
m
p
a
n
i
e
s
 
j
 
n
e
t
w
o
r
k
s
 
S
o
u
r
c
e
:
 
O
w
n
 
e
l
a
b
o
r
a
t
i
o
n
 
b
a
s
e
d
 
o
n
 
F
e
l
d
m
a
n
 
e
t
 
a
l
.
 
(
2
0
0
5
)
 
a
n
d
 
M
e
r
z
e
l
 
a
n
d
 
F
o
m
a
h
l
 
(
2
0
0
9
)
.
 ----- ---------- ------------- - - ---- - -------------------
52 
3.3 Biotechnology agglomerations 
The first biotechnology agglomerations emerged in the United States and the United 
Kingdom,  where  there  was  and  still  exists  a  favourable  environment.  This 
environment includes a scientific base, funding organizations, entrepreneurship, well-
defined  legal  frameworks  and  policy  incentives  (Chiaroni  and  Chiesa,  2006, 
Cockburn and Stern, 2010). During the last decades, sorne emerging countries have 
attempted to  create biotechnology agglomerations, however,  as  it will be presented, 
this  is  not an easy task given the  complex knowledge base of biotechnologies,  the 
way entrepreneurs can generate and obtain value from science, and the intervention of 
the governments to create and improve infrastructure that support the advancement of 
science and generate business opportunities (see Chapter IV). 
3.3 .1  Organizations and institutions 
The  creation  of an agglomeration  m  a  specifie  geographical  area  depends  on its 
particular organizations and resources, and the historical events trigger a stimulus -
internai or extemal (Prevezer, 1997; Chiaroni and Chiesa, 2006). Later, the growth of 
a biotechnology agglomeration depends on organizations and institutions that allow 
the growth of  the local enterprises, and the entrance of new enterprises. The following 
paragraphs descfibe the  organizations and institutions  involved in  the  dynamics of 
biotechnology agglomerations 
Organizations 
Several  authors  have  emphasized that  biotechnology  innovations  involve  different 
organizations such as university, DBFs, large, established firms,  venture capital, and 
government agencies  (Niosi et al.,  2005; Cockbum and Stem, 2010).  These actors 
interact  in  order  to  create  and/or  acquire  diverse  resources  such  as  knowledge, 
funding, specialized inputs and management guidance (Niosi et al., 2005). 53 
Universities  and  research  centres  are  the  mam  generators  of  new  scientific 
knowledge. In the case of biotechnology, discoveries imply a high degree of 'natural 
excludability', which means that often, new techniques are not well known and only 
certain researchers and their teams have access to that know-how (Fuchs and Krauss, 
2003:  4).  This  'tacitness'  influences  the  agglomeration effect;  scientists  and R&D 
researchers of finns (small and large) need to  be geographically close to  each other 
(in the same region or city) to  ensure good communication (Audretsch and Feldman, 
1996). 
Organizations  also  include  business  firms.  In the  specifie  case  of biotechnology, 
small  and  medium-size  firms  have  played  an  important  role  in  knowledge  and 
technology  trans  fer  from  universities  to  industry  (Audretsch,  2001 ).  Often,  star 
scientists,  who  are  convinced that their intellectual knowledge  could be  translated 
into  a product,  found  these  enterprises.  Innovative  biotechnology products  can  be 
final  goods  or services  for  the  end-user market (  e.g.  human health)  or specialized 
inputs  for  large  chemical and pharmaceutical companies (e.g.  enzymes)  (Niosi and 
Bas 2003). Large companies also play an important role as  consumers and source of 
funding  when a  complex biotechnology product is  going  to  be  developed (Cooke, 
2001).  These large companies  are much more  acquainted with markets,  regulatory 
agencies and " other key institutions than small-dedicated biotechnology firms are. 
Funding organizations are crucial for the development of biotechnology firms.  They 
include venture capital firms,  angels, research foundations (public or private  ),  stock 
markets and other. Venture capital firms support start-ups not only with investments, 
but also  with managerial  guidance.  For instance,  they  help  small  firms  to  acquire 
capabilities needed to manage efficiently intellectual property and alliances (Gompers 
and  Lemer,  2001).  Stock  market  and  governmental  funding  institutions  also 
participate  in the  funding  of DBFs  (Cooke,  2002). Venture  capitalists  and  angels 
provide funds  in the first  years  of the  DBF when the  start up  is  working in basic 54 
research, prototypes and proof of concept, as  well as  conducting initial market tests 
and building manufacturing plants. As the DBF evolves and grows, the research costs 
increase  (it  requires  more  research  personnel,  more  sophisticated  inputs,  larger 
facilities, and more ex pensive market tests), th us alliances and stock markets become 
key sources of  funding (Pisano, 2006). 
Institutions 
Key institutions in biotechnology involve the  rules,  norms  and  laws  established in 
order to  improve the competitiveness of industries using biotechnologies  and avoid 
uncertainty  and  risk  (North,  1990:  3-10;  Pisano,  2006).  Institutions  (as  rules)  are 
established by  govemment agencies  as  well  as  format  and inf01mal  collaborations 
between different organizations. The most salient institutions in biotechnology aim at 
investments in science, regulating intellectual property, and facilitating collaborations 
between organizations to complement resources and capabilities. 
Because  biotechnology is  based on scientific knowledge and  is  often generated  in 
universities  and  research  laboratories,  governments  supporting  the  creation  and 
adoption of biotechnologies have  to  make large  investments dedicated to  scientific 
activities (Chiaroni and Chiesa, 2006). These investments encompass the creation or 
revamping of public research centres  and  the  formation and  training of specialized 
workforce. Often, governments face a difficult task in allocating investments for the 
different agglomerations since the amounts required are so large (Cooke, 2002; Niosi 
et al.,  2005). Moreover, in sorne industries, such as  biophannaceutical, the time and 
investment required  to  achieve a  biotechnology products  is  so  long,  it  often takes 
decades (Pisano, 2006). 
Government agencies define the intellectual property regulations within a country or 
region. Intellectual property instruments, particularly patents, are seen as incentives to 
translate  scientific  knowledge  and  appropriate  economie  value  from  that.  In 55 
biotechnology,  national govemments decide  what  is  patentable and  what  is  not,  a 
decision that looms large on the structure of the national biotechnology sector. In the 
case of biotechnology, intellectual property rights often are incentives to  encourage 
star scientists to generate spin-offs from which they could receive profits in retum for 
their  intellectual  contribution (Zucker et  al.,  1998).  Scientific knowledge  could  be 
codified into a patent, which also may be a mean to  obtain funding through licenses 
sold  to  other  enterprises  (Niosi  et  al.  2005,  Pisano,  2006).  Patents  are  also 
commercial  and  novel  quality  indicators  of  scientific  knowledge;  they  help 
enterprises  to  obtain  VC  funding.  Given  that  financial  agents  cannot  accurately 
evaluate the  future  value of the DBF's R&D  in  its  first  years, patents  are  seen as 
quality indicator of  their research output (Rothaermel, 2002). 
Formai and informai collaboration among different actors  allow  them  to  reach  and 
enhance  their  resources  and  capabilities  (Powell  et  al.,  1996).  The  generation  of 
scientific  knowledge  requires  a  constant  flow  of  information  and  face-to-face 
feedback  among  scientists,  which  can  be  seen  as  informai  or  non-contractual 
collaboration (Cooke, 2007). Formai collaborations are exemplified in alliances and 
research  contracts  between,  for  instance,  small  and  medium  enterprises  and  large 
companies. The most salient characteristics of DBFs is  that they often spin-off from 
knowledge-creating organizations  and  they start as  small firms. Most of the  times, 
star scientists, who are engaged in scientific breakthroughs, establish or participate in 
the foundation of these spin-offs, and they do  not have the management capabilities 
to  conduct expensive  clinical  trials,  obtain  approvals,  produce  and  commercialize 
their  products  (Rothaermel,  2002).  Thus,  DBFs  establish  alliances  with  large 
companies that have the assets to  put new products into the market as well as  to  get 
funding  to  conduct  clinical  essays  and  obtain  drug  approval  (Rothaermel,  2002). 
·Large firms establish alliances with DBFs (or simply acquire them) in order to ob tain 
research results  that allow them to  conduct more ambitious R&D projects as  well as 56 
to replenish their product pipelines (Pichaud, 2002). 
Table 3.2  summarizes  the  organizations and  institutions  involved in biotechnology 
agglomerations,  their  function  and  their  importance  for  the  development  of 
biotechnology products. 
Table 3.2 
Organization and institutions of biotechnology agglomerations 
Organizations  Functions  Importance for biotechnology 
Universities  Generate new scientific  Biotechnology implies 'high degrees of 
and research  knowledge,  natmal excludability' (Fuchs and Krauss, 
centres  Training of  human resomces.  2003: 4). Given the rnix of codified and 
tacit knowledge, only few scientists have 
the ability to acquire and create new 
knowledge in this area (Audretsch, 2001: 
40) 
Firms using  Responsible for manufacture  There are different types of 
biotechnologies  and developed products and  bioteclmology firms: 
services.  •  Dedicated biotechnology firms 
(DBF) are essentially R&D 
companies and generally small and 
medium-size. They have been 
considered as knowledge and 
technology transfers from 
universities to industry (Audretsch, 
2001) 
•  Pre-existing industrial or commercial 
companies (  e.g. pharmaceutical, food 
additives producers or grain traders) 
that adopt biotechnology and develop 
new products on the basis of 
biotechnology. 
Innovative biotechnology products can be 
final products for the end-user market 
(e.g. human health dmgs) or specialized 
inputs for other industrial companies 
(Niosi and Bas, 2003). 
Funding  Public and private  Translating scientific results (from 
organisations  organisations provide funds at  biotechnology areas) into commercial 
different stages in the  products requires huge investmcnts. As a 
generation of  new products,  DBF evolves, it requires more research 
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from suppotiing basic  personnel, sophisticated inputs, and 
scientific research through  larger facilities, thus venture capital, 
establishment of  firms to  alliances and stock markets provide the 
commercialization of final  financial resources (Pisano, 2006; Cooke, 
products or licenses.  2007). 
Institutions 
11  Functions  Importance for biotechnology 
R&D  Government investments to  The scientific ad van  ces of the different 
investments  promote and support scientific  disciplines related to biotechnologies 
activities and create and  require large investments that facilitate 
revamp knowledge-creating  the access to qualified human resources, 
organisations.  specialized inputs and sophisticated 
equipment (Chiaroni and Chiesa, 2006). 
Intellectual  Govcmrnent organisations  Patents can be seen as incentives to push 
property rights  define the intellectual property  f01ward the establishment of  new 
regulations within a counhy or  biotechnology firms and to attract private 
reg10n.  investors (e.g. VC, Private Equity, and 
large companies) (Zucker et al,  1998) 
Collaborations  Governments often establish  The generation of scientific knowledge 
institutional frameworks to  requires a constant flow of  information 
enable and encourage formai  and face-to-face feedbacks among 
and informai collaborations  scientists, which can be seen as informai 
between different actors  or non-contractual collaboration (Cooke, 
(public or private) to  2007). Formai collaborations are 
complement resources and  exemplified by alliances and research 
capabilities.  contracts between different agents 
(Rothaermel and Deeds, 2004; Pichaud, 
2002). 
Source: Own elaboratiOn. 
Sorne  authors  have  used  the  concept  of  cluster  to  analyze  biotechnology 
agglomerations and they have defined the scope of the definition in different ways. 
For example, Prevezer (1997) defines clusters as "groups offinns within one industry 
based on one geographical area"  and suggests  that  the  mechanisms for clustering 
include  "both  the  phenomenon  of a  critical  mass  of one  sector  of an  industry 
developing in one place  ... and the force of attraction that a core sector of an industry 
has on auxiliary sectors of that same industry in that location" (p. 255). Feldman and 
11  Institutions involve the rules, norms and laws established in order to improve the competitiveness of 
the firms creating, adopting and commercializing biotech-related products and help to avoid 
uncertainty and risk (North, 1990: 3-10; Pisano, 2006) 58 
Braunerhjelm  (2006:  1)  propose  a  simpler  definition  of  the  cluster:  "regional 
concentrations of related firms and organizations". In both cases the general concept 
of cluster falls  short to  exptain the dynamics of the emergence and development of 
cluster,  the types of organizations  and institutions  involved in  these dynamics,  the 
geographicattimitation of the cluster, and what ldnd of  comptementarities are needed. 
3.3 .2 Dynamics of  biotechnology agglomerations 
Enterprises  performing  high-technology  activities  tend  to  agglomerate  in  specifie 
geographie areas. Often these agglomerations evotve gradually; there is  a process of 
attraction, creation and addition of organization and institutions over time. Given that 
one  of the  objectives  of this  research  is  to  evatuate  the  potential  Mexico  has  to 
devetop  a  biotechnology  agglomeration,  this  section  portraits  the  agglomeration 
dynamics based on the experience of devetoped countries (particularly in the case of 
the biopharmaceuticat sector). 
Emerging stage 
In the emergence stage,  at least three situations can trigger an agglomeration. The 
first one is  when the  specifie geography area or city had already the  conditions to 
encourage star scientists to  found new enterprises  for exptoiting a  new technotogy 
(e.g. San Francisco Bay area, Cockburn and Stern, 2010). The second one is when an 
externat shock (e.g.  changes in policies and regulations) pushes the establishment of 
new firms (e.g. Washington DC, Fetdman et al., 2005). Finally, the third one is when 
an agglomeration is  created by a  govemment mandate (  e.g.  Biopolis in Singapore  ). 
Whether the  triggering factor is  internai or externat to  the  geographical area,  these 
new  firms  are  often  few  and  small- and  medium-sized.  In  all  cases,  research 
universities and research centres are a necessary condition to  found a science-based 
agglomeration. High-level research organizations host scientists that work in different 
areas or fields developing cutting-edge knowledge and exptoring new techniques. In a 59 
systematic view, the RSI approach suggests that in this phase, there is  a process of 
critical mass development. Scientific relationships and collaborations among different 
knowledge-creating  organizations  allow  the  generation  of a  continuously  nurtured 
flow  of ideas  (Braunerhjelm  and Feldman,  2006).  This  collaboration  is  based  on 
particular norms  and  values  (culture)  shared  in  a  specifie  geography  area  (Owen-
Smith and Powell,  2006;  Cooke,  2007)  and  allow scientists  to  be  in  contact with 
flows of information and tacit knowledge (Audretsch and Feldman, 1996; Fuchs and 
Krauss, 2003). For that reason, at the early stages of a biotechnology agglomeration, 
knowledge-creating  organizations  and  their  scientists  are  key  players  as  anchor 
tenants (Feldman, 2003). At this stage, few scientist-entrepreneurs found companies; 
the ones that exist are located around the university or research centres to  access to 
new knowledge and skilled personnel (Kenney, 1986; Zucker et al., 1998; Niosi and 
Bas, 2003). 
During the transition stage first-ties appear: formai collaborations emerge and other 
organizations  contribute  to  the  creation  and  growth  of small  enterprises  in  the 
locality. DBFs often have scientific capabilities but they have neither sufficient funds 
nor the  managerial skills  to  develop  their products,  obtain the  necessary approvals 
from  govemmental regulatory bodies, and put their products into  the market.  Thus, 
VC  finns  (and also, angels  and governrnent R&D  subsidies) represent a source of 
seed funding in the first years of DBFs' life -where research is  crucial- and provide 
managerial  support  to  arrange  alliances  and  manage  intellectual  property.  VC 
investments  are  attracted by  the potential of DBFs,  which often is  reflected in the 
number  and  quality  of patents  (Chiaroni  and  Chiesa,  2006).  Alliances  with  large 
companies  also  provide  DBFs  with  other  resources  and  capabilities  to  develop 
distribution and marketing capabilities and put their products into the market. These 
firms  collaborate  with  DBFs  because  they  see  the  potential  commercialization  of 
products  or the  utility of the  new technologies  in the production processes. These 60 
alliances  imply that the  cooperating enterprises share the  same knowledge base.  In 
this  case,  the  incumbents  do  not  need  to  establish  research  facilities  in  the 
agglomeration (Prevezer, 1998; Niosi and Bas, 2003). At this  stage, where a critical 
mass  is  reached and first-ties  start to  appear,  the agglomeration begins to  define its 
technological profile. 
Alliances  and  VC  support  are  not  enough  to  support  knowledge  generation  and 
diffusion.  An appropriate  institutional  environment  has  been  created  where  other 
public  and  private  organizations  and  institution  emerge  to  encourage  ~echnology 
transfer and the  creation of new enterprises, and  to  facilitate  the  growth of already 
established enterprises: 
Govemment  institutions  (  e.g.  departments  of economie  development)  can 
improve the climate of business (R&D tax credit, investment tax  credit), and 
eventually attract other organizations and supplementary funds; 
Technology transfer offices  can help  to  launch new start-ups with potential 
investors (e.g. contact with VC); 
Research  hospitals  that  contribute  to  the  system  by  conducting  preclinical 
research and commercialization; 
Technology parks; 
Institutes to support new start-ups; 
Associations  that  group  biotech  firms  and  diffuse  information  about  the 
industry applications (Cooke, 2002; Niosi and Banik, 2005) 
These organizations "made it  easier for new firms  to  appropriate knowledge inputs 
and  sell  knowledge-intensive  products  in well-defined markets"  (Niosi  and Banik, 
2005: 355). Over time, these organizations develop patterns of behaviour that define 
local institutions helping to improve the institutional environments. At the same time, 61 
the locality is  acquiring its core competencies-"those that create value for markets 
outside the region,  that are co-specialized, and difficult to  imitate" (Niosi and Bas, 
2001:  32).  In  this  phase,  the  agglomeration  begins  to  define  agglomeration 
capabilities. 
As mentioned before, DBFs often need to sell their products and services in  order to 
obtain additional funding  (even if they  have financial  support from  angels  or VC 
firms). The customer or the commercialization organization could be a large company 
established (or not) in the same location; this has two implications for the origin and 
growth of  the agglomeration: (1) this large firm may be attracted by the specialization 
of the agglomeration originated by research organizations; or (2) i t was already in the 
region before the establishment of DBFs and had started to collaborate with the local 
universities,  thus  contributing  to  define  the  technological  trajectory  of  the 
agglomeration (Feldman, 2003). As a result, relationships between universities, DBFs 
and incumbents may produce geographical synergies (  e.g.  alliances or other types of 
collaborations).  In  this  way,  the  definition  of  the  technological  profile  of  a 
biotechnology  agglomeration  depends  either  on  the  lines  of  research  of  the 
universities,  or  on  the  technology  chosen  by  the  large  firm,  both  can  be  seen  as 
anchor tenants (Feldman, 2003). 
Growing stage 
The growth phase of the  biotechnology agglomeration's  life  cycle  is  based on  the 
increment of the number and size of the  DBFs and  the  attraction of other agents' 
activities (more alliances, and more VCs may establish in the area). At this stage, it 
seems  that  the  scientific  base  of the  agglomeration is  a  main factor  of attraction. 
However, a word of caution is  needed, although sorne authors suggest that scientific 
capabilities become specialized and those represent the strength of the agglomeration 
given the reinforcement of the knowledge base (Prevezer,  1997;  1998). Too much 62 
specialization can lock-in the agglomeration and hinder or delay the undertaking of a 
new cycle of growth
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. Therefore, ·as the scientific base is nurtured by universities and 
research centres, at  the  same time, they have to  generate new knowledge  in other 
areas that will allow the agglomeration to  venture in other fields: "add new work to 
old work" (Jacobs 1969) (see section 3.2.1). 
The growth of a DBF  within an  agglomeration often depends  on the  collaboration 
with  incumbents  in  its  own sector,  which have  more  experience  in  regulatory and 
commercialization issues. Once the earlier DBFs create their market or demonstrate 
their research potential, new entrants will be encouraged. These new entrants may or 
not  be  scientists,  but  they  will  be  attracted  by  the  knowledge  base  and  the 
infrastructure of the agglomeration (Chiaroni and Chiesa, 2006). Here it is  important 
to  mention  that  not  all  the  sectors  using  biotechnologies  grow  at  the  same  rate, 
because new entrants and incumbents  are more attracted to  agglomerations focused 
on human health sectors. Other sectors using agricultural, chemical or environmental 
biotechnology applications are either less developed, or large incumbents absorb most 
of  the  research  spillovers  emerging  from  DBFs  using  these  biotechnologies 
(Prevezer, 1997). Consequently, regions hosting biotechnology firms in agriculture or 
environment sectors face difficulties for attracting other agents. 
The expertise of  large, established firms becomes crucial to complement the scientific 
knowledge of the agglomeration. Therefore, at the growth stage, large companies can 
become  anchor  tenants.  According  to  Feldman  (2003),  "the  presence  of large 
established  entities  create  sorne  of the  well-known  advantages  of agglomeration 
economies such as  pools of skilled labour and demand for specialized inputs, which 
may benefit smaller start-ups" (p.  323). These start-ups (DBFs or firms related to  the 
12 For example, if a elus  ter is unable to jump from one (declining topic) such as ag-bio to the next (e.g. 
food additives), its specialization plays a dirty trick. Gertler and Vinodrai (2009: 256) mention the case 
of Saskatoon, Canada. 63 
industry) may be encouraged by the interaction among different actors located within 
the area, for example, "potential entrepreneurs may take ideas out of the established 
anchor and form new firms"  (ibid).  Thus, the  location will benefit from  a renewed 
base of entrepreneurship (Chiaroni and Chiesa, 2006). Romanelli and Feldman (2006) 
suggest  that  "only  those  regions  which  generate  a  community  of entrepreneurial 
activity ...  that  is,  firms  that  are started by  entrepreneurs  with  experience  in  other 
entrepreneurial  firms  in  the  same  industry,  may  be  capable  of long-term  cluster 
persistence." (p.  111 ). 
Sustaining stage 
In the sustaining stage, institutional frameworks  and the presence of different agents 
enable  the  agglomeration  to  reach  'well  functioning'  systems  of ümovation  and 
entrepreneurship (Feldman et al., 2005; Chiaroni and Chiesa, 2006).  Feldman et al. 
(2005) suggest the following characteristics of the maturity phase: 
"  [T]he creation of the regional public sector financing and grant-giving 
programmes.  Government  policy  creates  further  incentives  for 
investment.  Incubators  and other technology partnerships  are  created to 
promote  the  growth of the  industry.  Mergers  and acquisitions  begin to 
thin  out  the  companies.  Successful entrepreneurs  also  move  from  their 
initial  start-up  to  start  other companies,  becoming  serial  entrepreneurs 
with  deep  roots  in  the  community.  Additionally,  venture  capitalists 
relocate to  the area or open branch offices ... The maturing elus ter spurs 
policy changes as  govemments seek to  attract and provide a flourishing 
environment for even more high technology development· (Feldman et al., 
2005: 134) 
Institutional conditions that allow the interaction between different organizations are 
needed  to  maintain  the  competitive  advantage  of a  region  (Cockbum  and  Stem, 
2010).  In addition,  the  foundation  and  support  of new  DBFs  could  reinforce  an 
agglomeration (Niosi and Bas,  2003). Funding also plays a crucial role for the firms' 
growth; the availability of public and private funding ensures the maintenance of the 64 
agglomeration, especially in those related to human health sector (Cooke, 2002). 
As  mentioned  before,  DBFs  aim  at  different  markets  according  to  different 
applications.  In the  case of DBFs  in human health,  the  market encompasses  local 
hospitals, private  clinicat  organizations,  and  public  and  private  healthcare  systems 
(govemment). The presence of these actors in the region contributes to  the growth of 
the DBFs. The interaction between DBFs and users within the region facilitates  the 
leaming process; this allows enhancing the core competence of the region. Moreover, 
enterprises  within an agglomeration can  interact with organizations  located abroad. 
According to Niosi and Bas (2001: 33) "the core competencies ofthe region include 
the propensity and capacity to  cooperate and  leam from  other institutions ...  being 
closely  related  to  and  made  of knowledge,  they  increase  with  practice,  usually 
procuring sustained advantage to regions as well as firms". 
Finally, in the case of the health care sector, Cooke (2005) and Niosi and Bas (2003) 
mention that urban cities that put together aU the actors involved in the value chain of 
new  drugs  (  discovery,  testing,  production  and  commercialization)  are  called 
megacentres.  The  actors  that  converge  in  the  megacentre  require  different, 
sophisticated inputs, especially in R&D areas.  Thus, Niosi and Bas (2003) mention 
"R&D, particular in health science, has  moved from  a narrow discipline focus  to  a 
more  wide  trans-disciplinary  one,  the  new  biotechnologies  and  more  traditional 
pharmacology combine in the development of new drugs" (p. 791). This suggests that 
urban  cities  with  more  diverse  capacities  seem  more  likely  to  grow  than  more 
specialized ones (Niosi and Bas, 2001). 1 . 
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CHAPTERIV 
TECHNOLOGY POLICIES 
High technologies - biotechnology among them- play an important role in economie 
growth.  Consequently, governments interested in supporting economie growth have 
intervened  to  encourage  the  creation  and  support  of high-tech  industries  through 
public  policies,  particularly  science,  technology,  and  ümovation  policies  (STI) 
(Nelson, 1993; Dodgson and Bessant, 1996; Cimoli et al., 2009; Cockburn and Stem, 
201 0).  High  techno1ogy  industries  are  characterized  by  continuous  techno1ogica1 
change, large investment in R&D, and a strong growth rate (Oakey et al.,  1988). In 
addition,  the  support of these  technologies  relies  on  a  coherent,  sophisticated and 
long-term government commitment (Cimoli et al., 2009; Cockbum and Stern, 201 0). 
The chapter is  divided as  follows:  section 3.1  presents the theoretical arguments that 
support the  intervention of government in order to  achieve technological innovation 
and  show  the  relevant  dimensions  and characteristics  of public  policy focused  on 
innovation, section 3. 2 deals with the design and implementation of STI policies, and 
section  3.3  presents  the  experience  of  emerging  countries  in  formulating  and 
implementing  public  policies  to  support  the  creation  and  development  of 
biotechnologies. 
4.1  Public policies 
4.1.1 The role of govemment 
In the economies literature there are two main approaches that explain the importance 
of innovation in  economie growth:  the  neoclassical approach and the  evolutionary 
approach  (Lundvall  and  Borras,  2005;  Castellacci,  2007).  On  one  band,  the 
neoclassical  approach  downplays  policy intervention;  such  intervention is  justified 
only wh en there  is  a market failure  (  e.g.  lack of incentives to  invest in knowledge 
production).  On  the  other  hand,  the  evolutionary  approach  underlines  that ----------------------- ------------------------------------------------------------------------------
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technological  innovation  does  not  follow  a  linear  model  with  well-defined 
consecutive phases within the firm; on the contrary, in order to achieve technological 
innovation  different  organizations  and  institutions 
13  take  part - for  instance,  firms, 
universities  and  government  organizations  (Lundvall,  1992;  Nelson,  1993). 
Knowledge flows  and  leaming processes  are  embedded  in  these organizations  and 
institutions (Lundvall,  1992).  Although these elements are  created and accumulated 
in both, individuals and organizations, as routines, skills and capabilities (Nelson and 
Winter,  1982),  the  mechanisms  required  to  create  and  diffuse  technological 
knowledge and stimulate the leaming process often are supported and coordinated (in 
order to  give sorne coherence of the system) by govemment agencies (Dalum et al., 
1992). Thus, the importance of the govemment's role on the innovation process relies 
in its capacity to  create and maintain a coherent system: "[public sector]  is  involved 
in direct support of science and development, its regulations and standards influence 
the  rate  and  direction  of innovation,  and  it  is  the  single  most  important  user  of 
innovations  developed  in  the  private  sector"  (Lundvall,  1992:  14).  According  to 
Dalum et al.  (1992: 302-7), the govemment's role is to devote national efforts both in 
terms of resources and institutional capabilities to build specifie competencies based 
on the  formai  education system;  to  nurture investment in R&D  implementing legal 
frameworks  that facilitate  the appropriability of economie value; and to  ensure the 
creation and diffusion of relevant knowledge facilitating networking and cooperation. 
In  sum, the  role  of the  government is  to  provide an  institutional environment that 
allows the  interaction between different actors and support innovation activities that 
contribute  to  economie  growth.  Sorne  questions  arise:  how  should  govemrnents 
13  Innovation processes  involve  organizations  and  institutions.  North  (1990: 3-1 0)  defi ne  them  as 
follow:  institutions are  'the rules  of the  game  in  a society or,  more  formally, the humanly devised 
constraint  that  shape the human interactions'; these  institutions can be formai  and  informai: formai 
institutions  are  characterized  by  codified  rules,  for  example  laws,  white  informai  institutions  are 
simply  habits  or  social  nonns.  Organizations  are  'groups  of individuals  bound  by  some  common 
purpose to achieve objectives'. 67 
participate? What is the policy framework that could guide policy makers to  develop 
programs in order to  support innovation? The following paragraphs deals with these 
questions. 
4.1.2 Dimensions and characteristics of  public policies 
According  to  Metcalfe  (1994)  "technology  policy is  much  more  than  a  matter of 
supporting  R&D  expenditures,  it  covers  the  whole  spectrum  from  invention  to 
diffusion  and  from  basic  research  to  the  mastery  of  specifie  technological 
competencies"  (p.  936).  In  doing  that,  policy  makers  could  recognize  the 
complementary assets that allow firms to create and capture economie value, and also 
facilitate the diffusion of innovations. 
Niosi  and  Bellon  (1995)  underline  that  "public  policy  can  be  a  comparative 
advantage  if there  exists  a  good  definition  of development  programs  and  a  good 
definition of tasks, but especially there must be a good articulation between partners 
involved  in  the  tasks...  it  has  implication  with  the  rules  and  practices  of 
institutions ...  the  positive effects of po licy can be achieved only if the  re is  a good 
articulati\m" (p.  213-4). In order to identify the elements that allow the establishment 
of  an  appropriate  institutional  environment,  scholars  have  analyzed  different 
dimensions and ch_ aracteristics of the policies focused on encouraging technological 
innovation. These dimensions involve types of policies, scope, and relation with the 
environment. These elements have implications for the design and implementation of 
public policies. 
Dimensions 
Dodgson and Bessant (1996)  suggest th at  the  aim  of public policies  is  "[to]  assist 
firms to improve awareness of wh  y and how to invest in technology and to  overcome 
the complexities and uncertainties of innovation so as to  enhance their own and their 68 
nation's competitiveness" (p.  3).  Policy initiatives focused on supporting innovation 
as  competitive  advantage  have  to  consider carefully  the  firms'  needs  in  terms  of 
accumulation  and  combination  of  technological  resources,  in  order  to  create 
distinguished competences. 
Dodgson and Bessant (1996) distinguish three types of policies that help governments 
to achieve innovation: science, technology, and Îlmovation policies; each of them has 
different objectives, but they complement each other. 
Table 4.1 
Types of  public policies 
Po licy  Objective  Main features 
Science  Development of  science and the  Scientific education 
po licy  training of scientists.  Research in universities and 
government labs 
Basic research. 
Focus in big issues, e.g. space, 
nuclear power. 
lfechnology  Enhancement and development  Support for creation of 'strategie' 
tpolicy  of technology.  or 'generic' technologies, e.g. IT, 
biotechnology, nanotechnologies. 
Innovation  Improvement of the capacity to  Facilitating diffusion of 
lpolicy  innovate of  firms, networks,  technology 
industries and entire economies.  Encouraging "transfer sciences" 
Facilitate the interaction between SME focus 
different actors. 
Source: Dodgson and Bessant (1996: 4-5). 
Another  dimension  of public  policy  is  related  to  industrial  scope.  Teubal  (1997) 
suggests  two  different  types  of  policies  according  to  their  scope:  horizontal 
technology policies  (HTPs)  and vertical (targeted) technology policies. This  author 
mentions that these types of  poli  ci es are complementary to each other: 
"HTP are a category of technology policies whose objective is to promote technological development per se, irrespective of industrial branch or even 
technological area ... They also complement more specifie, vertical or even 
more  selective  policies  aimed  at  specifie  industrial  branches  and 
technological  areas.  Their  importance  derives  from  being  central 
components  of government  inducement  of  technology-based  structural 
change in a wide variety of  conditions" (Teubal, 1997: 1163, bolds added) 
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Metcalfe (1994)  mentions  that the  importance of distinguishing between  horizontal 
and  vertical  policies  "relies  in  that  each  technology  has  a  different  dynamic  of 
knowledge  accumulation  and  the  generating  activities  are  located  in  different 
communities  and  institutions"  (p.  936).  Thus,  policy makers  have  to  consider  the 
characteristics of the industry and the socio-economic dynamics within the country or 
regiOn. 
Another important dimension is the creation of a human capital market. According to 
Niosi (2010: 92) "[The] adoption, diffusion and use oftechnology depend not only on 
the amount of human capital but also on its institutions ... government policy has to 
create both supply and demand". Therefore, governments interested in technological 
development often create  incentives  to  improve  the  quality and  volume of human 
resources  (supply)  and  ensure  the  use  of those  resources  for  technological  and 
economical  development  (  demand).  On  one  hand,  universities  have  to  conduct 
teaching  and  research  activities  that  allow  researchers  to  generate  not  only  new 
knowledge  but  also  publication,  patenting  and  licensing.  On  the  other  hand, 
innovative firms require R&D activities, which demand highly skilled personnel. 
Table 4.2  presents  a variety of incentives  that  can be  implemented by public  and 
private organizations in order to leverage the human capital market. 70 
Table 4.2 
Incentives to create a human capital market 
Building the supply of human capital  Building the demand of human capital 
•  Grant loan systems for students  •  Tax allowance and credits for the 
R&D for private firms 
•  Research grants and fellowships  •  R&D subsidies for private SMEs 
•  Immigration and skilled labour  •  R&D loans for private firms 
•  lm  port of  foreign teachers  •  Subsidies aimed at the attraction 
of foreign R&D laboratories 
•  Incentive to graduate university  •  Intellectual property laws (patent, 
programs  copyright, industrial design, 
trademarks) 
•  Tax exemptions to foreign  •  Tax deduction for venture capital 
researchers 
•  Academie research funding  •  Public venture capital 
councils 
•  Accelerated immigration for  •  Public R&D laboratories 
foreign university students 
Source: N!OSI (20 10: 98) 
Another dimension is  focused on the relationship between the environment and the 
design of public policies. According to Sabatier (1986), there are two approaches that 
identify these relationships: top-down and bottom-up. 
"The  essential  features  of a  top-down  approach  are  that  it  starts  with  a 
po licy decision by governmental (  often central govemment) officiais  and 
then...  [they  will]  evaluate  the  factors  affecting  po licy  outcomes  and 
program outcomes ... The bottom-up approach ...  starts by identifying the 
network of ac tors involved in [an activity] ... identifying the local, regional, 
and national actors involving in the planning, financing,  and execution of 
· the  relevant  govemmental  and  non-governmental  programs"  (Sabatier, 
1986: 32). 
In  other words,  although  the  government plays  an  important role  as  designer and 
coordinator of different policies, sometimes the socio-economic interactions between ------ ------·  - - --
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different actors give place to  unexpected opportunities and  demands. In this  sense, 
socio-economic organizations can influence the design of  public policies. 
In sum, the successful incorporation of technological change in economie growth has 
been based on the implementation of different types of public policies. These policies 
need to  have coherence  in  terms  of objectives  and  mechanisms.  Therefore, policy 
makers  have  to  consider  the  characteristics  of strategie  industries  and  the  socio-
economic dynamics within the region or the country. 
Design and implementation of technology po licy 
The above paragraphs have shown the importance of govemment intervention in the 
innovation process and the different dimensions that policy makers have to  consider 
for encouraging and maintaining technological innovation. Here, the  interest tums to 
the analysis on how public po1icy is designed and implemented. 
The  design  and  implementation of public  policies  is  a  dynamic  and  evolutionary 
process (Niosi and Bellon, 1995; Teubal, 1996, 1997; Carlsson, 2006). The particular 
historical,  economical  and  political  characteristics  of a  country  determine  the 
behavioural pattern of actors  involved in the  innovation system;  at  the  same time, 
these ac tors define the design, implementation, continuity, and terminate of the public 
policies. Dodgson and Bessant (1996) suggest that the experience of other countries 
can help policy makers to  design the main programs of science, technological, and 
innovation policies; however, it is  important to consider the specifie characteristics of 
each country or region. According to Niosi and Bellon (1995:  222-3), the phases of 
the  technology policy's life can be  compared with the natural life  cycle;  it  means, 
birth, development, and selection (in terms of policy's continuity). In the birth phase, 
the policies are designed according to the commercial and technological environment, 
trying to cover the fmns' demands; in this phase, there may be little coherence among 
the  different initiatives.  In the  development phase,  the  policies  find  a market, and 72 
policies become more coherent.  Govemment seeks to  avoid duplication in  order to 
create  an  efficient  system.  In the  selection  phase,  the  results  of the  policies  are 
evaluated and govemment decides to continue with the policy or to end it.  According 
to  Teubal  (1996,  1997),  govemment  organizations  also  leam  by  the  experience 
("leaming by doing"), this implies that the design and implementation of new policies 
may be improved over time. Niosi (2002) mentions that not all  policymakers learn, 
and that the slow-leaming motion of government policy designers characterizes many 
developing countries. 
Public policies have  to  be monitored and evaluated in  order to  decide whether the 
programs,  institutions  and  mechanisms  are  weil  designed  and  coordinated.  In 
addition, the socio-economic conditions change over time, thus policy makers have to 
adjust these policies or create new ones according to those conditions. 
Evaluation procedures for STI policy 
As mentioned above, government plays an important role in promoting incentives for 
the creation of new knowledge and the perfonning of R&D activities. Therefore, STI 
policies have to be designed according to the particular socio-economic dynamics and 
technology  assessment  (Kuhlmann  2002).  In addition,  the  specifie  conditions  of 
countries, regions and industries have implications in the design, implementation and 
evaluation of public policies. The process of knowledge creation, and the translation 
of this knowledge into commercial products in volve the participation of severa! ac tors 
with  different  objectives.  Therefore, Gheorghiu  and  Roessner  (2000:  658)  suggest 
that evaluation has to consider three focal points: 
•  Evaluation of publicly supported research carried out in universities and public 
sector research organizations, 
•  Evaluations that focus  upon linkages,  including those of programs seeking to 73 
promote academic-industrial and public-private partnership, and 
•  Evaluation of  diffusion and extension programs. 
In  order  to  perform  these  evaluations,  govemment has  to  develop  a  strategy  that 
allows  it  to  identify the  benefits  and  weaknesses  of those  policies.  In this  sense, 
Kuhlmann  (2002)  defines  the  research  and  innovation  policy  evaluation  as 
"methodology based analysis and assessment of the appropriateness of research and 
innovation policy assumptions and targets of the related measures and their impacts, 
and  of the  goal  attainment".  In addition,  the  evaluation  of public  policies  has  to 
include the definition of clear objectives (Gheorhgiu and Roesnner, 2000; European 
Court  of  Auditors  (ECA)  and  Colling,  2007).  Thus,  government  reqmres  an 
evaluation  strategy  that  includes  the  objectives,  methodologies  and  diffusion  of 
results: 
"An evaluation strategy provides the conceptual framework within which 
evaluation activities are designed, planned, executed and used ... such a 
strategy  should  consider  the  main  legal,  organisational  and 
methodological issues surrounding programme evaluation. This  includes 
what evaluations are to  be carried out, by whom and when, how data are 
to be collected, what methodological approaches are to  be used and how 
findings  are  to  be communicated and followed  up." (ECA and Colling, 
2007: 23) 
Therefore,  an  important  step  is  to  establish  a  government  agency  and  design  the 
organizational structure of this agency to  carry out evaluations at different levels of 
aggregation and at different time horizons (ECA and Colling, 2007; Gheorghiu and 
Roessner,  2000).  The  creation  of panels  of experts  is  an  important  element  to 
decentralize an evaluation process: "a separate body from the  one implementing the 
program"  (ECA  and  Colling,  2007:  28).  Methodologies  are  another  important 
element  in  the  evaluation  process;  these  have  to  be  developed  according  to  the 
objectives of STI policies. The design of methodologies encompasses decisions about 74 
what kinds of data to  collect, and when and who bas  to be interviewed (Gheorhgiu 
and  Roesnner,  2000;  ECA  and  Colling,  2007).  The  final  objective  of policy 
evaluation is  "to provide relevant information and  analysis  that can be  effectively 
used for programme management and policy making" (ECA and Colling, 2007:47). 
Government and evaluation agencies have to ensure the dissemination of information 
toward stakeholders (Gheorhgiu and Roesnner, 2000; ECA and Colling, 2007). 
STI policies and agglomerations 
High  technologies  show  two  important  characteristics:  high  tech  enterprises 
concentrate  in  specifie  geographical  areas  and  they  often  contribute  to  economie 
growth.  Therefore, sorne governments have shown interest in  designing technology 
policies that allow them to  develop high-tech industries and  to  achieve competitive 
advantage  that  could be  reflected  in  economie  growth.  Since  the  1990s,  empirical 
research bas  concentrated in a  new policy mode!, which is  focused  on  innovative 
regions in high-technology industries: "These  studies concentrate on the  analysis of 
well  performing  regions,  dealing  with  the  questions  of  why  such  industries 
concentrate in particular locations, which kinds of linkages and networks exist, and to 
which  extent  knowledge  spillovers  can  be  observed"  (Todtling  and  Trippl,  2005: 
1204). However, sorne regions  'do not leam or do  it  in a slow pace' (Niosi, 2002), 
this  limits  the  creation  of relevant  organizations  and  institutions.  As  mentioned 
above,  the  formulation  and  implementation  of public  policies  relies  in  a  coherent 
system of organizations and institutions coordinated by the govemment. Niosi (2002: 
296)  identifies  sorne  obstacles  that  impede  the  flow  of knowledge  and inhibit  the 
leaming process:  organizational  and  institutional  inertia,  inadequate  system  rules, 
lack or limited number of key institutions, weak coordination among units, and lack 
of information  flows.  These  obstacles  are  more  frequent  in  developing  countries 
where the scarcity of resources limits the performance of institutions, or even worse, 
key  institutions  are  absent,  especially  those  institutions  focused  on  science, 75 
technology  and  innovation  (Niosi,  2010).  Consequently,  underdeveloped 
govemmental institutions are not able to  formulate and implement adequately public 
policies oriented to promote technological development and catching up, affecting the 
formation and training of human capital, and the creation of a critical mass that allow 
the local progress of  science and the creation and diffusion of new teclmologies. 
4.2 Technology policy in emerging countries 
Governments in industrial and sorne emerging countries do  intervene to  design and 
implement  policies  that  help  firms  to  acquire  and  develop  teclmological  and 
managerial  capabilities  to  generate  competitive  advantages.  Given  that  emerging 
countries  face  scarcity  of resources,  the  question  is  how  govemments  of these 
countries  should  design  and  implement public  policies  to  adopt  and  develop  new 
technologies and innovations. 
Teubal and colleagues have developed different approaches 
14 in order to ex plain how 
govemment could intervene to  promote technological improvement and Îlmovation. 
These approaches underline the relevance of two basic processes: 
•  Leaming is  a  social  process  (Nonaka,  1994):  in advanced  OECD  nations, 
govemment often intervenes in order to create an institutional environment to 
support the interaction between agents, in tum this will allow the creation of 
capabilities and competitive advantages. 
•  Evolutionary  selection  of firms  (Nelson  and  Winter,  1982):  the  way 
govemment supports firms should vary over time; in a first phase, enterprises 
depend  heavily  upon  government  support,  in  a  second  phase  enterprises 
usually become independent from public backing. 
14 Building technological infrastructure approach (Justman and Teubal, 1995); Emerging catalytic 
policy approach (Teubal, 1996); Horizontal technology policies approach (Teubal, 1997); Market-
stimulating teclmology policies approach (Lall and Teubal, 1998); Innovation and teclmology policy 
approach (Teubal, 2002); Evolutionary targeted approach (Avnimelech and Teubal, 2008). 76 
Summarizing the  different approaches proposed by Teubal and his  colleagues (see 
Table 4.3),  there are  at  least three  elements  that policy makers should consider for 
designing and implementing policies in a dynamic way: 
•  Infrastructures, 
•  Capabilities  (this  implies  the  rejuvenation  of the  business  sector  and  the 
creation of  new markets) 
•  Industrial scope 
All these elements are often accompanied by instihitional adaptation. 
Table 4.3 
Evolution of  public policies focused on in11ovation. 
First Qhase  ...  Second Qhase 
The role of govemment is catalytic  The role of  government 
and involves the following generic  diminishes in direct support to 
tasks:  firms but consolidates the 
structure and environment to 
produce innovations: 
•  Creating basic technological  .  ..  •  Supporting the creation of 
infrastructure,  advanced technology that 
•  Stimulating the business  contributes to innovation, 
sector to adopt new  •  Creating multi-agent 
technologies,  struch1res (  e.g. clusters, 
•  Diffusing relevant and non- markets, sectors, 
proprietary information and  industries), 
creating markets to support  •  Implementing vertical 
R&D activities,  /targeted policies. 
•  Implementing 
horizontal/neutra! policies. 
Institutional adaptation and innovation 
Source: Own elaboratiOn  based on Justman and  Teubal (1995), Teubal (1996, 1997, 2002); Lall and 
Teubal (1998); Avnimelech and Teubal (2008) 
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According  to  the  analysis  made  by  Teubal  and  his  colleagues,  at  the  first  phase 
(infant)  government plays  a catalytic role.  Setting a basic infrastructure is  relevant 
because it allows the 'assimilation of technology progress' by business organizations 
(Justman and Teubal, 1995). The main objective of  a basic infrastructure is to provide 
technological services to firms  (specially SME) and to diffuse information in order 
to  support  'the efforts  of [technological]  absorption'  of enterprises  (Teuba,  1997). 
These  activities  are  crucial  for  developing  local  capabilities  in  developing 
countries.  The  governrnent  should  stimulate  the  business  sector  to  adopt  new 
technologies  and capabilities that come from  external sources (technologies already 
used in developed countries). Local enterprises could be potential users of improved 
technologies,  however,  most  of the  times  they  do  not  have  access  to  relevant 
information  or  they  are  not  familiar  with  the  most  advanced  technology 
(inodernization).  Therefore,  institutional  adaptation,  new  or revamped  government 
agencies  (new  organizations)  and  institutions  (laws  and  regulations),  often  help 
enterprises  to  overcome  obstacles  related  to  diffusing  information  and  adopting 
advanced  technologies.  According  to  Teubal  (1997,  2002),  institutional  adaptation 
depends  on  positive  feedbacks;  however,  the  author  does  not  mention  how 
government  can  establish  feedback  mechanisms.  In  addition,  this  phase  is 
characterized by the implementation of horizontal/neutral technology policies. These 
policies  support  the  creation  of markets,  especially  markets  that  are  'missing  or 
particular difficult to create in developing countries' (e.g. financial services) (LaU and 
Teubal,  1998:  1370). The objective of these policies is  to  support firms  in  order to 
obtain technological and managerial capabilities. 
Second phase: 
When  firms  have  developed  sorne  managerial,  operational  and  technological 
capabilities, they could upgrade the level of technological complexity. Consequently, 
governments  invest  in  advanced  technological  infrastructure.  This  infrastructure 78 
"serves  high-tech,  leading-edge  industries,  providing necessary R&D  inputs  to  the 
specifie  innovations  of  development  projects  of  user  firms.  The  necessary 
capabilities ... are not available anywhere initially and must be created" (Justman and 
Teubal,  1995:  264).  The  creation  of  sector-specific  capabilities  implies  the 
implementation  of vertical  or  targeted  policies,  which  are  focused  on  specifie 
industries.  Once govemments have made a strategie choice,  they must allocate the 
national resources in a limited number of industries or generic technologies (multi-
agent structures)  (Avnimelech and Teubal,  2008).  Again,  govemments  support the 
innovation activities through institutional adaptation and innovation. 
Although the framework proposed by Teubal and colleagues seeks to  propose a way 
to  design and implement technology policies, they do not mention how to  assess the 
accuracy of programs. The authors mention that positive feedbacks  are  needed and 
govemment agents and policy makers would and should leam over time
15  (Teubal, 
1997; Lall and Teubal, 1998). In this sense, sorne authors have suggested evaluation 
procedures for STI policies (  e.g.  Gheorhgiu and Roesnner, 2000; ECA and Colling, 
2007)
16
, while sorne international organizations such as the OECD have suggested the 
creation of  indicators to monitor and evalua  te programs and policies. 
4.2.1 Importance of  indus  trial po licy 
Economie growth depends on the establishment of new industries or sectors (Rodrik, 
2004). In this  sense, govemments may formulate  a strategy to  identify and support 
specifie industries (Teubal, 2002;  Cimoli et al., 2009). This choice has to  be in  line 
with  macro-economie  policies,  "including exchange  rates,  taxation,  fiscal  policies, 
public investments, govemance of the labor market, and income distribution" (Cimoli 
15 An adequate pattern of  restructuring requires the following: objective evaluation routines within 
government, policy capabilities within goverrunent, and the political power to shut down programs 
(Teubal, 1997: 1182-3); 'policy learning' (Lall and Teubal, 1998). 
16 See 'Evaluation procedures for STI policies' in the Section 4.1.2 of this Chapter. 79 
et al., 2009:  11). 
How  is  industrial  policy  designed  and  implemented?  The  role  of government  in 
industrialized  countries  has  been  to  facilitate  the  mechanisms  to  develop 
technological  capabilities  and  managerial  skills  through  coherent  policies  and 
programs  (Rodrik,  2004).  In  order  to  formulate  and  implement  these  policies, 
govemments  have  worked  closely  with  business  and  industrial  organizations  to 
establish  priorities,  formulate  mechanisms  to  achieve  the  expected  results,  and  to 
react  to  market  and  political  threats,  as  well  as  scientific  and  technological 
discontinuities  (Evans,  1997;  Rodrik,  2004).  Thus,  it  can  be  said  that  close 
relationships between business circles and government institutions facilitate feedback 
mechanisms and allow the improvement of economie organization. Unfortunately, in 
developing countries (and sorne emerging countries) there is  a porous state structure, 
characterized by the  lack of relevant information and corruption (low autonomy of 
bureaucrats); however, in sorne countries there are sorne "pockets of efficiency" that 
could promote growth through public industrial policies (Evans 1997; Rodrik, 2004). 
How is government involved in the creation of new industries? The creation of a new 
industry  often  depends  on  the  strategie  choice  of governments  (Lall  and  Teubal, 
1998; Rodrik, 2004). Two elements are needed to successfully create a new industry: 
1)  choosing  strategie  industries,  and  2)  supporting  the  emergence of new  markets 
(supply and demand).  Govemment often is  in  charge of setting 'national objectives' 
and of allocation resources mechanisms; which  implies making choices and  taking 
risks.  Regarding  the  creation  of new  markets,  on  the  supply  side,  government 
supports the searching of  new ways of doing product or the creation of new products; 
while on the demand si de, government supports the use of those new products (Dalpé 
et  al.  1992;  Lall  and  Teubal,  1998).  Considering  the  two  phases  of STI  policies 
described  above,  in  the  first  phase,  governments  tend  to  facilitate  the  process  of 
'discovery'  in  which  entrepreneurs  can  find  new  technological  processes  and/or 80 
products,  and  establish  coordination  mechanisms  that  allow  firms  to  perform 
independently in a second phase (Lall and Teubal,  1998;  Rodrik, 2004). Here it  is 
important to emphasize the character of the STI policies: they support the creation of 
processes, for example, processes to achieve technological capacities and managerial 
skills (e.g.  leaming processes) more than specifie outcomes (e.g. increase the volume 
of  exports) for short-term (Doner and Ritchie, 2003; Rodrik, 2004). 
4.3 STI policies and Biotechnology 
New industries: the promise of  biotechnologies 
Biotechnology  involves  a  group  of technologies  that  can  be  applied  to  different 
industries.  Biotechnology per se is not an industry. Modern biotechnologies  can be 
seen  as  an  essential  component  of  new  industries  like  biopharmaceuticals, 
bioagriculture,  bioenvironmental  services,  and  bioinformatics.  Biotechnology 
applications  in  industrial  fields  are  perhaps  a  unique  situation  in  which  scientific 
knowledge is very likely to have an indus trial application (Pyka and Saviotti, 2002) 
17
• 
Therefore,  govemments  interested  in supporting  the  development  and  adoption of 
new biotechnologies in different industries (  e.g.  human or animal health, agriculture, 
or  environment)  have  to  consider:  large  investments  in  R&D,  the  importance  of 
scientific advances, and the establishment of relationships between SME developing 
and  using  biotechnologies  and  large,  established  companies  (like  pharmaceutical, 
chemicals,  and  seed  traders).  These  elements  do  vary  in  each  industry,  and  the 
govemment support may affect in different degree the performance of  each industry. 
STI policies supporting biotechnologies 
STI policies targeting the creation and development of biotechnology capabilities can 
17 Particularly interesting is the way in which this group ofteclmologies has affected the 
pharmaceutical industry by providing new techniques that may help in the drug discovery process, or 
may even constitute the core of  a new drug (Pisano, 2006). -------------- - --·-------- - ----- -·--
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be categorized according to the level of formulation and implementation (national and 
sub-national  level)  (Cooke,  2007)  and  their  objectives  (support  of  scientific, 
technological, and commercialization capabilities) (Arundel, 2003).  National public 
policy  is  in  charge  of the  macroeconomie  environment  and  the  scientific  and 
technological  policies  in  general  terms,  while  the  regional  public  policy  often 
encourages  the  agglomeration  of organizations  and  institutions  related  to  specifie 
industries: "national govemments are mainly responsible for delivering science policy 
and basic research funding, while regional govemance system (including private and 
public  sectors)  deliver  innovation  programmes.  These  are  usually  near-market 
incentives  to  firms  to  build innovation networks,  access  co-funding and engage  in 
joint  marketing  to  enbance  innovating  potential  and  competitiveness"  (Cooke, 
2007:1 09). Table 4.4 summarizes the objectives of public policies at the national and 
regionallevel. 82 
Table 4.4 
Objectives and themes of  national and regional STI policies for biotechnology 
Type of  National  Policy themes applied for  Regional 
po  licy  either national or regional 
governments 
Science  Education and basic  Funding for scientific  Creation of 'Centres of 
research in all fields  research and formation and  Excellence' in specifie 
(e.g. human health,  training of specialized  scientific applications. 
animal health,  workforce: 
agriculture,  S&T advisory body, 
environment).  S&T awards from 
government. 
Technology  Infrastructme to  Intellectual property laws,  Promote and facilitate 
support the  Training and guiding  uni  vers i  ty-industry 
coordination  inventors.  linkages in 
between agents in  competitive R&D 
strategie or generic  projects. 
technologies. 
Innovation  Facilitate the  Attraction of risk capital  Attraction of  investors 
diffusion of  (venture capital, angels,  and strategie partner 
technology and the  private research foundations)  to support the 
creation of  markets.  Tax incentives/Tax credits,  commercialization of 
Technology acquisition by  specifie teclmologies. 
the government, 
Technology 
commercialization funds. 
Source: Own elaboratiOn based on Dodgson and Bessant (1996), Cooke (2007), N!OSI and Bas (2004). 
National  and  regional  policies  complement  each  other.  National  govemment  is 
responsible  for  STI  policies  focused  on  fostering  strategie  sectors  using 
biotechnologies in the economy, while sub-nationallevels allocate funds and support 
efforts regarding biotechnologies according to  their resources and size.  In this sense, 
Cooke  (2007)  suggests  the  design  of a  'regional  science  policy'  where  regional 
administration plays an active role in demanding public research funds  and looking 
for  the  support of national and intemational organizations (  e.g.  foundations such as 83 
the Welcome Trust, venture capital) to generate 'Centres of  Excellence' -which could 
be born from centres of  expertise 
18
• 
STI  policies  described  in  the  paragraphs  above  are  based  on  the  expenence  of 
developed countries which have maintained a long-term commitment to ensure funds 
for scientific research, set up favourable intellectual property laws, and facilitate the 
adoption and diffusion of modem biotechnologies (Niosi and Bas.  2004;  Cockburn 
and Stem, 2010).  Contrary to  that, in  sorne emerging and developing countries the 
formulation and implementation of STI policies  are  carried out by underdeveloped 
institutions, suffering from scarcity of resources, and weak capabilities (Niosi, 201 0). 
However, sorne emerging and developing countries 
19  have implemented STI poli ci es 
for  developing  and using  biotechnologies  in  different  sectors,  and  they  have  paid 
special attention to the biopharmaceutical industry. 
In sum, biotechnology enterprises require as  a main input scientific knowledge;  this 
fact  has  a direct implication for  the  science policy.  Most of the  new enterprises  in 
biotechnology are small and their intellectual capital is  their single value asset,  thus 
this should be taken in account when designing intellectual property laws, which is an 
important  part  of the  technology  policy.  As  the  small  biotechnology  enterprises 
evolve they need to collaborate with other organizations (e.g. VC, large firrns). In this 
sense, innovation policies have to be in charge of creating those linkages. In addition, 
it  is  important  to  identify strategie  sectors  and  define  horizontal  and  vertical  STI 
policies. Finally, evaluation and re-design of policies is important in order to improve 
results. 
18 In Canada and the USA, education is a provincial or state responsibility, white centres of excellence 
are mostly national. 
19 Sorne countries have achieved successful biopharmaceutical products: Brazil, China, Cuba, India, 
Israel, Singapore, South Africa, South Korea (Nature Biotechnology, 2004) CHAPTER V 
SYSTEMS OF INNOVATION: THE CASE OF MEXICO 
The concept of national systems of innovation (NSI) has  been an important tool  to 
identify the  different agents  that participate in the  innovation process.  Govemment 
intervention often supports knowledge flows  and leaming processes. However this is 
not an easy issue, especially in developing countries where centralization of  decisions 
and problems of govemance are common. The objective of this chapter is to mention 
the characteristics of  the Mexican national system of innovation. In the first section of 
this chapter,  the definition and characteristics of the NSI are  presented. The second 
section illustrates  the  characteristics of the NSI in  developing countries.  Finally,  in 
the third, the case ofMexico is portrayed. 
5.1  Systems of innovation: national, regional and sectoral 
The concept of national system of innovation appeared in the mid-1980s as  a tool to 
design and implement industrial policies in Europe (Sharif, 2006). Since then, it has 
been used in both academia and policy-making fields (Sharif, 2006; Nelson, 2000) to 
analyze  and  assess  the  interaction  between  agents  and  public  policies  to  support 
innovation. Consequently, the main objective of NSI,  as  analytical framework,  is  to 
identify the main institutions and agents involved in the innovation process as well as 
the interaction between those agents. Often these interactions are supported by public 
policies.  The  NSI  has  been  defined  in  different  ways,  which  stress  different 
components  of the  concept.  For  example,  one  definition  stresses  the  scope  of the 
organizations  involved in the  NSI from  exclusive R&D  organizations  to  all  social, 
political and economie aspects affecting scientific and technological knowledge and 
leaming: 
"the  narrow  definition  would  include  organization  and  institutions involving  in  searching  and  exploring  -such  as  R&D  departments, 
technological institutes and universities. The broad definition ... includes 
all parts and aspects of the economie structure and the institutional set up 
affecting  learning  as  well  as  searching  and  exploring  (Lundvall,  1992: 
12). 
Another definition puts the emphasis in  the broad scope of each component of 
the concept: 
"Innovation [is]  the process by which firms  master and get into practice 
product  designs  and  manufacturing  processes  that  are  new  to  them, 
whether or not to  the universe, or even to  the nation  ... System [is a]  set of 
institutions  whose  interactions  determine  the  innovative  performance  ... 
[N]ational. The concept may be too broad" (Nelson, 1993: 4-5) 
Still, the following definition underlines the institutional aspects of the system: 
"[a]  set  of institutions  that  Uointly  or  individually)  contribute  to  the 
development  and  diffusion  of  new  technologies.  These  institutions 
provide  a  framework  within  which  governments  form  and  implement 
policies to  influence the  innovation process. As  a such it  is  a system of 
interconnected  institution  to  create,  store,  and  transfer  of knowledge, 
skills  and  artefacts  which  define  new  technologies."  (Metcalfe,  1995, 
cited by Sharif, 2006: 745) 
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Although there  are  different NSI definitions,  there  are  at  !east three  main or basic 
elements  for  an  innovation  system  to  exist:  fi1ms,  universities,  and  governments 
(including agencies and STI policies) (Nelson, 2000). The innovation system concept 
seems  to  be  flexible:  it  can  be  adapted  to  the  particular  local  conditions  (social, 
poli ti cal  and  economie),  to  the  different  levels  of analysis  (local,  regional  and 
national),  and  to  the  different economie activities  (sectori
0  (Nelson,  2000;  Sharif, 
2006).  The relevance of the NIS  is  that it  allows governments  to  identify the  basic 
elements and key linkages, and in terms of policy "it helps legitimize the importance 
of  different aspects which are important but underestimated" (Sharif, 2006: 758). 
2°  For more about Regional innovations systems see, for example, Niosi et al (2005); Cooke (2002) 
and Sectoral innovation see Malerba (2004) ------- ---------~ -
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Do all countries have a NSI? It depends on the scope of the definition. On the  one 
band,  the  narrow definition of the  NSI stress  the  generation  of new  technologies 
based on R&D institutions -which requires large investments in  R&D capabilities, 
and generates new knowledge and learning; in this  sense, not all  countries have the 
capacities  to  establish  these  kind  of institutions.  On  the  other  band,  the  broad 
definition of the NSI, suggests that leaming processes can take place in almost any 
circumstance. Given that innovation may be new for the country, for the industry or 
for  the  firrn,  therefore  all  countries  have  room  for  leaming  capacity  (  e.g.  using 
foreign technology) (Shariff, 2006). The broad definition can be applied to  emerging 
and developing countries, but the more restrictive definition put forward by Richard 
Nelson and others is more precise, and also bas different policy implications than the 
larger one advanced by B.-A. Lundvall. It means  that if government is  willing  to 
promote radical technological innovation then it bas to  consider the establishment of 
R&D  organizations  and  STI  policies  aimed  to  foster  scientific  research  and  to 
promote business opportunities for new technologies. 
What are  the incentives to  promote industrialization?  According to  Nelson (2000), 
countries differ basically by their resources endowments and size; for those reasons, 
governments  have  to  make  strategie  choices  about  industries  to  foster.  The  NSI 
reflects  "conscious  decisions  to  develop  and  sustain economie  strength  in  certain 
areas ...  build and shape comparative  advantage" (Nelson,  2000:  16).  Governments 
have to  design and implement public policies  targeting scientific and technological 
progress  in  liJ:?.e  with macroeconomie policies  (such  as  fiscal,  monetary  and trade 
policies) (Cimoli et al., 2009). In this sense, industrial policies are crucial to  identify 
and shape the industries that will become the COfi!petitive advantages of  a country. 
Since  the  1990s;  the  concept of regional  systems  of innovation  (RSI)  has  gained 
relevance. This concept underlines regional characteristics; regions within countries 
also differ according to their resources endowment, and size (in terrns of market size) 87 
(Nelson 2000).  The  importance of regions  resides  in the  close interaction between 
socio-economical agents (Cooke, 2002; Niosi et al., 2005i
1
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In earl  y 2000s, the concept of sectoral system of innovation (SSI) appeared: 
"A sectoral  system  of innovation  and  production  is  a  set  of new  and 
established products for  specifie uses and the set of agents carrying out 
market and non-market interactions for the creation, production and sale 
of those products. A sectoral system has a knowledge base, technologies, 
inputs  and  an  existing  emergent  and  potential  demand.  The  agents 
composing  the  sectoral  system  are  organizations  and  individuals  (  e.g. 
consumers,  entrepreneurs,  scientists) ...  Agents  are  characterized  by 
specifie  leaming  processes,  competencies,  beliefs,  objectives, 
organizational structures and behaviours. They interact through processes 
of communication,  exchange,  co-operation,  competition  and  command, 
and their interactions  are  shaped by institutions  (rules  and regulations). 
Over  time,  a  sectoral  system  undergoes  processes  of  change  and 
transformation  through  the  co-evolution  of  its  various  elements." 
(Malerba, 2002: 250) 
In brief, the building blocks of the sectoral systems are:  knowledge and technology, 
actors and networks, and institutions (Malerba, 2002). The relevance of a SSI relies 
on interactions  that take place within a sector:  "it forms  the  locus  of interaction of 
numerous networks generating particular kind of knowledge"  (Edquist et al.,  2004: 
440).  Knowledge,  technologies,  actors,  institutions  and  interactions  are  specifie  to 
each  sector  and  have  implications  for  the  development  of  those.  Therefore, 
govemments  willing  to  support  specifie  sectors  have  to  identify  the  specifie 
knowledge, agents and interaction related to the sectors. 
Given  that  the  creation of new  technology requires  large  investments  in terms  of 
funds  and human resources, in each country the concentration of those resources is 
often placed on few  regions  and in  few  technologies.  The following  section deals 
with the implications ofNSI, RSI and SSI for developing countries. 
21  The definition of  this concept is presented on section 3. 1 in the Chapter III. 88 
5.2 Innovation systems in emerging and developing countries 
As mention above, one of  the main objectives of  the system of innovation approach at 
any level (region, sector or nation) is  to  guide policy makers in the formulation and 
implementation of STI policies in a coherent way. The innovation systems literature 
emerged in the context of developed countries, which present historical  conditions 
(  e.g.  institutions  related  to  the  system  of  govemance  and  accountability)  and 
resources (e.g. funds, human resources, state-of-the-art research institutes) that allow 
them to create and support technological innovations. 
Since the  1990s, sorne authors have analyzed the  environments and policies carried 
out by the govemments of emerging and developing countries (  e.g. Argentina, Brazil, 
Korea,  Singapore,  Taiwan  and  others,  more  recently  China and  India). The  most 
salient characteristic of successful innovation systems in emerging countries is  that 
most of them are focused on one or a few high technology sector(s)
22  (e.g.  Korea on 
automobile and electronics, Singapore on micro-electronics and biopharmaceuticals, 
India on information technologies, Israel on software and biotechnology, Brazil on 
aircraft). High technologies involve science and technology inputs and sophisticated, 
complex manufacturing.  In order to  create these  high-value products, governments 
have made large investments in qualified education and training,  support high-tech 
enterprises,  and  build  govemment  agenciès  in  order  to  coordinate  the  efforts. 
Govemments in emerging countries have  focused  on few  high  tech sectors, and in 
most  cases,  the  organizations  (universities,  enterprises  and  govemment  agencies) 
related to  these sectors are  located in  specifie regions.  As  mention before (Chapter 
IV),  the  govemment efforts  to  encourage  and  support a  variety  of capabilities  to 
generate and commercialize sophisticated products must be accumulated over time. 
Successful emerging countries have followed a pattern in the implementation of STI 
22 The exception is China, which seems to be pursuing a very broad spectrum of  high-technology 
industries at the same time. 89 
policies:  i)  support  for  the  creation  of techno1ogical  capabilities  (education  and 
training); horizontal policies, ii) the prioritizing industrial sector (high-, medium-, and 
low- technologies); and establishing vertical policies. 
5.3 National innovation system of  Mexico 
The  aim  of this  section is  to  outline  the  characteristics  of the  national  system  of 
innovation (NSI)  of Mexico.  As  mentioned above,  the  NSI concept involves  three 
main elements: knowledge-creation institutions, enterprises and government agencies. 
In turn, each of  these elements includes different agents and relations between them. 
5.3.1 Economie performance 
Although the process of industrialization in Mexico started in  latel880s, the role of 
the  government  as  designer  of industrial  policy  started  circa  1930  (Haber,  1989). 
Since then, different industrial policy approaches have been adopted (i.e.  attraction of 
foreign  investment,  import  substitution).  Recently,  the  OECD  carried  out  an 
assessment of the economie performance of Mexico. The document summarizes the 
results as follows: 
"Mexico's economie performance in terms of growth of GDP per capita 
has  been respectable but still insufficient to  close  the gap  vis-à-vis  the 
most  advanced  OECD  countries  in  terms  of the  population's  living 
standards and overcoming widespread poverty. To shift the economy to a 
path of higher, sustainable  growth,  Mexico's economie policy needs  to 
boost productivity growth.  In  the  past,  it  has  been sluggish. Given  the 
salient role of innovation in driving  the  long-term productivity growth, 
the  challenge  is  to  encourage  innovation  throughout  the  Mexican 
economy. Achieving this goal will require significant, broad-based reform 
and dedicated efforts." (OECD, 2009a: 63). 
5.3 .2 Public poli  ci es and the formation of the NSI 
Government pla  ys  a major role in the transformation of economies. In this sense, the 90 
consolidation  of a  NSI  depends  OJ!  the  evolutionary processes  of public  policies. 
Dutrénit  et  al.  (20 1  0)  analyzed  extensive1y  the  historical  evolution  of science, 
technology  and  innovation  policies  in  Mexico.  According  to  these  authors  the 
evolution of STI policies can be divided into four phases: 
Phase I 1935-1970: The foundation of the knowledge-creation institutions, 
Phase II 1970-1981: The creation ofthe CONACYT, 
Phase III 1982- late-1990s: Structural changes, 
Phase IV After 1999: Efforts to design innovation policies. 
Phase e
3  is  characterized by the  establishment  of universities
24
,  national  research 
institutes,  and  university  research  centres.  In  this  period,  sorne  domestic  large 
enterprises  established  R&D  facilities  in  different  sectors  such  as  cement,  steel, 
chemistry,  pharmaceuticals,  glass,  and  brewing.  These  organizations  shaped  the 
scientific and  technological activities in this  phase. In addition, two  developmental 
agencies were created: Nafin (a development bank)  and Bancomext (a trade  bank). 
These  agencies  sought  to  encourage  technological  activities. The  main  feature  in 
Phase  II  was  the  creation of the  National  Council  on Science  and  Technology of 
Mexico (CONACYT in Spanish). Since then, the mandate of this institution has been 
to  design and implement science and technology policies according to  the economie 
policy  of the  country.  New  organizations  were  created,  such  as  research  public 
centres, national research institutions, and new higher education institutions. In Phase 
III,  incentive  programs  were  implemented  to  improve  the  perfonnance  of the 
knowledge-creating  institutions  (  e. g. the  National  System  of Researchers,  SNI  in 
Spanish).  However,  the  national  government  subsequently  adopted  neo-liberal 
23 The description of the four phases ofSTI policies is based on Dutrénit et al.  (2010) Ch. 3, pp. 142-
152. 
24 The National Autonomous University of Mexico (UNAM in Spanish) was founded in 1910. The 
National Polytechnic Institute (IPN in Spanish) was creates in 1936 with the mandate to generate 
human resources to accomplish industrial and applied research for the economie development of  the 
country (Dutrénit et al., 2010: 143). 91 
policies that limited its intervention in the economy.  Consequently, the national STI 
policies were almost entirely focused on the education system. In the 1990s, a variety 
of  programs were created to encourage the development of  technology and innovative 
capabilities by the private sector. These programs aimed to encourage R&D activities, 
technological  upgrading,  strengthen  scientific  and  technological  capabilities,  and 
promote  the  university-industry  partnerships  as  well  as  establish  incubators  for 
technology-based firms.  Also,  the  government introduced sorne  changes  related to 
Intellectual  Property Law.  In  Phase  IV,  the  Law  for  the  Promotion of Scientific 
Research  and  Technological  Development  (1999)  was  implemented.  This  set  the 
basis  for  designing  the  scientific,  technological  and  innovation  policies  in  recent 
years. 
After  this  process  of creation  and  restructure  of organizations,  institutions  and 
policies, the current Mexican NSI includes the following agents (Dutrénit et al., 2010: 
63-92): 
Govemment organisms and institutions 
National council of science and technology, CONACYT; 
Scientific and technological consultative forum, FCCT; 
National network of state councils and organizations for  science and 
technology, RENACECYT; 
Science and technology committees of the legislature 
Public research institutes 
Public research centre-CONACYT (under the aegis of Conacyt); 
Public research centres, PRC (run by different Ministries); 
Research institutes and centres (administrated by HEis). 
Mexican system of  higher education institutions, HEL 
Innovative enterprises in the private sector. 
Intermediate funding  and coordinating institutions  (such as  foundations  and 92 
associations). 
At least part of the financial system. 
The  Mexican  NSI  includes  a  variety  of organizations  and  institutions  that  have 
different interest; this circumstance affects interactions between agents. Dutrénit et al. 
(2010: 92-94) summarize the relationships between agents within the NSI as  follows 
(see Figure 5.1): 
"The Mexican NSI has  two  main characteristics  regarding  interactions 
[between agents].  First, the productive sec tor acts  almost as  an isolated 
agent within the  system.  Although it maintains strong interactions with 
the govemment -which is mainly a result of macro-economie policy and 
sorne industrial incentives from govemment regulations- there is  a clear 
lack of regular linkages with other economie and social agents ... the  re are 
not  strong,  dense  and  regular  ties  with  intermediate  and  financial 
institutions. Neither are there strong ties to generate knowledge (HEl and 
PRC)  .. . The weakness  of these linkages  is  a  key factor  to  ex  plain the 
slow  development  of national  innovation  capabilities.  Second,  most 
interactions  take  place  between  public  institutions  [CONACYT  -public 
HEis,  CONACYT  -PRC,  and  between  public  HEis  and  PRC]  ...  This 
configuration  has  been  built up  over  the  years,  from  a  STI  [science, 
technology and  innovation]  policy based on a  linear  conception of the 
innovation pro  cess ...  where production and trans  fer of knowledge from 
HEis [universities] and PRC [public research centres] were at the centre 
of the system." Figure 5.1 
Interactions between agents of  the Mexican NSI 
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Therefore, the Mexican NSI is unstructured based on the fact that:  the private sector 
and  the  knowledge-creating  organizations  have  different  interests  (Cimoli,  2000; 
Dutrénit  et  al,  201 0),  In  order  to  improve  this  situation,  in  the  last  decade,  the 
Mexican government has implemented sorne programs and policies to foster domestic 
technology development as well as  emphasize research collaboration and promote its 
relevance  for  enterprises  in  order  to  accomplish  successful  innovative  products ------------------- ------------------------------------------------------------------------~ 
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(OECD, 2009a). Some of the programs and policies are the following: 
•  Science  and  Technology  Laws  1999  and  2002  (Leyes  de  Ciencia  y 
Tecnologia):  they  are  se  laws  are  focused  on mechanisms  to  improve  the 
interactions and coordination between agents 
•  Science and Technology Special Program 2002-2006 (Programa Especial para 
la Ciencia y la Tecnologia, PECYT) the main objective of this pro gram was to 
guide the design and implementation of public policy to improve the National 
System of  Researchers (SNI). 
•  Science, Technology and Innovation Special Program 2007-2012 (Programa 
Especial en Ciencia, Tecnologia e Innovaci6n, PECITI)  the  objective of this 
program is to reinforce the PECYT 2002-2006. 
Definition of  priorities 
One of the main objectives of the NSI is to  identify the organizations and institutions 
that contribute to innovation. In the case of more sophisticated products (such as high 
tech products), the  locus  of innovation is  located in networks of specialized inputs 
(Powell et al., 1996). In order to ·enable the interaction between different agents, some 
governments in industrialized countries have developed institutional frameworks and 
implemented a coherent package of STI policies. As mentioned in the Chapter 4, the 
design  of STI  policies  takes  in  account  priorities  rooted  in  the  national  context 
(  existing  capabilities  and  political-socio-economical  environments  ).  However,  the 
establishment of those priorities seems not to  be an easy task, especially in a country 
where  different  groups  of interest  do  not  arrive  to  a  consensus  about  the  basic 
socioeconomic needs. 
According to  Dutrénit el al.  (2010), the Mexican govemment has faced problems to 95 
define the priority sec tors that would guide the economie development of the country. 
Although the  mandate of CONACYT is  to  design and implement the  STI policies, 
this task has been limited by the "scientific elite, which has a strong influence on the 
establishment of priori ti es  and the design of the STI policies" (Dutrénit et al., 2010: 
153). In the last decade, sorne efforts have been made in order to define the strategie 
sectors of the country:  for  example,  the PECYT 2001-2006 attempted,  for  the  first 
time,  to  define  the  strategie sectors;  however,  that  definition was  in  a  broad way, 
without clear specifications of goals. The PECITI 2007-2012, after sorne prospective 
studies, defined eight strategie areas: 
•  Food and agro-industry 
•  Aeronautics 
•  Automobile and auto parts 
•  Electrics and electronics 
•  Pharmaceutical and health sciences· 
•  Metallurgy 
•  Metal-mechanics and capital goods 
•  Chemical and petrochemical 
As mentioned in the section 5.1, each sector requires a specifie knowledge base and 
has  different  dynamics  to  generate  and  exploit  business  opportunities.  Therefore: 
"one  of the  problems  govemments  may  face  is  the  inability  to  understand  the 
specificity of the sector, the technology or the institutional setting in which po licy bas 
to take place" (Edquist et al., 2004: 442). 
5.3  .3 Regional systems of  innovation in Mexico ---- ---~ ------- --- -
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Empirical research has shown that enterprises, especially in high-tech sectors, tend to 
agglomerate in specifie geographical areas, emphasizing the importance of regions in 
economie development. Therefore, regional innovation policies can be seen as  a tool 
to  reach  national  innovation  (OECD,  2007).  However,  national  policies  play  an 
important role in defining the  macroeconomie environrnent and strategie sectors.  In 
the  case  of Mexico,  "the national  policy  framework  does  not  sufficiently support 
clusters or regional innovation systems" (OECD, 2009b:  20).  In Mexico there exist 
strong regional disparities that are reflected in economie performance, education and 
training,  and  poverty.  These  disparities  are  the  result  of a  lack  of coordination 
between  the  national  and regional  policies  and  other structural  and  administrative 
problems: 
•  The central government concentrates the basic tax responsibilities; states have 
few tax capabilities and suffer chronic financial deficits; they are thus unable 
to nurture by themselves any regional innovation system. 
•  The  national  policy  framework  does  not  support  sufficiently  cluster  or 
regional innovation systems, it does not acknowledge the spatial dimension of 
the sectors being supported. 
•  High level of territorial concentration of innovation resources (funds, science 
and technology human resources, infrastructure) in the capital city. 
•  Lack of  vertical coordination, low transparency. 
•  Lack of coordination between federal  and state  levels  to  formulate  policies 
attracting FDI, and how  this  could be related and supported by science and 
technology policies. 
•  Lack of  long-term strategy at national and sub-nationallevel. 97 
•  There is not a clear po licy to support the development of SMEs and indicators 
to track firm development over time. (OECD, 2009b: 21-22) 
In recent years, the government of  Mexico has implemented new programs in order to 
emphasize  research  collaboration  and  its  relevance  for  enterprises  in  order  to 
accomplish innovative products: 
•  Scholarships and the National System ofResearchers. 
•  Tax  credits  (focused  on  SME,  new  technologies  and  improvement  of 
competitiveness  ). 
•  CONACYT  mixed  funds,  FOMIX  (focused  on  scwnce  and  technology 
promotion at sub-nationallevels). 
•  FORDECYT  (this  program  complements  FOMIX,  "the  fund  has  an 
innovative  approach  by  targeting  both  geographie  regions  (neighbouring 
municipalities  or  stated)  and  thematic  regions  (group  of municipalities  or 
states that share a common problem) (OECD, 2009b  ). 
However,  the  mechanisms  to  assess,  monitor,  and  evaluate  the  sc1ence  and 
technology  capacities  at  sub-national  level  remain  unclear:  "there  are  no  formai 
assessments of sub-national science, technology and innovation needs or mechanisms 
for  recognizing the nature of science and  technology expertise by region"  (OECD, 
2009b: 25). 
In sum, the current Mexican context offers too few incentives to push private firms to 
conduct R&D  activities -by their own or in collaboration- and innovate:  there is  a 
lack of financial support and efficient legal frameworks that can stimulate the flow of 
knowledge  and  learning;  in  terms  of STI  policies  there  are  problems  to  define 
priori  ti es  (  e.g.  strategie  sec  tors),  and  there  is  a  lack  of mechanisms  to  design, 98 
implement and assess the pertinence and coordination of them. 
Recently,  in  2009,  the  S&T  policy  was  modified,  an  Inter-sector  Committee  for 
Innovation  was  created  to  design  and  implement  innovation  policies
25
.  This 
institutional  body  allows  collaboration  between  government,  enterprises  and 
universities. 
In  sum,  it  seems  that  the  Mexican  institutional  framework  has  generated  sorne 
incentives  to  explore new  technologies  through  scientific  activities;  however sorne 
obstacles  persist  and  they  hinder  the  collaboration  between  different  agents.  The 
efforts  to  foster  scientific  research  are  falling  short  in  terms  of the  number  of 
institutions  dedicated  to  biotechnology  research  (see  Chapter  VIII)  and  the 
government  investment  in  R&D  activities.  Table  5.1  shows  the  government 
investment  in  R&D  activities  with  respect  to  the  GDP  in  the  period  1999-2008; 
Mexico not only has  the  lowest percentage among the  OECD members, but also  it 
has decreased to reach 0.37%, while other emerging countries like China, Brazil and 
India have a higher percentage than Mexico and also  increased in the  same period 
(OECD, 2010). 
25  Comité  Intersectorial  para  la  Innovaci6n  (Cil)  in  Spanish.  Information  retrieved  from 
http://www.economia.gob.mx/comunidad-negocios/innovacion!innovacion-comite  (Accessed  on  24 
February 2012). 99 
Table 5.1 
Gross Expenditure on R&D activities as percentage of GDP 
Country 
1999 or first  2008 or latest 
available year  available year 
Selected OECD members 
Sweden  3.61  3.75 
Japan  3.02  3.44 
United States  2.64  2.77 
German  y  2.40  2.53 
United Kingdom  1.82  1.88 
Canada  1.80  1.84 
Ital y  1.02  1.18 
Mexico  0.39  0.37 
Non-OECD members 
China  0.76  1.44 
Brazil  1.02  1.13 
In  dia  0.77  0.88 
South Africa  0.73  0.95 
Source: Factbook OECD 2010 (mformatwn retneved August 30, 2011). 
In spite of a weak institutional framework and the absence of crucial actors for  the 
adoption  of  biotechnologies,  sorne  firms  are  adopting,  using,  and  developing 
biotechnologies in Mexico. CHAPTER VI 
THEORETICAL FRAMEWORK 
The objective of this  chapter is  to  present the  integration of the  different concepts, 
reviewed in the previous chapters in order to  analyze the theoretical question of this 
dissertation, which is to understand firms' adoption of generic high technologies th at 
usually  require  complementary  knowledge  from  other  agents,  in  an  institutional 
environment not well developed in terms  of knowledge production, financing,  and 
small government support. 
The strategie management literature includes the concept of business models that is 
useful  to  analyze  why  and  how  agents  create  and  capture  economie  value.  The 
relevance of this concept relies in the fact that biotechnology enterprises are science-
based businesses, which require a degree of scientific capabilities to create economie 
value.  However,  capturing  economie  value  from  science-based  products  is  not 
evident.  It depends on internai and external factors  to  the fitm.  Internai factors  are 
related  to  the  strategies,  value  chain/capabilities, partners/value  networks,  location 
and  finance  structure,  white  externat  factor  are  associated  to  scientific  and 
technological progress, and changes in policies and consumer preferences. In order to 
identify  the  business  models  adopted  by  biotechnology  enterprises  in  emerging 
countries I considered two main elements: capabilities and collaborations. Given the 
scientific knowledge base of biotechnologies and the variety of organizations that are 
involved in the creation ofbiotechnology products, the type of capabilities (scientific, 
production  and  commercialization)  and  collaborations  define  the  biotechnology 
business  models  (Figure  6.1).  The  externat  factors,  in  turn,  are  related  to  the 
institutional  environments  in  which  the  finn  interacts.  I  use  the  term  institutional 
environment to describe the policies and institutions that allow the scientific progress 
and  the  interaction  between  different  actors  to  achieve  the  creation  and 
-----, commercialization of biotechnology products. 
Figure 6.1 
Components of business models in biotechnology 
• Scientific/ research capabilities 
Capabilities  • Managerial capabUities 
• Production and sales capabilities 
(Hyd<ll. 2DIO; Ahboti,  20 i 0 ~ Hollw•y)OW) 
Collaborations 
• Universit:ies and research centres 
• Firms (DBF and ~1NE) 
• Funding organizations (VC, private equity, gov. agcncles) 
Business 
mo dels 
• Other support organizations (associations, incuba  tors) 
Cl a.~s ical 
bio tech 
businEss 
model 
'Large, vertical 
intcgrated 
busine.1 s madel 
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I  used  three  concepts  of the  high  technology  agglomerations  literature  - clusters, 
regional  system  of  innovation  and  anchor  tenant- to  analyze  what  kinds  of 
organizations are present, what kinds of relationships are established and who is  the 
main attractor in a biotechnology agglomeration in the different stages of its lifecycle. 
Scientific knowledge is  a key input to develop biotechnology products. In this sense, 
universities and research centres and the heterogeneity or specificity of the scientific 
knowledge  play an  important role,  as  anchor tenants,  to  create new enterprises  or 
attract other organizations. Also, the  government support plays an important role to 
encourage entrepreneurship and attract experienced enterprises, which can contribute 
to the growth of the agglomeration (Figure 6.2). Figure 6.2 
Lifecycle stages of  a biotechnology agglomeration 
Cluster (C): 
v'ibo are there 
(Sw-.tt <1 al, 1998; 
Aud:tèl'lth 2001; 
Otioroni •ll<l Cllieia, 2006) 
Regional system 
of  innovation 
(RSl) : What are 
the interactions 
(N:o~i l!rtd  nas ~ 2(10 l ,2003; 
Nio!li tt at 2003; 
Cook<. 201l2, !007) 
Anchortenant 
(AT): 
Who is the 
main attractor 
(l'dJo""' 2003) 
Embryonic stage 
• C, RSI: univernities and research labs 
• AT: universities and rcsearch labs and 
enterpriscs 
Creation stage 
• C, RSI, AT: univcrnities and research labs 
BUT, AT:  firms has the managerial and 
commercial expertise 
Growth stage 
•  C: entrcpreneurship, 
•  RSI: entrepreneurship and creation of  new 
inst. 
• AT: cntrepreneurship with expertise in the 
technological path. 
Different 
knowlcdgc 
Definition 
of 
tech ni cal 
profile 
' 
Technical 
profile+ 
new 
knowledge 
./ 
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Finally,  I used  the  STI policy literature  to  analyze and  identify how governments 
could  intervene  for  supporting  the  adoption  of high  technologies.  ln the  case  of 
biotechnologies,  governments  have  to  play  an  active  role  in  the  development  of 
institutional environments, through the creation of organizations and implementation 
of STI policies, which allow the interaction between different actors and support the 
growth of  enterprises (see Table 4.4, Chapter IV). 
Table  6.1  integrates  the  different  concepts  used  as  theoretical  framework  in  this 
dissertation.  Column  names  show  the  lifecycle  stages  of  a  biotechnology 
agglomeration,  while  rows  names  show  the  relevant  elements  of a  bioteclmology 
agglomeration.  Therefore, reading the  table from  left  to  right the  integration of the 
concepts is as follows: 
Emergent stage: Knowledge creating-organizations play an important role as anchor 103 
tenants.  Few  scientists/entrepreneurs  from  these  knowledge-creating  organizations 
found small start-ups and they maintain informai collaboration with their colleagues 
to  have access to  the  state-of-the-art knowledge and know-how. Maybe sorne angel 
capitals or venture capitalists are present in the region and they can provide financial 
support  to  the  start-ups.  Based  on these  characteristics  these  star-ups  adopt  BDF 
business model. 
Transition  stage:  knowledge-creating  organizations,  still  play  the  role  of anchor 
tenant, and begin to define the technological profile of the agglomeration. More start-
ups  are  founded  and sorne  alliances with other actors  appear, for example, venture 
capitalists  start  to  support  new  ventures.  In  addition,  governments  create 
organizations  and  design  programs  to  support  entrepreneurship.  Biotechnology 
enterprises adopt DBF, product and platform business models. 
Growth stage:  the agglomeration has developed a specifie scientific base and more 
start-ups  are  founded.  Large  firms  -with  production  and  commercialization 
capabilities- are  attracted  to  the  agglomeration,  and  may  play  the  role  of anchor 
tenants.  There  are  dense  collaborations  between  different  organizations.  Venture 
capitalists  are  more active and government implements programs  to  support firms' 
growth. Biotechnology enterprises adopt DBF, product and platform business models. 
Sustain stage:  the  agglomeration maintains  its  scientific  base, which attracts  more 
firms.  Collaborations  are  stable  and venture  capitalists  are  present  in  the  location. 
Governments  implement  specifie  programs  to  attract  new  actors.  Biotechnology 
enterprises adopt DBF, product and platform business models. 
New opportunities:  new knowledge is generated and collaborations with new actors 
are  established.  Government is  active supporting the  adoption of new technologies 
and the creation of  new markets. New business models emerge. 1
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 CHAPTER VII 
HYPOTHESES AND METHODOLOGY 
This chapter has two objectives:  the first one is  to  recall the objective and questions 
of this research, and to  present propositions and hypotheses. The second objective is 
to present the research design for this thesis. 
7.1  Research objectives and questions 
The general  objective of this  research is  to  understand firms'  adoption of generic 
high technologies that usually require complementary knowledge from other agents, 
in an institutional environment not weil developed in terms of  knowledge production, 
financing and small govemment support. I propose to  analyze this situation with the 
case  of Mexico,  which  is  an  emerging  country  that  recently  has  started  to  adopt 
biotechnologies, and three groups of  research questions are presented: 
•  Ql What kinds  of biotechnology users, actual or potential,  exist in  Mexico 
and what kinds of biotechnologies have been adopted? What business models 
are emerging in the Mexican-specific economie environment? 
•  Q2  Given that high technologies tend to  agglomerate, does Mexico have the 
potential  to  create  and  support  a  biotechnology  cluster?  What  kinds  of 
collaboration, if any, have emerged? 
•  Q3  How  public  policy  framework  could  be  improved  in  an  emergmg 
economy such as  Mexico in order to  support the  adoption and diffusion of 
high technologies, especially biotechnologies? 
7.2 Hypotheses 
In order to  operationalize and contextualize these questions  in  a meaningful way, I 
present sorne propositions  that take  into  account the context of emerging countries. - - ---------- ------- -·--------
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However this  research has  neither the  time nor resources to  analyze and test all of 
them,  th  en  I  decided  to  enunciate  these  propositions  as  'General  hypotheses'.  In 
addition,  based  on  the  literature  review  and  research  question,  I  propose  sorne 
empirical hypotheses (H) that will be test for the case of  Mexico. 
7 .2.1 Business models 
In  the  strategie  management  literature,  a  business  model  is  a  planning  tool  for 
enterprises that includes two main processes: creating economie value and capturing 
that value (Magretta, 2002; Chesbrough, 2007).  A business model also  involves an 
ongoing process of evolution and adaptation (Shafer et al., 2005; Francis and Bessant, 
2005;  Chesbrough, 2007). Interna]  and externat elements can influence the  manner 
through  which  enterprises  accomplish  these  processes  (Onetti  et  al.,  2010).  The 
internat elements are those related to capabilities, while externat elements are related 
to  interaction  with  other  organizations  and  institutions  (Teece,  201 0).  In  the 
technological  change  and  evolutionary  economies  literatures,  the  enterprises' 
technological and managerial capabilities are crucial for the accomplishment of R&D 
and other innovative activities (LaU,  1992; Kim, 1997; Niosi and Bas, 2001).  Also, 
collaboration agreements  play an important role  to  complement firms'  capabilities 
and  knowledge,  especially  in  enterprises  using  high  technologies  (Powell  et  al., 
1996).  In  the particular case of biotechnology, R&D capabilities are crucial for the 
enterprise  perforn1ance  (Hayden,  201 0;  Abbott,  201 0),  besides  technological 
capabilities  (production  activities)  and  managerial  capabilities  (organizational 
activities  ). 
In the case of advanced OECD countries, biotechnology enterprises have developed 
business  models  closely  related  to  scientific  results.  Therefore,  discoveries  in 
different  disciplines  have  been  associated  with  more  complexity  and  diversity 
(McKelvey,  2004),  generating  opportunities  for  the  creation of new products  and 107 
enterprises. In developed countries, two well-defined business models have emerged: 
the  classical  biotechnology  model  (based  mainly  on  R&D  activities)  and  the 
vertically integrated company business model (integrating the complete value chain, 
from  R&D to  commercialization) (McKelvey, 2008) or 'Genentech model'.  As  the 
use  of biotechnologies  has  expanded,  different  business  models  have  emerged 
depending of the socioeconomic conditions of each country (Fisken and Rutherford, 
2002; Nosella et al.,  2005; Konde, 2009). Emerging countries like China, India and 
Brazil have encouraged and supported the creation of biotechnology enterprises; they 
have  attempted  to  reproduce  biotechnology  business  models  from  developed 
countries, particularly the classical business model (based mainly on R&D activities). 
In  other  emerging  and  developing  countries,  relevant  components  that  allow  the 
adoption  of the  well-defined  biotechnology  business  models  are  missing  (such  as 
R&D capabilities, collaborations and competitive markets), nevertheless, enterprises 
in these  countries still have adopted modern biotechnologies and have created new 
products (Nature Biotechnology, 2010). 
General  Hypothesis  1:  Given  the  scarcity  of financial,  human  and  technology 
resources  and  the  lack  of government  vision  to  establish  priorities.  Therefore,  a 
variety of business models, which differ from those of developed countries, are likely 
to arise in order to adopt modem biotechnologies in such conditions 
General  Hypothesis  la:  Even if the  generation  of biotechnologies  has  achieved 
limited success in emerging and developing countries, sorne of the ir applications have 
been used in production processes in those countries. Given that local firrns are more 
concemed with biotechnology applications rather than biotechnology generation, they 
tend to pursue "imitative innovation" business models. 
General Hypothesis lb: Biotechnologies require a certain degree of capabilities and 
resources  by the  finn using  them.  Since  the  institutional  infrastructure  supporting 108 
biotechnology is weak in sorne emerging and developing countries, firms have to rely 
to a great extent on their own expertise and resources. 
General Hypothesis 2:  Internai elements like strategy or financial structure are not 
the  only  orres  that  affect  the  generation  of a  business  model;  the  environment in 
which enterprises perform also has an impact on the kind of business models  these 
enterprises may adopt. 
Ql. What kinds ofbiotechnology users, actual or potential, exist in Mexico and what 
kinds of biotechnologies have been adopted? What business models are emerging in 
the Mexican particular economie environment? 
Hl. In an emergent stage of a biotech cluster within an emerging country with 
limited institutional support, the business models that are more likely to emerge 
are  more  related  to  exploitation  and  imitation  capabilities  rather  than 
exploration capabilities. 
7 .2.2 Geographie agglomerations 
High  technology  enterprises  tend  to  agglomerate  in  specifie  geographie  areas 
(Sexenian,  1994;  Swann  et  al.,  1998;  Niosi  et  al.,  2005),  given  the  positive 
extemalities  they  can obtain in  specifie  areas,  such  as  qualified  human resources, 
specialized services,  and access  to  funding  (Braunerhjelm and Feldman, 2006). At 
least  three  concepts  have  been  used  to  analyze  the  creation  and  evolution  of 
agglomerations: cluster, regional system of innovation and anchor tenant. The Cluster 
literature has  pointed out the participants of the  agglomeration (Porter, 2000:  254, 
2003;  Braunerhjelm  and  Feldman,  2006).  The  Regional  system  of innovation has 
focused on the analysis of the interaction between the agglomeration actors (Cooke, 
2004; Niosi et al., 2005). Finally, the anchor tenant concept stresses the role of main 
attractor(s)  to  the  agglomeration  (Agrawal  and  Cockbun,  2003).  The  creation  of 109 
agglomerations  is  caused  by  three  different  events:  1)  relevant  organizations  are 
already in the geographie area,  2)  changes in policies and laws push foundation of 
new enterprises, and 3)  govemment mandate. Whatever the  triggering event is, the 
development of high tech agglomerations depends upon the government intervention 
for  building an  environment that allows the  creation, attraction, and design of new 
organizations and institutions (Cockbum and Stem, 2010;  Feldman, 2003, Chiaroni 
and Chiesa, 2006). 
Different scho1ars have used these concepts to analyze biotechnology agglomerations 
in  developed  countries.  They have underlined  the  relevance  of specifie  agents  to 
adopt modem biotechnologies: universities, research centre, research laboratories in 
large  enterprises  (Swan  et al.,  1998;  Audretsch  2001;  Chiaroni  and  Chiesa,  2006; 
Niosi et al.,  2005;  Cooke, 2002, 2007; Feldman, 2003).  Since the  mid-1980s, sorne 
emerging  countries,  for  instance  China,  India,  and  Singapore,  have  attempted  to 
create biotechnology clusters  imitating  organizations  and  institutions  of developed 
countries;  however,  the  potential  to  create  and  maintain  biotechnology 
agglomerations  relies  on  the  existence of resources,  organizations,  institutions  and 
public policies, which sometimes are not available. 
General  Hypothesis  3: Even though  sorne  emerging and developing countries  do 
have  an  important  scientific  base  able  to  perform  cutting-edge  research  in 
biotechnology, attempting to launch complex biotechnology-related products is rather 
difficult. This is because there is a lack of  relevant agents that provide support for the 
commercial development of those products (  e.g. research agencies with star scientists, 
experienced financial organizations, testing product organizations). For this reason, in 
countries  with  an  underdeveloped  system of biotechnology  support,  the  more 
likely efforts are to be found in low to medium complex biotechnologies. 
General Hypothesis 3a: Although in emerging countries finns rely to  a great extent ~~------- ~--------
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on their own resources, modern/complex biotechnologies usually require a varied set 
of capabilities that no  single firm can master entirely. Therefore, these firms need 
to  look for  sorne  collaboration  wüh  external  agents,  at  least  to  a  certain degree. 
When they do not find a suitable partner in their home country they will try to  find 
one abroad. 
General  Hypothesis  4:  In countries  with  unstructured  institutional  environments, 
there  is  no  specifie  anchor  tenant.  Knowledge-creating  organizations  and 
enterprises may adopt biotechnologies but their capabilities and their location are the 
result ofhistorical events (almost no relation to biotechnology). 
General Hypothesis 5:  In environments where there is  a lack of incentives to  create 
new  start-ups,  the  more  likely  source  of entrepreneurship  is  large  companies, 
which have the  commercial, productive, and scientific capabilities to  apply modern 
biotechnologies. 
General  Hypothesis  6:  In  the  initial  stage  of a  biotechnology  agglomeration 
lifecycle,  the  support for  scientific and  technological  capabilities  is  not enough  to 
foster new businesses. Although these capabilities are relevant, the development of 
biotechnology  agglomerations  relies  enormously  on  the  financial  system  (venture 
capital,  stock market,  banks,  government  agencies)  and  on  the  organizations  and 
institutions  focused  on  supporting  managerial  and  networking  capabilities 
(technology transfer offices, government agencies, associations). Therefore, countries 
looking to  foster biotechnology agglomerations  often put in place initiatives that 
facilitate  technology  transfer,  and  support  different  business  models  that  are 
emerging from large enterprises and SMEs. 
General  Hypothesis  7:  As  a  result  of policies  a1mmg  for  advancing  scientific 
knowledge  related  to  biotechnology,  research  centres  and  laboratories  have  been 
created. Since the policy approach has  been most often based on the linear mode!, 111 
other types of institutions are not well developed or are even inexistent. 
Q2:  Given that high teclmology enterprises tend to  agglomerate, does Mexico have 
the  potential  to  create  and  support  a  biotechnology  cluster?  What  kinds  of 
collaboration, if  any, have emerged? 
H2:  In  the  emerging  stage  of a  biotechnology  agglomeration  in  emergmg 
countries,  with  weak  financial  support  for  new  ventures  and  a  poor 
entrepreneurship  drive,  universities  and  research  centres  partially  act  as 
anchor  tenants  by  means  of  project  collaborations  but  not  as  spin-off 
generators, which may be accomplished in later stages. 
H3: Companies that have developed scientific capabilities are more likely to 
establish  collaborations  with  national  -and  international- partners  for 
exploration activities.  Universities and  research  centres would be the  more 
likely  targets  of  collaboration  for  firrns  seeking  to  nnprove  or 
complement/upgrade their capabilities. 
7.2.3 STI policy 
The role of government is  to  create and diffuse technological knowledge, stimulate 
learning processes, and create and maintain a coherent institutional system through 
public policies (Dalum et al.,  1992; Niosi and Bellon, 1995; Carlsson, 2006; Cimoli 
et al.,  2009;  Cockburn and Stern, 2010). The dimensions  that influence the  design 
and  implementation  of public  poli  ci es  are:  the  kind  of poli  ci es  (  e.g.  science, 
technology  and  innovation),  the  scope  (e.g.  horizontal  or  vertical  teclmology 
policies), the relationship with the environment (e.g.  top-down and bottom-up), and 
the  geographie  scope  (e.g.  nation,  region,  sector)  (Metcalfe,  1994;  Dodgson  and 
Bessant, 1996; Teubal, 1997; Todtling and Trippl, 2005). Developed countries have 
implemented a variety of STI policies to provide both, incentives and support to the 112 
creation and commercialization of  new high technologies.  In this sense, the following 
propositions are aimed to  suggest a framework of STI public policies to  encourage 
and support biotechnologies in emerging countries. 
General  Hypothesis  8:  The  establishment  of  priorities  and  the  creation  of 
institutions  to  generate  business  opportunities  seem  crucial  steps  to  design  and 
implement  STI  policies,  and  in  tum,  generate  incentives  to  pursue  business 
opportuni  ti es. 
General Hypothesis Sa:  Large, domestic companies are expected to  acquire and 
imitate  new  technologies  given  their  access  to  own  financial,  human  and 
technological  resources.  In this  sense,  the  eventual  adoption and diffusion  of high 
technologies  will  rely,  at  first,  on  the  establishment  of new  organizations  and 
institutions  that  support  the  business  models  emerging  from  those  large 
companies. 
General  Hypothesis  Sb:  Given  that  the  accomplishment  of new  biotechnology 
products  require  a  collection  of  different  capabilities,  the  generation  of  new 
biotechnology products rely on the upgrading of institutional environments  that 
foster, facilitate, and nurture the collaboration among different organizations. 
Q3.  How  could  the  Mexican  public  policy  framework  be  improved  in  order  to 
support the adoption and diffusion of biotechnologies? 
H4:  Given the  lack of VC and entrepreneurship, growth can be  achieved by 
enhancing scientific capabilities in existing firms;  which may be accomplished 
by  government  efforts  like  awareness  campaigns  (including  promotion  and 
funding),  and  strengthening  the  links  between  companies  and  knowledge-
creating organizations by means of  public policies. 113 
7.3 Expected theoretical and conceptual contributions 
Three bodies of literature are used to accomplish this research. The first one involves 
a  managerial  view  of business  that  includes  business  model,  capabilities,  and 
collaboration through networks. These different views are  closely related, and allow 
the understanding of the important role of creation and support of technological and 
managerial  capabilities.  In  the  case  of biotechnology,  the  knowledge  base  and 
multidisciplinary  nature  make  room  for  the  'participation'  of different  actors  at 
different leve1s  of aggregation (worldwide, national, and regional). In this sense, my 
contribution  resides  in  understanding  the  business  models  of jirms  using 
biotechnologies  thal  evolve  in  emerging  countries  under  conditions  of meagre 
government support. 
The  second body of literature  involves  regional  agglomerations  concepts  - cluster, 
regional innovation system, and anchor tenant.  These concepts focus  on the  forces 
that  attract  other  organizations  and  suggest  the  characteristics  of  institutional 
environments that could support the growth of local firms and agglomeration. In the 
case of biotechnology, several au  thors have emphasized the role of organizations and 
institutions that allow knowledge exchange. In addition, sorne authors have analyzed 
the  dynamics  of  creation  and  development  of  biotechnology  agglomerations, 
especially  in  developed  countries,  but  little  has  been  said  about  the  potential  of 
emerging  countries  to  create  and  develop  biotechnology  agglomerations,  and 
especially how to generate these agglomerations.  In this sense, the contribution to  the 
agglomeration literature is to understand how different organizations (enterprises and 
non-enterprises)  interact  in  unstructured  institutional  environments  of emerging 
countries, and how the creation and development of  biotechnology agglomerations in 
those  countries  calls  for  the  creation  of institutions  that  support  the  emerging 
business  models  which  are  struggling  to  establish  relationships/networking  with 
other organizations to increase/complement their capabilities. 114 
Public policies aiming to  support and improve STI activities  are  the  third body of 
literature.  Severa[  authors  have  emphasized  the  role  of govemment  to  create  and 
support  technology  markets.  In  the  case  of biotechnology,  empirical  research  in 
developed countries shows that govemment intervention in different ways (  directly or 
indirectly)  has  been crucial to  consolidate  organizations related  to  biotechnologies 
(universities  and  research  centres  and  enterprises).  In  the  case  of emerging  and 
developing  countries,  the  adoption  and  diffusion  of  new  technologies  face 
institutional obstacles and limited resources. In this sense, the contribution resides in 
suggesting  that  in  emerging  countries  the  adoption  and  improvement  of high 
technologies,  such as  biotechnologies,  require an evolving institutional environment 
that  allows  the  creation  of ad hoc  institutions for  the  emerging  business  models 
related to  high  technologies, and over time  the adaptation of institutions fostering 
incrementa! innovation and eventually accomplish radical innovations. 
7.4 Research design 
The objective and questions of this research deal with different bodies of knowledge 
and  possess  a  multidisciplinary  character.  Strategie  management,  regional 
agglomeration and STI policies literatures are interweaved to explain the adoption of 
biotechnologies  in  Mexico.  This  research  combines  qualitative  and  quantitative 
methods to analyse the phenomenon. 
7.5 Sample construction 
At  least  two  organizations  are  relevant  for  the  adoption  of  biotechnologies: 
knowledge-creating organizations and enterprises (see Chapter II). 
Given  the  scientific  base  and  multidisciplinary  nature  of biotechnologies,  crucial 
agents  are  knowledge-creating  organizations  such  as  universities,  research  centres 
and govemment research laboratories. These organizations are characterized by their 115 
research  capabilities  reputation  m  tenns  of human  resources  and  research  lines. 
Therefore, the first step to define the sample was to identify Mexican universities and 
research centres carrying out bioteclmology research. Mexico has a vast telTitory that 
encompasses 31  states and the Federal District (Mexico Cit):).  ln all  the  states and 
Mexico City, there is  at least one technical institute or university for training human 
resources  in  biotechnology  at  different  levels  (from  technician  to  PhD  level) 
(Secretaria  de  Economia,  2010).  There  are  around  130  education  and  research 
organizations  that  have  biotechnology  programs;  sorne  of  them  conduct 
biotechnology research activities covering different degrees of complexity (Bolivar et 
al.,  2003;  Secretaria  de  Economia,  2010).  Among  these  organizations,  only  25 
knowledge-creating organizations are the main scientific publishers in biotechnology 
applications (see Table 7.1 ). 116 
Table 7.1 
Number ofbiotechnology publications in Mexico, 1996-2008 
Organizations  #Publications*  States 
Universidad Nacional Autonoma de México- 818  Mexico  City,  Morelos, 
UNAM  and other states 
Instituto Politécnico Nacional-IPN  553  Mexico  City,  and  other 
states 
Universidad Autonoma Metropolitana-UAM  291  Mexico City 
Research Centres of  CONACYT  278  Mexico and other states 
Instituto Mexicano de Segura Social-IMSS  139  Mexico  City,  Morelos, 
and other states 
Universidad Autonoma de Nuevo Leon  94  Nuevo Leon 
Universidad de Guadalajara  72  Jalisco 
Instituto Mexicano de Petroleo  70  Mexico City 
International Maize and Wheat Improvement  64  State ofMexico 
Centre-CIMMYT 
Universidad Aut6noma del Estado de Morelos  51  Morelos 
Universidad Aut6noma del Estado de  42  Coahuila 
Coahuila 
Universidad de Guanajuato  42  Guanajuato 
Clinica Ruiz de Puebla  35  Puebla 
Instituto National de Salud Publica  35  Morelos 
Instituto Tecnol6gico de Veracmz  30  Veracruz 
Instituto Tecno16gico de Estudio Superiores de  28  Nuevo  Leon  and  other 
Monterrey-ITESM  states 
Instituto Nal. Cardiologia Ignacio Chavez  23  Mexico City 
Universidad Aut6noma de Baja California Sur  23  Baja California Sur 
Universidad Aut6noma de Yucatan  22  Yucatan 
Universidad de Sonora  22  Sono  ra 
Instituto Nacional de Ciencia Médicas y  21  Mexico City 
Nutrici6n Salvador Zubiran 
Tnstituto Tecnol6gico de Celaya  21  Guanajuato 
Universidad Aut6noma de San Luis Potosi  19  San Luis Potosi 
Universidad Veracruzana  18  Veracruz 
Universidad Aut6noma de Querétaro  15  Querétaro 
"Data for 20.08: January-September. 
Source: Science-Metrix, as compiled for Canada Research Chair on the Management ofTechnology. 
There  are  only  five  research  organizations  with  more  than  100  biotechnology 
publications  in the  period  1996-2008:  UNAM (818),  IPN (553),  UAM (291),  the 117 
research centres of CONACYT (278), and IMSS (139)
26
. They are located mainly in 
the demographie and political centre of the country: for example UNAM, IPN, UAM 
and IMSS have their main campus and offices (headquarters) in Mexico Citl
7
;  they 
perform research activities  in different fields  of biotechnology such as  human and 
animal health, agriculture, food processing, and environment. 
In  addition  to  research  organizations,  enterprises  are  key  agents  to  generate  and 
capture  economie  value.  I  searched  for  information about  Mexican biotechnology 
enterprises
28
.  The identification of enterprises was based on an Internet search using 
key words (  e.g. biotechnology firms in Mexico; bio  tech Mexico, Mexican bio tech, in 
English  and  Spanish),  and  secondary  sources  (web  sites  of research  centres  and 
specialized literature  ).  Also,  I asked for  a directory of biotechnology enterprises in 
Mexico to different organizations, such as the Mexican Association of Biotechnology 
and Bioengineering (Sociedad Mexicana de Biotecnologia y Bioingieneria), Ministry 
of Economy, and CONACYT. Unfortunately, none of these organizations had at that 
moment a biotechnology directory. Table 7.2 summarizes the results of my search for 
Mexican biotechnology enterprises. 
26 The number of  publications of  each institution encompasses different campus or research centres. 
For example, the case ofUNAM could include the publications of  scientist attached to the 
Biotechnology Institute, the Centre for Genomic Science, the Faculty of  Medicine,  and the Faculty of 
Engineering. 
27 Other states relative!  y near to Mexico City host important research centres, for example, the Institute 
of Biotechnology-UN  AM is located in Morelos, CINVEST  A  V-IPN is located in Guanaj uato. 
28 As defined by the OECD, see footnote 6 in Chapter I. 118 
Table 7.2 
Distribution ofbiotechnology firms in Mexico 
State  Number of enterprises* 
1  Mexico City  19 
2  State ofMexico  12 
3  Jalisco (Gu ad al  a  j ara)  5 
4  Chihuahua  3 
5  Morelos  3 
6  Nuevo Leon (Monterrey)  3 
7  Quereéaro  3 
8  Sinaloa  3 
9  Coahuila  2 
10  Aguascalientes  1 
11  Baja California Sur  1 
12  Co  lima  1 
13  Michoacan  1 
14  Puebla  1 
Total  58 
*Own search 
According to  my search, 58  enterprises using biotechnologies are located in fourteen 
Mexican entities:  Mexico City hosts nineteen enterprises, the  State of Mexico hosts 
twelve enterprises and the other states host between one and five enterprises. 
Here it is  important to  mention that in August 2010, after I conducted my fieldwork 
(September-October 2009),  the  Ministry of Economy published a  study  about  the 
situation  of  biotechnology  in  Mexico.  The  document  lists  306  biotechnology 
enterprises, however,  the document also  mentions that from  these,  only around 67 
enterprises  perform  activities  related  to  the  development  of biotechnologies  (see 
Annex C). I compared my results with the list of the Ministry of Economy to validate 
my  search:  50  of the  enterprises  I  found  on  my  own  search  match  with  the 
information of the biotechnology report. 119 
Criteria of selection 
Historically the main industrial and economie activities are located in three cities -
Guadalajara (Jalisco),  Monterrey (Nuevo Leon),  and  Mexico City- and part of the 
State of Mexico. A priori I expected that these  states  hosted consolidated research 
organizations and biotechnology enterprises. 
•  Knowledge-creating  organization  cri teri on:  according  to  Table  7.1, 
organizations  with  more  biotechnology publications  are  located  in  Mexico 
City and Morelos,  followed  by Nuevo  Leon,  Jalisco,  State  of Mexico  and 
Guanajuato. 
•  Biotech enterprises criterion:  according to  the  list of enterprises with biotech 
activities (Table 7.2 and Figure C.l in Annex C), Mexico City and the State of 
Mexico host the  large  number of enterprises,  followed  by  Jalisco, Morelos 
and Nuevo Leon. 
Following  these  criteria  (number  of  knowledge-creation  organizations  and 
biotechnology  enterprises),  I  decided  to  consider  three  locations  with  quality 
research,  number of firms  and presence of linkages  offices:  Mexico City,  Morelos 
and State ofMexico. 
7.6 Data sources 
Different  techniques  were  used  to  collect  data:  questionnaires/interview  and 
document review. 
Questionnaires/Interviews 
After  identifying  the  sample  of organizations  usmg  biotechnologies,  (  enterprises, 
universities and liaison offices)  in the central area of Mexico, I contacted them by - - - - - ·-------- - ------------- -
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phone.  In this  call I briefly presented myself, the intention of the research and why 
their participation could be useful. After this first communication, an invitation letter 
was sent,  by postal mail and e-mail, to  the  contacts  to  formally ask them for  their 
participation. 
I  asked  for  an  interview  to  all  enterprises  in  Mexico  City,  Morelos  and State  of 
Mexico (34 firms  according to  my own search) and also to  the most salient research 
institutes  in  biotechnology  within  those 'locations.  Finally,  sixteen enterprises  and 
four  research  organizations  answered  the  main  questionnaire  and  five  technology 
transfer  and  liaison  offices  answered  the  second  questiom1aire.  Ail  data  were 
collected in  a face-to-face  interview in their facilities.  Table 7.3  presents a general 
description of the interviews carried out for this research. In addition, I met managers 
from  other  three  enterprises  (two  multinational  pharmaceuticals  and  one  service 
enterprise)  and  one  university,  however,  they  did  not  accept  to  complete  the 
questionnaire. The fieldwork was carried out from September 9
111  to October i'\ 2009. -----~~-
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Table 7.3 
General descriptions of interviews carried out for this study 
ID  Sec  tor  Position  Location 
Enterprises 
1  Human health  General Manager  Mexico City 
2  Human health  Biotechnology Manager  State ofMexico 
3  Human health  Biotechnology Research Manager  Mexico City 
4  Agriculture  General Manager  Mexico City 
5  Agriculture  Technical Manager  Mexico City 
6  Agriculture  Chief of  regulation and marketing  Mexico City 
7  Agriculture  General Manager  State of Mexico 
8  Agriculture  General Manager  State ofMexico 
9  Agriculture  General Manager  State of  Mexico 
10  Agriculture  General Manager  State of  Mexico 
11  Food processing  Technology Development  State of Mexico 
12  Food Processing  General Manager  State ofMexico 
13  Food processing  General Manager  Mexico City 
14  Environment  Technical Manager  Mexico City 
15  Environment  Innovation and Technology  Mexico City 
development Manager 
16  Environrnent  Manager of Quality Assurance and  Morelos 
Monitoring 
University and research centres 
1  University  Technical Secretary ofTechnology  Morelos 
Management and Technology Transfer 
2  Research Centre  Coordinator of Health Research  Morelos 
3  University  Chief of the Biotechnology Department  Mexico City 
4  Research Centre  Research Director  Mexico City 
Technology transfer and liaison offices 
1  University  Chief of  Technical Support  Mexico City 
2  Federal  Director ofEntailment and Institutional  Mexico City 
governrnent  Development 
3  University  Coordinator of Academie Liaison  Mexico City 
4  State govemment  Director  Morelos 
5  University  Technical secretary of technology  Morelos 
management and technology transfer 
The most important  source was  a  questionnaire  focused  on  information related to 122 
enterprises and research centres: "Questionnaire about activities and characteristics of 
enterprises .  that  use  and  develop  biotechnologies  in  Mexico"
29  (Annex  D).  This 
questionnaire was inspired by the Statistics Canada biotechnology questionnaire, and 
is used in a larger project including Argentina, Brazil, Chile, China, India, Singapore 
and South Korea directed by Jorge Niosi and supported by FQRSC
30
,  as  well as  the 
Canada Research  Chair on  the  Management of Technology  directed  by  Dr Niosi. 
Another important source of information was  a questionnaire for  liaison offices  of 
universities  and  government  agencies:  "Questionnaire  for  technology  transfer  and 
liaison offices related to biotechnological products and processes"
31 (Annex F). 
The  main  questionnaire  includes  questions  that  were  useful  to  answer  the  three 
groups  of research  questions.  The  group  of research  questions  dealing  with  the 
characteristics  and  capabilities  of Mexican  biotechnology  firms  were  answer  by 
Question 1, which asks for biotechnologies in use and development, Questions 10 and 
11  ask  for  biotechnology  products  and  processes,  Questions  2,  3  and  4  ask  for 
capabilities, and Questions 21  and 22  ask for  foreign  trade. The group  of research 
questions about agglomerations were answered by  Questions 5,  which asks for age, 
motives  and  advantages  of  the  establishment,  Questions  14  and  15  ask  for 
collaborations.  The  group  of questions  about  public  policy  were  answered  by 
Question  13,  16,  17,  19,  and 20,  which ask for  issues  about regulation  law,  IPR, 
funding and tax credits. 
Technology transfer and liaison offices play an  impmiant role to  support university-
industry interactions. The second questionnaire includes questions about the services 
offered by the liaison and support agencies:  Question 1 asks  for age, Questions 2,  3 
29 The Spanish version was titled "Cuestionario acerca de las actividades y characteristicas de las 
empresas que utilizan y desarrollan biotecnologias en Mexico". 
3°  Fonds québécois de la recherche sur la societé et la culture (Quebec, Canada). 
31 The Spanish version was titled "Cuestionario para oficinas de vinculaci6n tmiversidad-empresa y 
transferencia tecnol6gica relacionados con productos y procesos biotecnol6gicos" 123 
and  4  ask for  motives  of the  establishment (mandate),  Questions  5  and  6  ask for 
collaboration with other centres (in general and in biotechnologies), Questions 10-13 
ask for  services  targeting biotech enterprises  and the  assessment of those  services. 
Question 14 asks for results of the centre. 
Document review 
In order to  validate the data collected, other sources of information were consulted 
(Yin,  1999;  Patton,  2003).  Quality  research  in  biotechnology  and  potential 
commercialization are related with scientific publication and  patents  (Kaplan et al, 
2004).  In this sense, I used a journal database, compiled by Science-Metrix for the 
Canada Research  Chair  in  Management  of Technology  that  provides  information 
about universities and PRC publications in biotechnologies fields  during the period 
1999-2008. In  addition, I consulted the  US  Patent and Trademark Office (USPTO) 
that is one of the most important patent offices. In order to identify the patents related 
to  biotechnologies  I  used  the  International  Patents  Codes  (IPC)  proposed  by  the 
OECD (Beuzekom and Arundel, 2009: 52): 
•  AOlH 1/00  •  C07K 16/00  •  GOIN 33/55 
•  AOIH 4/00  •  C07K I7/00  •  GOIN 33/57 
•  A61K 38/00  •  C07K I9/00  •  GO lN 33/68 
•  A6IK 39/00  •  C12M  •  GOlN 33/74 
•  A6IK48/00  •  CI2N  •  GOIN 33/76 
•  C02F 3/34  •  CI2P  •  GOIN 33/78 
•  C07G II/00  •  CI2Q  •  GOIN 33/88 
•  C07G 13/00  •  Cl2S  •  GOIN 33/92 
•  C07G IS/00  •  GOIN 27/327 
•  C07K 4/00  •  GOIN 33/53 
•  C07K I4/00  •  GOIN 33/54 
Other documents such  as public official  documents,  consulting enterprises  reports, 
and specialized literatures also were also used. 124 
7. 7 Data treatment 
Three databases were created, one for each kind of participant: enterprises, research 
centres,  and  liaison  and  technology  transfer  offices.  Given  the  small  number  of 
participants  in each  group,  nonparametric tests  - Spearman Rank-order  correlation, 
. Biserial correlation, and Chi-square with Yates correction for continuity statistics
32
-
were used to  test relationships  between variables.  The Table 7.4 presents  how  the 
research questions were addressed. 
The answers of the main questionnaire were transformed in order to  operationalize 
them. For example, in the case of number of employees, this variable was considered 
as  an ordinal scale variable
33  given the big difference among the answers (from 3 to 
900). I transformed this variable into a rank arder variable (see process in Annex H). 
Other  variables  like  import  activities  and  collaborations  were  transformed  into 
continuous dichotomous variables, whose values were YES and NO. 
32 The statistical softear to obtain this statistic was PSPP (a free program). 
33  "A dichotomous variable  is a mesure of two  conditions ... A continuos dichotomous variable has 
some type of order to  the  two  conditions ...  Ordinal scale data describe  values  that occw- in  some 
order.  However,  distance between any two  ordinal  values  holds  no  particular meaning"  (Corner ad 
Foreman, 2009: 3). 125 
Table 7.4 
Variables and sources of  information 
Research questions  Variables  Sources of information 
1.  What kind of biotechnology  Type ofbiotechnology  Main questionnaire 
users, actual or potential,  activities: kinds of  (Section 1) 
exist in Mexico, and what  biotechnologies used, pmposes 
kinds of  biotechnologies have  of  using biotechnologies 
been adopted?  Type of  capabilities: size, size  Main questionnaire 
What business models are  biotechnology, export  (Section 2, 3, 4) 
emerging in the Mexican- activities, kinds of 
specifie economie  biotechnologies adopted 
environment?  Complementary elements to  Main questionnaire 
define business models:  (Section 5, 6, 7) 
collaborations, funding 
sources, and strategies 
2.  Given that high technologies  Research capabilities: number  Government 
tend to agglomerate, does  of  knowledge-creating  documents, websites of 
Mexico have the potential to  organizations, number of  universities, 
create and support a  publications and patents.  publication database, 
biotechnology cluster?  patents database 
What kinds of collaborations,  Business opportunities:  Government 
if any, have emerged?  distribution of the potential  documents and 
entet-prises in the different  specialized literatme. 
regions of the country 
Institutional environment:  Second questionnaire 
characteristics of liaison and  and government 
technology transfer units, and  documents. 
complementary organizations  Main questionnaire 
Collaborations: kinds of  (Section 3, 5) 
relationships and motives for 
those collaborations 
3.  How could the Mexican  Design and implementation of  Specialized literature, 
public policy framework be  STI policies in other emerging  government docwnent, 
improved in order to support  countries and Mexico  consulting reports. 
the adoption and diffusion of 
biotechnologies? ,---~------
PART II. EMPIRICAL EVIDENCE AND CONCLUSIONS 
CHAPTER VIII 
EMPIRICAL EVIDENCE 
This  chapter presents  the  analysis  of the  empirical  results  in  order  to  answer  the 
research  questions  related  to  business  models  and  .  biotechnology  regional 
agglomerations.  The  next  chapter  deals  with  the  STI  policies  implemented  in 
emerging countries and presents sorne tessons for Mexico. 
8.1  Biotechnology enterprises and business models 
Sorne emerging countries,  like China, India and Brazil, have been  encouraging the 
adoption of modem biotechnologies. These countries have  attempted to  imitate the 
experience of developed  countries  through  the  support of R&D  activities  and  the 
creation of institutional  frameworks  that  allow  SME enterprises  to  commercialize 
biotechnology products (see Chapter IX for details).  The most cited organizations in 
the adoption of biotechnologies are universities and research centres and DBFs. The 
business model that characterizes these DBFs is  the classical biotechnology business 
model  (see  Chapter  II):  SME  focused  mainly  on  R&D  activities,  at  least  in  the 
pharmaceutical  sector.  Emerging countries  also  have  tried  to  generate  and  support 
DBFs  that  follow  the  classical business  model
34
.  However,  SMEs are  not the  only 
ones adopting and developing biotechnologies. Traditional pharmaceutical companies 
in  emerging countries  are  also  adopting biotechnologies  in  order  to  remain in  the 
market (Nature Biotechnology, 2010). Therefore, other kinds of business models are 
taking place in emerging countries. 
Before analyzing the kinds of business models followed by the sample of enterprises 
interviewed in Mexico, it seems useful to identify the us ers of biotechnologies. 
34 Nature Biotechnology published in 2010 special repmts focused on biotechnology in China and 
India. These reports highlight the potential of  the biotech enterprises to become part of  the value chain. - -----------------------------, 
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Ql: What kinds of biotechnology users, actual or potentia1, exist in  Mexico and 
what kinds of biotechnologies have been adopted? The main questionnaire gathers 
information about the  kinds  of biotechnologies  used by the  firms  interviewed  and 
their purposes  (current production, product/process development and  environment), 
as  well  as  characteristics of the  firms  in  terms  of kinds of products,  size, age  and 
foreign trade. 
Table 8.1 
Biotechnologies and their uses by firms established in Mexico 
Use  Production 
Product/process  Enviromnent 
Biotechnologies  development  al reasons 
YES  %  NO  %  YES  %  YES  %  YES  % 
DNA codification  2  12.5  14  87.5  2  100  2  100  1  50 
Proteins and  3  18.8  13  81.3  3  100  3  100  0  0 
molecules 
Cell and tissue  6  37.5  10  62.5  5  83.3  5  83.3  0  0 
culture and eng. 
Process  9  56.3  7  43.8  9  100  6  66.7  3  33.3 
biotechnologies 
Sub-cell organisms  1  6.3  15  93.8  1  100  1  100  0  0 
Bioinformatics  0  0  16  100  0  0  0  0  0  0 
Nanobiotechnology  1  6.3  15  93.8  0  0  1  100  0  0 
Enviromnent biotech  3  18.8  13  81.3  2  66.7  2  66.7  0  0 
Other (e.g. enzymes)  6  37.5  10  62.5  3  50  4  66.7  3  50 
n=16 
Table 8.1 presents a summary of the kinds of biotechnologies adopted and the  their 
purposes.  Most  of the  enterprises  interviewed  have  adopted  and  currently  use 
biotechnologies  related  to  process  biotechnologies  (56.3%),  followed  by  cell  and 
tissue  culture  and  engineering  (37.5%),  proteins  and  molecules  (18.8%),  and 128 
environmental biotechnologies (18.8%), white more complex biotechnologies such as 
DNA codification (12.5%)  and nanobiotechnologies (6.3%)  have  been adopted  by 
few  firms;  bioinformatics is  not used by the  interviewed enterprises.  These results 
show  that  very  few  firms  have  adopted  modern bioteclmologies;  low  to  medium 
complex biotechnologies are more prevalent. 
Regarding the purpose of using biotechnologies, Table 8.1  shows that all firn1s  use 
biotechnologies  to  aïd  their production and product development processes. In the 
case ofbio-nanotechnology, only one firm is using it for product development. In this 
sense,  in  this  sample no  firm  is  dedicated  to  develop  complex  products  based  on 
modem biotechnology perse; rather, they use biotechnologies to improve production 
processes of products th at are already in the market (  e.g. like biogenerics medicines  ). 
In  sorne  cases,  firms  use  biotechnologies  for  environmental  reasons  (  e.g.  water 
treatment (see Table 8.2). 
Table 8.2 
Biotechnology products and services 
Sec tor  Products/services 
Human  Erythropoietin 
health  Recombinant anti-poison drugs 
Vaccines 
Agriculture  Bio-fertilizers 
Bio-pesticides 
Bio-regulators 
Micro propagation 
V  eterinary medicines 
Food  Animal feed 
processmg  Diagnostic kits 
Microbial enzymes 
Environrnent  Absorbent fiber for industrial substances 
Odor control and treatment 
Wastewater treatment 129 
In order to characterize the users of biotechnologies in Mexico, the questimmaire asks 
about products in the market and development processes in different industries (  e.g. 
diagnostics  and  therapeutics  in  human health;  plant  biotech  and  animal  biotech; 
genetics  and  molecular  modeling  in  bioinformatics;  air,  water,  and  soil  in 
environment).  According to  that information,  the  interviewed firms  produce goods 
and  services  that  can  be  categorized  into  the  following  industries:  agriculture, 
environment, food processing and human health. 
Table 8.3 
Characteristics of  Mexican enterprises using bioteclmologies 
Creation  Number of  years  Number of 
Sec tor  ID  year or  using biotech.  employees  Export 
restructure  (2009)  (2008) 
Hu  man  1  1999  NA  500  NO 
Health  2  1970  20  900  YES 
3  1990  19  108  YES 
Agriculture  4  1976  33  94  YES 
5  2004  5  16  NO 
6  2003  6  42  NO 
7  1995  12  3  NO 
8  1990  15  110  YES 
9  1992  2  14  YES 
10  1986  23  34  YES 
Food  11  1974  35  108  YES 
processmg  12  1986  10  165  NO 
13  1998  10  18  NO 
Environment  14  1995  14  21  YES 
15  1999  2  14  NO 
16  1996  13  33  NO 
What  business  models  are  emerging  in  the  Mexican-specific  economie 
environment?  Information  in  Table  8.3  summarizes  the  characteristics  of  the 
interviewed  enterprises:  age,  years  of experience  using  biotechnologies,  and  their ---------------
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participation in foreign markets. Based on this information, two kinds of users were 
identified. The first one includes those enterprise currently using bioteclmologies that 
were established since the 1970s (numbers 2, 3, 4, 10, and 11  in Table 8.3). Some of 
these enterprises have had products in the market for around 30  years and they also 
have used biotechnologies almost since then.  In some cases, they have restructured 
their  business  organization  (  e.g.  to  change  company  miSSIOn  and  rename  the 
company)  and  their  production  lines  (  e.g.  to  enter  new  markets  or  improve  their 
processes  ).  In  addition,  they  have  foreign  trade  activities.  In  these  cases  one  can 
intuitively  suggest that  these  kinds  of firms  have  improved  their  biotechnology 
processes in order to  maintain their position in the market. Also, the accumulation of 
capabilities has allowed  these firms  to  adopt modem biotechnologies for  improving 
production processes, and eventually to enter in new markets with new products. The 
second kind ofusers includes those enterprises which are relatively young -they were 
founded  since  the  1990s-, they  are  small  and  do  not  have  activities  in  foreign 
markets  (numbers  5,  6,  9  and  15  in  Table  8.3).  These  enterprises  have  few  years 
adopting  biotechnologies;  they  seem  to  look  for  improving  their  processes  and 
products in order to move their position in the local market. 
Based on the information of Table 8.1  that contains current production, process and 
product  development,  and  environment  reasons,  and  Table  8.3  that  summarizes 
information about age, number of years using biotechnologies, and foreign trade: the 
adoption of  biotechnologies in Mexico seems to  be carried out main/y by medium 
and large enterprises that are already in the market and look for improvements on 
their processes or fines of  businesses. In addition, firms that have capabilities related 
to  biotechnologies as  well as  production and commercialization capabilities in local 
and foreign markets are more able to adopt modem biotechnologies. 
In order to  test this proposition, I conducted non-parametric tests (see Annex H)  to 
measure the relationship between 1) size and size of biotechnology, 2) size and years 131 
using  biotechnologies,  and 3)  years  using biotechnologies  and  export activities.  A 
Spearrnan rank-order correlation produced significant results (rs=0.8640, p<O.OS);  it 
means  that  there  are  a  strong  relationship  between  the  size  and  the  size  of 
biotechnology.  This  result  suggests  that  according  to  the  size  of the  firrn  (total 
number of employees), it bas developed a capacity to  have a number of employees 
dedicated to  biotechnology activities - either full- or part-time. In addition, a biserial 
correlation  produced  significant  results  (r&=0.4804,  p<O.OS)  when  measuring  the 
relationship between firm size and the number of size biotechnology, which suggests 
that  there  is  a  strong  relationship  between  these  two  variables.  Regarding  the 
relationship  between  years  using  biotechnologies  and  export  activities,  a  biserial 
correlation also produced significant results (r&=0.8358,p<O.Ol); these results suggest 
that there is a strong relationship between the firm's years using biotechnologies and 
its export activities. 
Medium and large enterprises using biotechnologies have been in the market for more 
than 30 years and in sorne cases they have more than ten years using biotechnologies. 
This information confirms that large firms have developed scientific, managerial and 
commercialization capabilities that help them to  adopt modem biotechnology. Most 
of these enterprises are not generating new products for the world;  instead they are 
improving  their  processes  and  product  lines  to  remain  in  the  market.  They  have 
developed "imitative business models". 
Other internai factors that affect the creation of business models, besides capabilities, 
are collaborations with other organizations, finance  structure, location, and strategy 
and objective/mission (see Chapter Il). 
Regarding the funding sources, the interviewed enterprises have not received support 
from  venture capitalists. Most of them have received funding  support from family 
and  friends. Two  firrns  have received  funding  from  government because  they  are 132 
government-owned, one of them also receive funding from international institutions 
(  e.g.  World Health Organization).  Other three  firms  mentioned they have obtained 
funding from government in addition to the family support. Only one finn mentioned 
to  have private placement.  This  information confirms  the  limited financial  support 
that biotechnology firms have. Commercial banks and public equity markets have a 
small  participation  in  supporting innovative  initiatives,  especially of those  coming 
from small and medium enterprises: "During the last ten years, the [VC] industry has 
predominately been governed by foreign investors who primarily focus  on late-stage 
investments" (Charvel et al, 2006:  311 ).  The venture capital industry in Mexico is  in 
its infancy phase; private and institutional players do not have incentives to  take high 
risks (Charvel et al, 2006; Lavca, 2010). 
In  order  to  analyze  the  strategies  implemented  by  the  enterprises  m  2008,  the 
questionnaire  asks  for  two  types  of strategies:  knowledge  strategies  and  business 
strategies  (Table  8.4).  Regarding  knowledge  strategies,  the  enterprises  mentioned 
they captured and used knowledge obtained from externat sources, particularly from 
knowledge-creating  organizations.  In  addition,  ail  enterprises  encouraged  staff 
education. Although these enterprises encouraged the adoption of  new knowledge and 
improvement  of skills,  they  were  not  enthusiastic  with  the  implementation  of 
intellectual property. Most of the  enterprises have several trademarks, however, few 
firms  have patents, either granted or applications. Regarding the  business strategies, 
most of the enterprises increased market penetration, began new R&D project, and 
expanded into foreign markets. 133 
Table 8.4 
Strategies implemented by Mexican biotechnology enterprises, 2008 (percentage) 
Agri.  Env.  Food  Hum. 
Knowledge strategies  proc.  health 
Captured and used knowledge obtained from other  29  100  100  100 
industry sources 
Captured and used knowledge obtained from  71  100  100  100 
know ledge-creating organizations 
Development of  new knowledge through  57  50  33  100 
collaborative agreements 
Used and updated databases of scientific  71  100  67  67 
information 
Developed firm policies and practices for IP  29  100  0  67 
protection 
Developed or encouraged staff education!upgrading  100  100  100  100 
Conducted an IP audit in all stages of  development  14  0  0  33 
Used IP to signal competency  43  100  67  100 
Business strategies 
Increased finn size tlu·ough acquisitions, merger or  29  50  0  33 
joint-ventures 
Provide products and services to other firms  14  0  33  0 
Increased market penetration (product trials/adapted  86  100  100  33 
products or processes) 
Began new R&D project(s)  86  100  67  100 
Expanded into foreign markets  71  50  67  67 
Other (niche market)  0  0  33  0 
n= Agriculture: 7; Environment: 2; Food processing: 3; Human health: 3; NA:  l. 
8.2 Potential biotechnology clusters in Mexico 
High  technology  agglomerations  require  govemment  intervention  for  creating 
organization  and  institutions  that  support  their  growth.  Several  countries  have 
designed initiatives to  create high technology agglomerations (  e.g.  regional clusters, 
industrial  parks).  Mexico  is  not  an  exception,  and  sorne  initiatives  have  been 
presented  to  encourage  the  creation  of agglomeration  in  different  regions  of the 
country.  The  PECITI 2008-2012  recognizes  the  importance  of university-industry 134 
collaborations;  accordingly,  sorne  industrial parks have  been proposed  in different 
Mexican  states,  for  example,  Aguascalientes·,  Baja  Califomia,  Chihuahua,  Jalisco, 
Morelos, Nuevo Le6n, State of Mexico, Sonora and Yucatan (PECITI, 2008). At least 
two  technology  parks  have  been  designated  to  encourage  university-industry 
collaborations for developing biotechnologies. 
Table 8.5 
Technology parks supporting biotechnologies in Mexico 
Name of  the park  Location  Supporting areas  Participants 
related to 
Parque de Investigaci6n e  Monterrey,  Biotechnology,  Private initiative, 
Innovaci6n Tecnol6gica  Nuevo Le6n  nanotechnology,  HEl, and research 
de Monterrey (PUTt  mechatronics, ICT,  centres. 
and health 
Parque Tecnol6gico  Cuernavaca,  Biotechnology,  Federal and State 
Cuemavacab  Morelos  ICT, mechatronics,  govemments and 
and health  HEL 
a Park ofresearch and technology innovation of  Monterrey, Nuevo Le6n 
b Technology Park Cuernavaca, Morelos 
Somce: PECITI (2008: 23) 
Regarding  the  creation of bioteclmology agglomerations,  specifie organization and 
institutions are needed to  support their development (see Chapter III).  Sorne scholars 
have mentioned that those organizations and institutions that support the adoption of 
biotechnologies in developed countries are difficult to  find or create in emerging and 
developing countries. In this sense, this section deals with the analysis of the potential 
Mexico have for creating a regional biotechnology agglomeration. 
8.2.1 Regional scientific capabilities 
Q2:  Given that high  technologies  tend  to  agglomerate,  does  Mexico  have the 
potential to crea  te and support a biotechnology cluster? The creation of scientific 
and technological capabilities relies  strongly on  institutional structures  nurtured by 135 
governments. As mentioned in Chapters II and III, high technologies enterprises tend 
to  agglomerate  in specifie geographie areas.  Biotechnology agglomerations rely on 
the existence of a variety of organizations that support the creation of capabilities in 
the  area.  The  following  paragraphs  describe  the  organizations  and  institutions  of 
different regions in Mexico. 
Figure  8.1  shows  the  number  of knowledge-creating  organizations  and  research 
centres  located  in  each  Mexican  state  and  the  federal  district  (Mexico  City). 
According to the Ministry of Economy, in 2008 Mexico had about 130 education and 
research  organizations  with  programs  related  to  biotechnologies,  these  include  48 
master  programs  and  21  PhD  programs  dedicated  to  areas  such  as  biochemistry, 
biology, bio-processing, pharmacology, genetics, and food processing (Secretaria de 
Economia,  2010:  251).  These  programs  represent  8%  of the  total  postgraduate 
programs  in Mexico (ibid,  p.  252).  Among the universities  and research centres  in 
Mexico, only 25  have biotechnology publications in international joumals (see Table 
7.1  in Chapter VII) and only 10 organizations had more than 50  publications during 
the period 1996-2008 (see Table 8.6). 136 
Figure 8.1 
Number ofuniversities and research centres with biotechnology activities in Mexico 
State of  Mexico=6 
Mexico City=l9 
M oœtqs=J 
Source: Own elaboration based on Secretaria de Economfa (20 1  0). 137 
Table 8.6 
Number of  publications in different biotechnology areas, 1996-2008 
Human 
Other than 
Organizations  Total* 
health 
Agriculture  human health 
and agriculture 
Universidad Nacional Auton6ma de  818  594  72  137 
México-UN  AM 
Instituto Politécnico Nacional-IPN  553  340  93  116 
Universidad Aut6noma  291  179  26  82 
Metropolitana-UAM 
Research Centres of CONACYT  278  135  52  82 
Institutio Mexicano de Seguro Social- 139  131  4  1 
IMSS 
Universidad Aut6noma de Nuevo ,  94  61  14  17 
Leon 
Universidad de Guadalajara  72  50  10  11 
Instituto Mexicano de Petr6leo  70  27  1  40 
International Maize and Wheat  64  12  47  5 
lmprovement Centre-CIMMYT 
Universidad Aut6noma del Estado de  51  28  7  13 
Morelos 
*Data for 2008: January-September 
Source: Science-metrix as compiled for Canada Research Chair on the Management ofTechnology. 
In addition to  publications, the number of patents is a quality indicator of research. 
Table  8.7  shows  that  very  few  Mexican  universities  and  research  centres  have 
registered scientific advances in the USPTO, the most dynamic patent office. These 
registrations started in the 1990s. 138 
Table 8.7 
Patents granted to Mexican universities by the USPTO, 1976-2010 
Universities and research  Year 1  st  Total 
Total 
biotechnology  State 
centres  patent  patents 
patents 
CINVESTA  V - IPN  1990  6 
Mexico City  17 
Guanajuato 
Universidad Aut6noma de  1998  3  Nuevo Le6n  4 
Nuevo Le6n 
UNAM  1990  12 
Mexico City  16 
Morelos 
Escuela N acional de  2004  1  Mexico City  3 
Ciencias Biol6gicas - IPN 
ITESM  2008  1  Nuevo Le6n  2 
Source: Own elaboratiOn based on USPTO, August 2010 
According to the information of Figure 8.1  and Table 8. 7,  in spi te of Mexico having 
sorne training and research organizations ali over the country, there are few Mexican 
states  with  the  potential  to  undertake  cutting-edge  biotechnology research.  These 
locations host universities and research centres with research tradition: Mexico City, 
Morelos, State of  Mexico, Jalisco and Nuevo Le6n. 
The  central  region  of Mexico  (Mexico  City,  Morelos  and  State  of  Mexico), 
particularly Mexico  City,  hosts  the  largest universities  in  the  country,  in  terms  of 
student  population  and  research  activities:  UNAM,  IPN  and  UAM.  UNAM  has 
faculties  conducting  biotechnology  research  in  Mexico  City  (  chemistry,  sc1ences, 
medicine,  bio-sciences,  engineering)  and  Morelos  (biotechnology  and  gen01mc 
sciences). IPN bas also sorne schools and faculties related to biotechnology research, 
in  Mexico  City  (biology  sciences  and  biotechnology),  Guanajuato  (plant 
biotechnology  and  genomics),  and  Tlaxcala  (applied  biotechnology).  UAM  has 139 
research  activities  m  two  campuses  located  in  Mexico  City  (Iztapalapa  and 
Xochimilco  ).  These  organizations  have  been  actively  involved  in  biotechnology 
research for  more  than 25  years,  in  the  case  of modem biotechnology (e.g.  DNA 
coding, bioinformatics) for more than 10 years
35  (Table 8.8). 
Table 8.8 
Biotechnologies used in Mexican universities, 2008 
Biotechnologies  University! 
Research 
University2 
Research 
centrel  centre2 
Number of  researchers  304  48  57  155 
Number of 
biotechnology  184  43  52  93 
researchers 
SNI researchers 
59  42  100  29 
(percentage) 
Biotechnology research activities 
DNA codification  YES  NO  YES  YES 
Proteins and 
YES  NO  YES  YES 
molecules 
Cell and tissue culture  YES  NO  YES  YES  and engineering 
Pro cess  YES  YES  YES  NO 
biotechnologies 
Sub-cellular  YES  NO  YES  YES 
orgamsms 
Bioinformatics  YES  NO  YES  YES 
Nano-biotechnologies  YES  NO  YES  NO 
Environment  YES  NO  YES  NO 
biotechnologies 
Others 
Genomics,  Bioprospecting,  Bio food  Genomics 
Proteomics  Phytomedicines 
Historically,  scientific research  has  been concentrated in  the  centre  of the  country 
35 Information from interviews with universities 140 
where the main campus of the three universities mentioned before are located. In an 
attempt  to  decentralize  research  activities,  sorne  of their  faculties  and  institutions 
were relocated to other states. However, the concentration of  research activities in the 
centre of the country remains solid; for example, in 2004 INMEGEN was created, a 
new research centre which aims to carry out genomics research. This centre is  located 
in Mexico City too. 
The state of Jalisco  also  has  developed biotechnology research activities  mainly in 
two  organizations:  the University of Guadalajara (UdeG) and the  State of Jalisco's 
Research and Assistance in Technology and Design Centre (CIATEJ in Spanish). The 
UdeG  carries  out  biotechnology  research  activities  in  the  University  Centre  for 
biological  and  livestock  sciences  (CUCBA  in  Spanish),  which  host  almost  70 
researchers registered with  the  SNI
36  and  the  research  lines  include bioagriculture, 
phytopharmacology,  inmunobiology,  animal  and  vegetal  genetics. Also,  the  UdeG 
has a partnership with the Civil Hospital of Guadalajara, the main research hospital of 
the region. Other important organization is  the CIA  TEJ, a Conacyt-sponsored centre, 
which  host  more  than  30  researchers  register  with  the  SNI
37  in  areas  like 
biotechnology,  micropropagation  and  vegetal  genetic  improvement,  microbial 
biotransformation, and quality of agrifood. In addition, sorne efforts have been made 
to  promote and  encourage the  adoption of biotechnologies  in  the  West region. For 
example, Biocluster de Occident AC is  an association between research centres and 
govemment. The founders  were the Institute of Higher Studies of West (ITESO in 
Spanish), Regional Chamber of Transformation lndustry of Jalisco (CAREINTRA in 
Spanish),  State  of Jalisco  Council  for  Science  and  Technology  (COECYTJAL in 
Spanish), the govemment of the State of Jalisco, and Jalisco's major veterinary and 
36 Information retrived from http://udg.mx/investigacion/directorio/centro/cucba (Accessed on 30 May 
2012). 
37 Information retrived from http://www.ciatej.net.mx/index.php/investigacionlinvestigadores/?lang=cs 
(Accessed on 30 May 2012). 141 
pharrnaceutical companies. 
38 
The state of Nuevo Le6n hosts the strongest research university in the Northeast of 
Mexico:  UANL.  This university carries  out research  activities  in  areas  of biology, 
biotechnology and  food  sciences  through  the  School of Biological Science,  which 
hosts more than 60 researchers registered with the SNI
39
. A private university also is 
involved  in  the  development  and  adoption  of biotechnologies  in  the  region:  the 
ITESM'  Biotechnology Centre.  In addition,  The State govemment in  collaboration 
with the federal  govemment and research universities have been active to  generate 
economie development based on high technologies, including biotechnologies
40  and 
have promoted the capital city of the State, Monterrey, as  the "International City of 
Knowledge". 
In sum, there are few locations with biotechnology research capabilities: the centre of 
the  country  that  includes  Mexico  City  and  Morelos,  and  potentially  Jalisco  and 
Nuevo Leon. 
8.2.2 Technology transfer and liaison offices 
Technology transfer and liaison offices also play an important role for incubation and 
licensing  activities.  Emerging  countries  supporting  actively  the  adoption  of 
biotechnologies  have  established  incubators,  technology  parks,  and  technology 
transfer  offices.  In  Mexico  sorne  universities  and  research  centres  have  extension 
units - these units are in charge of the elaboration of research contracts,  licensing and 
in sorne cases technology transfer agreements. 
38 Information retrieved from http://www.bioclusteroccidente.com (Accessed on 01  June 2012). 
39 Information retrieved from 
http :/  /www. fcb. uanl.  mx/Investigaciones/Profesores  _SNI/SN  I%2  0  Datos%2 0 Rec i  en tes/SNI_ Profesores 
vigentes_del_2010.htm (Accessed on 01  June 2012). 
40 Information retrieved from http://www.mtycic.org:8080/node/174 (Accessed on 01  June 2012). 142 
I interviewed five  technology transfer and liaison offices related to  biotechnologies 
located in Mexico City and Morelos. The general characteristics of these offices are 
presented in Table 8.9. According to this information, technology transfer and liaison 
offices  depend on different  institutions,  such as  universities,  state government and 
federal  government.  These  offices  have  assisted  in  the  incubation and  creation of 
spin-offs. Y et, there are other offices dedicated almost exclusively to  assist research 
and technology contracts. Although the number of new enterprises is  very low, these 
offices are enthusiastic about the creation of new enterprises; however, there are no 
well-defined mechanisms to follow-up the incubated enterprises after "graduation".
4 1 
Table 8.9 
Incubation and liaison offices 
ID 
Year 
Depend of  Location  Incubation  Spin-offs 
foundation 
1  1987  University  Morelos  1  4 
2  2007  State government  Morelos  2  0 
3  Mid-1970  University  Mexico City  0  0 
4  2004  Federalgovernrnent  Mexico City  10  0 
5  2004  University  Mexico City  5  1 
Villasana (2011) analyzed the  case of technology transfer offices of two  important 
universities  in Monterrey, Nuevo Le6n:  UANL and ITESM. She mentions  that the 
creation  of these  offices  was  based  on  the  State  Development  Plan  and  other 
programs  airned  to  support  the  foundation  of new  technology  based  enterprises. 
However,  these  technology  transfer  offices  have  had  problems  to  develop 
relationships with private firms,  and biotechnology researchers are poorly informed 
about the services of these organizations (Villasana, 2011: 50-51). 
Based  on the  infonnation gathered in the  interviews  and the analysis  of Villasana 
41 Information from interviews with incubation and  liaison offices 
----- ---, 143 
(2011), the creation of  organizations in charge oftechnology transfer in Mexico is 
relative/y young and undeveloped. In order to improve this situation, the government 
has  promoted the  creation of new organizations  and  institutions  to  encourage  and 
assist technology transfer. In 2009, the modifications to  the  S&T Law established a 
new  mechanism  for  technology  transfer:  Liaison  and  Knowledge  Transfer  Units 
(UVTC in Spanish).  In fact,  on December 2011  it was  established the  first UVTC, 
which involved two research centres and a government agency. 
42 
8.2.3 Regional business opportunities 
In 2002, Francisco Bolivar and colleagues conducted a study about biotechnology in 
Mexico. These authors identified industries where biotechnologies could be applied: 
agriculture, human and animal health,  environment, aquaculture and livestock.  In  a 
recent study,  the  Ministry of Economy (2010)  identified about 304 enterprises that 
potentially could become biotechnology users  in  different sectors:  agriculture,  food 
processmg,  environment,  fermentation  and  biology  products,  livestock, 
pharmaceutics, and services. Figure 8.2 shows the distribution of these enterprises by 
sector: pharmaceutical (39.14%), agriculture (21.71 %), and food processing (11.85%) 
are the sectors with a larger participation in Mexico. 
42 Information retrieved from 
h  ttp :/  /todos.  cicese. mx/index.  php?  option=com  _content&  view=articl  e&id=2 7  6: se-crea  -la  -primera-
unidad-de-vinculacion-y-transferencia  -del-conoci miento&catid=9: b  reviario&I temid= 1  00 (  Accesscd 
on 24 February 2012). Figure 8.2 
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The Mexican states that host more potential us ers (  enterprises) of biotechnologies are 
Mexico  City  (46.38%),  the  State  of Mexico  (13.16%),  and  Jalisco  (12.5%)  (see 
Annex C). 
Considering the  regional capabilities  to  develop scientific research, the  activities of 
technology and liaison offices, business opportunities, there are few  states that have 
the potential to create and support biotechnology agglomerations:  1) Mexico City and 
Morelos, 2) Jalisco, and 3) Nuevo Leon. 
8.2.4 Collaborations in Mexico 
What kinds of collaboration, if any, have emerged? As mentioned in Chapter III, 145 
the  adoption  and  development  of biotechnologies  reqmres  the  collaboration  of 
different organizations. The collaboration between these agents often is  coordinated 
and nurtured by a favourable institutional framework that promotes the incentives to 
push forward  scientific  advances  related  to  biotechnologies,  and  the  adoption  and 
diffusion of th ose novelties. Therefore, wh  en institutional frameworks are limited and 
without a long-term strategy, the collaboration between different agents faces several 
obstacles. 
The institutional framework in which Mexican firms interact is unstructured, then a 
priori collaboration between different agents seems difficult to achieve. Nevertheless, 
Mexican firms  using  biotechnologies  have  started  to  establish  sorne  collaboration 
agreements.  ln  order  to  clarify  this  point,  the  main  questionnaire  asks  about 
collaboration with different organizations in Mexico and abroad, and the motives of 
those collaborations. 
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Figure  8.3  shows  that  in  2005,  only  31.3%  of the  interviewed  firms  established ------------- - -----
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collaborations, after 2005, this percentage increases to 68.8%. Regarding the kinds of 
collaborations,  Table  8.10  shows  the  different agents  with whom  these  firms  have 
established collaboration agreements, and the purposes ofthose collaborations. 147 
Table 8.10 
Collaboration between different agents and purposes of collaboration 
Collaboration  Reasons to  Agriculture  Environment  Food  Human 
with  colla  borate  processmg  health 
Other biotech  To conduct R&D  YES  YES 
enterprise  Access to others' 
patents 
YES 
Access others' 
YES 
knowledge/skills 
Access market  YES 
Production/ 
YES 
manufacturing 
Pharmaceutical  To conduct R&D 
YES 
enterprise 
Enterprise other  Production/ 
YES 
than biotech or  manufacturing 
ph  arma  Acccss market  YES 
Academie  To conduct R&D  YES  YES  YES 
institutions/  Access to others' 
Hospitals  patents 
YES 
Production/ 
YES  YES  YES 
manufactming 
Access IP  YES 
Access others' 
YES  YES 
know ledge/skills 
Government  To conduct R&D  YES  YES 
agencies or labs  Production/ 
manufactming 
YES  YES 
Access capital  YES 
Access IP  YES 
Access others' 
YES  YES 
knowledge/skills 148 
Table  8.10  shows  in  general  terms  that  the  most  active  firms  establishing 
collaboration agreements  are those related  to  human health,  followed  by  those  in 
agriculture, environment, and finally food processing industries. In the case of firms 
in the human health industry, they collaborate with a variety of agents, such as other 
biotechnology  firms,  pharmaceutical  companies  and  other  kinds  of enterprises, 
academie  institutions,  and  government  laboratories.  The  motives  for  these 
collaborations are related to the access to scientific advances and the adoption of  new 
knowledge (e.g. to conduct R&D, access others' knowledge and skills, and access to 
IP).  Collaboration  with  other  companies  aims  to  complement  production  and 
commercialization  capabilities:  productionlmanufacturing  and  access  to  markets. 
Firms  in  the  agricultural  sector  collaborate  with  other  biotechnology  enterprises, 
academie  institutions  and  government  laboratories.  The  purposes  of  these 
collaborations are  to  conduct R&D, to  access  others' knowledge and  skills,  and to 
access IP.  Here it  is  important to mention that  other purposes  such as  'Access to 
capital',  'Regulatory  affairs',  and  'Low  expenses'  did  not  appear  as  a  factor  to 
establish collaborations. 
In addition  to  national  collaborations,  the  interviewed firms  also  have  established 
collaborations with organizations and institutions from other countries, which means 
that collaborations are not limited to local and national actors. 149 
Table 8.11 
Collaborations with organizations located in other countries 
Country  Agents  Agriculture  Environrnent 
Food  Hu  man 
processmg  health 
Biotech enterprise  YES  YES 
USA 
Enterprise other than  YES 
biotech or pharma 
Universities/hospitals  YES 
Europe  Biotech enterprise  YES 
Other*  Biotech enterprise  YES  YES 
*ConfidentJal 
Table 8.11  shows that the interviewed enterprises using biotechnologies in the human 
health sector are  more dynamic  in terms  of collaboration with other countries,  the 
motives  for  this  collaboration  are:  to  conduct  R&D  activities,  regulatory  affairs, 
production/manufacturing, and  access  to  market.  Most of these collaborations have 
been  established  with  agents  located  in  developed  countries.  Access  to  capital, 
patents and other IP were not motives to collaborate with foreign agents. 
It seems that medium and large enterprises with higher technological and managerial 
capabilities are more active in the adoption of modem biotechnology and  more able 
to  establish collaboration agreements with international partners.  In  order to  test this 
proposition, biserial tests were conducted to  evaluate the relationship between 1) the 
firm  size· and  biotechnology  capabilities,  2)  size  biotechnology  and  international 
collaboration,  and  3)  firm  size  and  international  collaborations.  The  biserial 
correlations produce significant results  for  each pair of variables: size and extemal 
collaboration  (rb=0.4 797,  p<O.l 0),  bioteclmology  size  and  ex te mal  collaboration, 
(rb=0.4423,  p<0· .010),  and  years  using  biotechnology  and  extemal  collaboration 150 
(r&=0.4808, p<O.Olü) (see Annex H). 
This  pattern of collaboration confirms the  need  to  seek complementary knowledge 
with other actors.  Also,  an important issue emerges.  Even if the  local institutional 
framework  offers  not well-coordinated support,  firms  try  to  use  it  no  matter how 
limited it is,  and when they need extra help  they look for collaboration abroad.  For 
this  collaboration  to  take  place  Mexican  firms  need  to  have  a  certain  absorptive 
capacity that is present in sorne large established companies but that is absent in small 
orres.  Thus,  the  latter  are  at  disadvantage  because  they  are  stuck  with  only  the 
resources available from local institutions. CHAPTERIX 
STI POLICIES TO ADOPT BIOTECHNOLOGIES IN EMERGING 
COUNTRIES 
Sorne  emergmg  countries  have  implemented  public  policies  in  order  to  adopt 
biotechnologies. The objective of this chapter is two-fold: to describe the STI policies 
that were and have been implemented in three different emerging countries - China, 
India and Singapore, and to identify the pattern of STI policies implemented in those 
countries  and propose policy recommendations  to  improve the  adoption of modern 
biotechnologies in Mexico. 
I selected these countries given the active involvement of their governments to adopt 
modern biotechnology and to support biotechnology agglomerations. China and India 
have been in the spotlight as new economie powers, while Singapore has been seen as 
an important player in  the  economy landscape. The governments of these countries 
have tried to  generate economie growth through the  promotion of high  technology 
industries.  Therefore,  they  have  defined  development  strategies  with  long-term 
objectives; accordingly and have implemented a variety of STI policies. 
9.1 China 
Importance of  technology and science 
The particular characteristic of China is  its  transition from  central planning (1949-
1978)  to  a  regulated  market  economy  (since  1978).  In  the  early  1950s,  the 
government  of  China  realized  the  importance  of  technology  as  the  engine  of 
economie growth. Consequently, the government designed programs that allow China 
to create and use knowledge as well as  to  develop capabilities in strategie industries: 
public policies were focused on the creation of research units and the development of 152 
the  Chinese  research  and  production  capabilities  (Lui  and  White,  2001 ).  In this 
period,  different  institutions  were  involved  in  creating  technological  capabilities, 
however,  the  State  Planning  Commission (SPC)  was  the  most influential  decision 
maker,  with  "ultimate  control  over  economie  plans,  resource  allocation  and 
oversight" (Lui and White, 2001:  1  097). 
Later,  during  the  late  1970s  (the  period  of refonns),  the  Chinese  government 
recognized the inefficiencies and lower effectiveness of a centrally planned economy 
in  practice  (Lui  and  White,  2001:  1098).  Therefore,  institutional  changes  were 
implemented to decentralize economie decision-making: 
"The  aim  has  to  shift  from  a  government-led  model  of  technical 
innovation  principally  centred  around  the  programmes  or  plans 
prioritizing  areas  of R&D  and  given  financial  incentives,  towards  an 
enterprise-centred  technology  innovation  system  shifting  away  from 
public  research  institutes  towards  private  enterprises  as  the  centre  of 
innovative activity" (Prevezer, 2008: 364). 
Focus on biotechnology 
Since 1985, the Chinese government has been promoting policies focused on the life 
sciences. The implementation of these poli  ci es can be divided into two phases: 
•  1985-1995: creation of  a favourable environment, 
•  After 1995: promotion ofbiotechnology business. 
In the  first  phase  (1985-1995),  public  policies  were  focused  on  the  creation  of a 
favourable environment: "strengthening infrastmcture and creating funding programs 
that target R&D in particular technologies, biotechnologies among them" (Prevezer, 
2008:  364).  In  addition,  the  government  allowed  the  creation  of spin-offs  from 
research institutes, universities and large companies (Prevezer, 2008). 153 
In  1986,  the  National  High-Tech  Research  and  Dev:elopment  Plan  (the  863  Plan) 
targeted biotechnology as a strategie element for the industrial development: 
•  In 1988, the Torch program promoted the commercialization of key high-tech 
projects, including biotechnology; 
•  Key Laboratory Programs were established to fund R&D. 
In the  second phase (since mid-1990s), public policies have been more focused on 
promoting start-up companies,  encouraging entrepreneurship, promote national  and 
international  collaborations,  and  modifying the  p_ atent  law  in  order  to  promote  the 
foundation  of technology  based start-ups  (Konde  et  al.  2004:  41;  Prevezer,  2008: 
365): 
•  Incentives  towards  start-ups  and  helping  entrepreneurs:  these  programs 
includes  creating  service  centres,  institutions  for  innovation  funds,  and 
building incubators; 
•  Development  of human  resources:  m  arder  to  redefine  the  research  and 
development strategy of research centres with biotechnology activities, more 
than  250  research  institutions  were  privatized during  1998-1999,  and other 
non-profit research institutions have been reorganized since 2000. 
•  Policies targeting "retumees" drawing back scientists from abroad:  different 
programs have been established in arder to  create a research environment that 
attracts retumees; 
•  Location policies  to  stimulate the  clustering of enterprises in science parks: 
since 1991, the Chinese govemment has established more than 53  science and 
technology  parks  in  different  locations.  The  most  dynamic  biotechnology 
locations are Shanghai, Beijing and Shenzhen; 154 
•  Policies  focusing  on  establishing  a  venture  capital  industry:  in  1996  the 
Chinese  government  promoted  the  creation  of a  venture  capital  industry, 
however,  the  incentives  to  develop  this  industry  sector  seem  to  be 
underdeveloped. 
Different organizations have been involved in the promotion and coordination of the 
biotechnology policies, for example, government agencies including the Ministry of 
Science  and  Technology,  the  Ministry  of Agriculture  and  the  Ministry  of Health 
among  others;  also,  scientific  organizations  including  the  Chinese  Academies  of 
Sciences, the National Committee for Development and Technology and the National 
Research Institutions (Konde et al., 2004: 41 ). 
As  it  bas  been  shown,  the  Chinese  government  bas  been  concerned  with  the 
technological development in both phases:  central planning  and  reform.  The  main 
objective of these phases was and bas been the creation of  scientific and technological 
capabilities.  As  the  Chinese government considered high-technologies industries  in 
its economie development agenda, it started to formulate and implement STI policies 
focused  on the development of capabilities for  those  technologies:  promoting R&D 
activities,  funding  activities  to  accomplish  innovation,  and  encouragmg 
collaborations between different organizations (  e.g. knowledge-creating organizations 
and enterprises). However, Lui and White (2001) and Prevezer (2008) emphasize the 
lack of coordination among public policies  (e.g.  incentives  from  central  and  local 
governments), and the "lack of interaction and networking both between public and 
private enterprises and between foreign and domestic firms" (Prevezer, 2008:  368). 
These  circumstances  have  affected  the  adoption  and  diffusion  of biotechnologies 
among the Chinese enterprises. 
In  sum,  since  the  1950s  the  Chinese  government bas  implemented horizontal  STI 
policies, which means that the government bas invested resources in the  creation of 155 
capabilities  m  a  variety  of industries.  As  the  country  reached  sorne  industrial 
capabilities  -specifie  knowledge  and  leaming- ,  the  government  of  China 
implemented vertical STI policies focused on high-technology industries.  However, 
the demand and supply sides of technological and funding markets seem to  be not 
well coordinated.  According to  Prevezer (2008), the  main obstacles faced  by small 
enterprises are  the  lack of funding and networking between different organizations 
that complement capabilities. 
9.2 India 
Policies to develop scientific and technological capabilities 
Since the 1940s, the government of India has implemented public policies in order to 
reduce  the  technological  dependence.  Therefore,  the  government has  implemented 
STI policies  in order to  develop  own technologies.  The evolution of technological 
and scientific capabilities can be divided into three phases (Chaturvedi, 2005): 
•  1947-1970: creation of  scientific and technological infrastructure, 
•  1970-1990: creation of  indigenous capacity, 
•  Since 1990: new economy reforms. 
In  the  first  phase  (1947-1970),  immediately  after  Independence,  the  Indian 
government  implemented public  policies  focused  on  the  creation of scientific  and 
technological  infrastructure  in  the  country  (Mani,  2004).  In  this  phase,  the 
government strongly supported the creation of knowledge-creation organizations. In 
1958,  the  Scientific  Policy  Resolution  was  approved by  the  Indian Parliament  to 
generate  new  capabilities:  "Creating  a  base  in  science  was  seen  as  crucial  for 
absorbing and eventually replacing the foreign technology as well as generating new 
capacities in technological innovation for the indus trial development of the country." 156 
(Krishna,  1996:  131 ). Consequent!  y,  the number of universities increased and major 
science agencies were established or expanded
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. 
In the second phase (1970-1990), India announced its  first  Science and Technology 
Plan (1974-79). The main objective of this plan was to  develop indigenous scientific 
and technological capacity to  avoid technological dependence. In this sense, during 
the  1970s  and  1980s,  the  policies  on  self-reliance  and  import  substitution  were 
strengthened  through  various  mechanisms  of  economie  protection  and  through 
restrictions  on  technology  imports  (Krishna,  1996:  132).  In  addition,  the  Indian 
Patents  Act,  1970  was  an  important  element  to  encourage  the  national  industry: 
"product patents [  were] not granted for pharmaceutical products, agro chemicals and 
food  products.  Therefore,  Indian companies, especially in the  pharmaceutical field, 
could do  reverse engineering and develop more optimal processes for manufacturing 
known products." (Mani, 2004: 858). 
In 1983, the Indian governrnent am1ounced the Technology Policy Statement (TPS) to 
increase  technical  competence  and  self-reliance  especially  in  strategie  areas.  An 
outcome of the  TPS  was  the  Technology Information and Forecasting Assessment 
Council  (TIFAC),  created  in  1988,  whose  main  objectives  have  been  technology 
forecasting and technology market surveys in order to  promote specifie home grown 
technologies with the industry (Mani, 2004). 
In the third phase (after 1990), the TPS of 1983 has remained as  a framework for the 
Indian technology policy. After 1990, the Council of Science and Industrial Research 
(CSIR) had to  establish mechanisms to  generate a percentage of its  own budget.  In 
order to  do  that, the  agency bas  established research contracts  and consultancy for 
non-government organizations (Mani 2004). In addition, in the mid-1990s, the Indian 
43  For example: the Department of  Atomic Energy, the Council of Scientific and lndustrial Research, 
the Defense Research and Development Organization, the Indian Space Research Organization, the 
Indian Council of Agriculture Research, and the Indian Council ofMedical Research (Krishna, 1996). 157 
govemment developed regulatory policies focused on the venture capital industry in 
the country:  Securities and Exchange Board of India, SEBI (Venture Capital Funds) 
Regulations of 1996; Guidelines for Overseas Venture Capital Investments issued by 
the  Ministry  of Finance,  1995;  and  Central  Board  of Direct  Tax  Guidelines  for 
Venture Capital Companies, 1995 (Mani, 2004). 
In  January  2003  the  Prime  Minister  announced  a  new  S&T  policy,  whose  main 
objective is to raise India's overall research intensity. The policy bas eleven different 
strategies and four new features: 
•  The recognition that although India has a large pool of  scientists and engineers, 
their density is low, 
•  There is an explicit statement towards managing the brain drain from the 
country, 
•  An emphasis has been given to increased patenting both at home and abroad, 
•  There is an explicit articulation about the need to monitor the implementation of 
this policy (Mani, 2004: 860). 
However, the financial resources dedicated to this new policy have fallen short to 
achieve the desired results (Mani, 2004). 
Focus on biotechnology 
According  to  Ramani  (2002)  the  strategy of the  Indian  govemment  to  adapt  and 
diffuse bioteclmology can be divided into three phases: 
•  1981-1986: the initiation 
•  1986-1990: creation of scientific competences 
•  Since 1990: reaching out of the private sector 158 
Since the early 1980s, the Indian government has established agencies focused on the 
development of biotechnologies. In 1982, the National Biotechnology Board (NBTB) 
was created.  Later,  in  1986 a separate government department replaced the NBTB, 
creating  the  Department  of Biotechnology (DBT).  This  department  is  run  by  the 
Ministry  of  Science  and  Technology.  Given  that  biotechnology,  as  a  generic 
technology,  requires  the  development of a variety of competencies in  a  variety of 
scientific  disciplines,  "[t]he  establishment of the  DBT served  as  a  signal  that  the 
government considered biotechnology to  be a priority area for development.  It  was 
welcome by academies, national laboratories as  weil as  industrials" (Ramani, 2002: 
5). 
During  the  period  1986-1990,  the  Indian  government  supported  the  creation  of 
scientific  core  competencies  on  biotechnology  (Ramani,  2002:  5).  In  this  sense, 
grants were given to  universities, public research centres and teaching and research 
institutions  partially  supported  by  the  government  to  undertake  biotechnology 
projects.  In  addition,  the  DBT  crated  new  research  institutions  focused  on 
biotechnologies:  the National Institute of Irnmunology, the  Centre for  Cellular and 
Molecular Biology, the National Facility for Animal Tissue and Cell Culture, and the 
International Centre for  Genetic Engineering (in collaboration with United Nations 
Industrial Development Organization, UNIDO). 
Besides scientific knowledge, government intervention is  needed for the  translation 
from  scientific knowledge into  commercial products.  In this  sense,  after 1991,  the 
Indian  government  has  implemented  new  STI  policies  to  consolidate  the 
commercialization ofbiotechnology products (Konde, 2008: 48): 
•  The creation of technology parks with the support at central and state leve!:  the 
objective  of  theses  technology  parks  is  to  facilitate  up-scaling,  pilot-leve! 
production, and finally commercialization of indigenous biotechnology products. 159 
•  Industry  promotion:  sorne  initiatives  have  been  implemented  to  promote  the 
creation of biotechnology enterprises, to  monitor and nurture R&D in SME, and 
enabling public-private partnerships. 
•  Funding:  the  Indian govemment has promoted the  creation of funds  that allow 
biotechnology enterprises to grow. 
•  Academy-industry collaborations:  although  India has  an important countrywide 
network of research  institutions,  there  are  sorne  problems  to  establish  linkages 
between research organizations and industry. 
In sum, India has a long history designing and implementing public policies to create 
and  develop  scientific  and  technological  capabilities;  since  the  1950s  the  Indian 
govemment has  implemented horizontal  STI  policies.  Once  India developed  sorne 
indigenous  capabilities  (mid-1980s  ),  the  government started  to  implement vertical 
STI policies in specifie industries. Although India has achieved important results in 
the  development  and  commercialization  of  high  technology  products,  the 
consolidation of  industries using biotechnologies have faced sorne troubles: 
"India has been successfully able to develop the nuclear bomb, satellites 
and supercomputers, because such projects involved a group of scientists 
who were given directives under a 'mission mode', i.e.  under a cleared 
defined system of milestones targets  and  associated rewards.  This route 
cannot  be  pursued  in  the  integration  of biotechnology  . . .  [there  is  a] 
variety  of techniques  with  multi-sectoral  applications  . . .  the  Indian 
govemment  [has]  to  consider  more  intervention  in  the  creation  of 
networks  between  Indian  fi1ms  and  between  public  laboratories  and 
private firms themselves through national programs" (Ramani, 2002: 16). 
Once again, managing the collaboration between different organizations seems to  be 
a difficult process to achieve. 160 
9.3 Singapore 
Creating technological capabilities 
Since the early 1960s, the Singaporean government has been engaged in the creation 
and development of technological  capabilities:  "The 1961-1964 Development Plan 
actively  sought  domestic  industrialization,  erecting  trade  barriers,  providing  tax 
incentives  to  foreign  investors,  and  initiating  a  large  infrastructure  investment 
pro  gram" (Y ong, 1992: 20). 
After the late 1980s, the government of Singapore has established policies in order to 
encourage  the  adoption  of  biotechnologies.  These  policies  support  different 
organizations  and  institutions:  supporting  research,  creating  industrial  parks, 
developing  a  venture  capital  industry,  promoting  star-up  firms,  and  establishing  a 
legal framework to encourage experimentation. 
Focus on biotechnology 
In  1988,  the  Economie  Development  Board  (EDB)  implemented  the  National 
Biotechnology Program. The objective of this program was  to  make Singapore 'the 
hub  of commerce for the  Asia-Pacific region'.  The  plan had  five  stages  (Boisvert, 
1998: 6): 
•  Promote  biotechnological  research  m  Singapore  (five  research  institutions 
were founded); 
•  Construct  an  infrastructure  that  would  simplify  development  of 
biotechnology; 
•  Train personnel; 161 
•  Develop  economie  measures,  including  tax  incentives  and  approaching 
companies directly; 
•  Promote biotechnology to Singaporeans, particular with private investors. 
In 1995, the  Singaporean government designed the Biotechnology Cluster Plan. The 
main  idea  was  "to  integrate  infrastructures  and  personnel  to  increase  the 
competitiveness of biotechnology industry in the areas of R&D, bringing to  market 
and services" (Boisvert, 1998: 7). 
Focus on human health sector 
Singaporean government has attempted to  redefine the  national institutional context 
in order to  transform Singapore in the Asia's Hub for biomedical science with world-
class capabilities across the entire value chain, from  basic research to  clinicat trials, 
product/process  development,  full-scale  manufacturing  and  healthcare  delivery 
(Chaturvedy,  2005;  Gin,  2007).  In order  to  achieve  this  project,  the  Singaporean 
government created three agencies which are in  charge of the implementation of the 
biomedical science initiatives:  the functions  of these  agencies  are  to  formulate  the 
plans, to generate spin-offs and to support funding and academie research. 
Education and Training: the National Biotechnology Program (NBP) is  in charge of 
the training at alllevels and the update of  academie courses (Chaturvedy, 2005) 
•  Funding:  different  mechanisms  have  been  implemented  to  encourage 
investments  in  biotechnology;  these  include  a  variety  of tax  exemptions, 
allowances  and deduction/exemptions for  venture capital investments, R&D 
activities  and  international  consulting  (Boisvert,  1998).  Another  source  of 
funding  is  the  Economie Development Board (EDB), which  supports  start-
ups. Other programs followed by the Singapore government to promote equity 
investments in commercial projects in biomedical sciences are the  attraction 162 
of international  compames  and  attraction  of international  venture  capital 
(Chaturvedy, 2005) 
•  Legal framework: an important element in the development of biotechnology 
is intellectual property protection. In 1995 a new patent law was implemented: 
"The  principal  features  of  the  new  law  cover  a  similar  definition  of 
protractible subject matter as that of the European Patent Convention. The law 
proposes that novelty will  be assessed on a worldwide basis, with regard to 
both publication and use" (Chaturvedy, 2005: 117). 
•  Networks: the Singapore governrnent has taken into account the collaboration 
required  for  the  development  of biotechnology,  therefore,  the  initiatives 
"include arrangements like financial support;  a clear strategy for  supporting 
contract research organizations; open po licy for imports of skilled manpower; 
promotion  of  close  cooperation  with  firms;  and  arrangements  for  the 
emergence of public attitude" (Chaturvedy, 2005: 109-11 0). The collaboration 
has to involve actors at national and internationallevel (Chaturvedy, 2005). 
The BIOPOLIS:  In  October 2003,  Singapore made tangible  the  efforts  to  create  a 
place  that  encompasses  all  the  elements  required  to  achieve  biopharmaceutical 
products, a place in which all stages of the value chain are present - from  scientific 
research to marketing and delivery.  Biopolis "is an integrated R&D complex of two 
million square feet of space that bouses Biomedical Research Council's five research 
institutes as well as R&D laboratories of  numerous phannaceutical and biotechnology 
companies"  (Gin,  2007:  1134). With  this  science park,  the  Singapore  govemment 
seeks to  consolidate its position in pharmaceuticals and molecular biology  research, 
and become a biomedical market at internationallevel (Chaturvedy, 2005). 
In sum, since the 1960s the Singaporean government bas been focused in the creation 163 
and  development  of  teclmological  capabilities.  ln  the  1980s  the  Singaporean 
government  started  to  implement  vertical  STI  policies  in  order  to  encourage  the 
creation and development of biotechnology capabilities in the hu man health sec tor. 
9.4 STI policies in emerging countries 
This section summarizes the STI policies implemented by the government of China, 
India and  Singapore. These emerging countries  have achieved successful results  in 
the adoption ofbiotechnology, particularly in the biopharmaceutical sector, which bas 
been one of the most dynamic sec tors using modem bioteclmologies. 
According  to  the  information  presented  in  the  previous  section,  a  pattem  m  the 
evolution of the STI for increasing scientific and technological capabilities bas been 
identified: 
1.  Creation of scientific and technological capabilities in different fields, 
2.  Focus on biotechnologies that could be applied in different sectors, 
3.  Focus  on  biotechnologies  related  to  biopharmaceutical  industry  or  human 
health. 
Govemments  embracing  economie  growth  through  the  development  of  high 
technology  industries  have  implemented  STI  policies  focused  on  the  creation, 
development  and  support  of scientific  and  technological  capabiliti~s.  In  order  to 
achieve  that,  governments  have  created  institutions  with  the  mandate  to  design, 
implement, and evaluate STI policies and programs,  in turn this  activities allow the 
coordination between different programs and the establishment of a coherent pattem 
of  po licy choices. 
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investments to  modemize universities - for  scientific research and training- and set 
R&D  incentives,  which  underpinned  a  variety  of capabilities  used  in  different 
industries within the country. Once scientific and technological capabilities reached a 
point,  in  which  the  national  govemment  considered  the  country  could  face  the 
challenge to create and develop high-technology industries, a combination of  vertical-
horizontal STI policies were implemented.  Vertical STI policies  are  those policies 
focused  on specifie  industries.  Given  that  biotechnology  is  not  an  industry,  but  a 
group of techniques that can be applied to  different industries, horizontal STI were 
implemented  to  develop  scientific  and  technological  capabilities  in  different 
biotechnology  applications,  for  example,  agriculture,  human health,  animal  health, 
and environrnent.  Finally,  when national  or regional  govemments  considered  they 
have acquired adequate capabilities,  and at  the  same time a supporting institutional 
framework was built, they implemented vertical STI policies focused on one sector, 
for instance, biopharmaceuticals (in the three countries -China, India and Singapore). 
In addition,  other institutions  were created to  collect, evaluate and diffuse relevant 
information for the development of  ~iopharmaceutical industry. 
The  design and implementation of vertical  STI policies vary among countries  and 
regions.  Regarding the  characteristics proposed  by Dodgson and Bessant (1996)  to 
differentiate  science,  technology  and  innovation  policies,  some  examp1es  are 
mentioned here based on the experience of these three countries: 
Science and technology policies 
•  Creation  or  revamping  of national  laboratories  in  specifie  biotechnology 
applications (  e.g. agriculture, human health, environment) 
•  Support personnel training from technical to Ph.D. education. 
•  Improvements  in  scientific  collaborations  through  research  networks  at 165 
national and international leve!. 
•  Improvement ofuniversity-industry linkages and support of competitive R&D 
projects  via  mutual  cooperation  (  e.g.  projects  must  invol.ve  at  least  one 
university/research lab and one enterprise). 
•  Revision  of intellectual  property  law  as  stimuli  to  create  spin-offs,  which 
means allowing academie researchers to generate and obtain economie value. 
•  In  sorne  countries,  a  program  targeting  retumees  could  help  to  recruit 
qualified  scientific  researchers  trained  abroad  in  the  state-of-the-art 
biotechnologies. 
Innovation policies 
•  Creation of organizations to support DBFs, including grants for entrepreneurs 
to register patents, build prototypes, and design business plans. 
•  Creation  of organizations  to  facilitate  the  establishment of new  DBFs  and 
promote entrepreneurship  (start-ups),  including technological incubators and 
industrial parks. 
•  Foundation  of  agencies  and  programs  to  finance  the  entire  process  of 
iru1ovation - from  scientific research  to  the  launching of DBFs,  including a 
variety of tax incentives (  e.g. R&D tax). 
•  Creation  of  a  venture  capital  industry  and  attraction  of  foreign  VC 
(allowances and deduction/exemptions for VC investments). 
•  Attraction  of  foreign  investors  and  strategie  partners  (  e.g.  large 
pharmaceutical  and  chemistry  companies)  through  tax  incentives, 
intemational  level  of R&D  infrastructure,  and  providing pre-seed funds  to 
promote commercialization. 166 
•  International consulting 
•  Promotion to contract foreign skilled manpower. 
The cases of these emerging countries (China, India and Singapore)  show that the 
design  and  implementation  of STI  policies  seem  to  imitate  the  experience  of 
developed  countries.  However,  given  the  different  socio-economic  conditions  and 
institutional frameworks of each country, the intervention of the government and the 
results of STI policies vary. China has the potential to attract investments to different 
industries  using  biotechnologies  given  its  potential  market  and  commercial 
incentives.  India  has  developed  a  strong  scientific  base  and  has  re-converted 
traditional industries (  e.g.  chemical and pharmaceutical) into biotechnology us ers that 
are focused on export market. Singapore bas focused its efforts on the most dynamic 
industry using biotechnologies: biopharmaceutical. 
9.5 Mexico 
As  mentioned  in  Chapter V,  since  the  1970s,  the  Mexican government  started  to 
implement public policies to  develop scientific and technological capabilities. In the 
last decade, the federal government bas implemented public policies aimed to achieve 
innovation.  However,  these public policies  have no  clear priorities.  In  the  Special 
Program on Science, Technology and Innovation (PECITI, 2007-2012), the Mexican 
government  bas  attempted  to  define  strategie  industries  in  medium  and  high 
technologies. 
Sorne  Mexican  research  institutions  and  enterprises  have  adopted  and  developed 
modern biotechnologies  (see  Chapter VIII).  The translation  from  scientific  results 
into commercial biotechnology products bas faced severa! institutional obstacles. The 
objective of this section is  to  show the public policies and programs that have been 
implemented  in  Mexico  in  order  to  improve  the  adoption  and  diffusion  of 167 
biotechnologies. 
9.5.1 Science and technology policies 
The National Program for Technological and Scientific Development 1984-1988 was 
the  first  program  to  establish  explicit  guidelines  for  biotechnology  development 
related to  national priorities such as  food and health (Solleiro,  1995).  In  this period 
the  specifie  research  lines  included  development  of biotechnologies  like  genetic 
engineering, tissue  culture,  and enzyme engineering, unicellular protein production. 
Also,  sorne  programs  were  implemented  to  encourage  the  adoption  of 
biotechnologies  (Solleiro,  1995:  31 ).  The  main  result  of these  policies  was  the 
incorporation of biotechnology to  the national research agenda and the strengthening 
of research capabilities (Solleiro,  1995;  Corona, 2006), for example, the creation of 
the Institute ofBiotechnology-UNAM and the CINVESTAV-IPN (Possani, 2003). 
In the 1990s the role ofthe Mexican govemment was focused on supporting scientific 
development and leaving technological improvement to  the private sector (Solleiro, 
1995;  Dutrénit et al.,  2010).  Therefore, in  this  period  there was  no  specifie  policy 
focused on the adoption ofbiotechnology (Solleiro, 1995). 
In  the  2000s,  the  ST  policies  introduced  biotechnology  as  strategie  sector.  The 
PECYT  2001-2006  recognizes  the  importance  of biotechnology  and  proposes  a 
National  Program  of Biotechnology and  Genomics;  however  the  Program did  not 
define  any  budget for  this  purpose  (PECYT,  2001:  155-177;  Corona,  2006).  The 
PECITI 2008-2012 and the National Development Plan (PND in Spanish) are in line 
re garding the  importance of biotechnology (Table 9.1 ).  However, the  guidelines of 
PECITI are  focused  only  on bio-safety and  scientific research  issues.  There  is  no 
description  about  the  mechanisms  to  translate  research  results  into  commercial 
products. 168 
Table9.1 
Strategie areas for PND and ST policy 
PND 2007-2012  PECITI 2008-2012  Strategie industries 
-Health  -Biotechnology  -Food and agro-industry 
-Education  -Medicine  -Aeronautics 
-Food  -Energy  -Automobile and auto parts 
-Environment and  -Environment  -Electrics and electronics 
climate change  -Indus  trial technologies  -Pharmaceutical and health 
-Energy  for manufacturing  sciences 
-Economie growth and  -Materials  -Metallurgy 
sustainable development  -Nanotechnology  -Metal-mechanics and capital 
-Fight poverty  -Information and  goods 
-Govemance  communication  -Chemical and petrochemical 
-Population, equity and  technologies 
gender  -Applied mathematics 
-Infrastructure  and modeling 
-Tourism 
Source: PECITI (2008: 48-49). 
In the last decade, sorne efforts have been made to propose the guidelines to elaborate 
a national plan of biotechnology. Dr. Bolivar and colleagues (2003) and the Ministry 
of Economy (Secretaria de Economia, 2010)  elaborated comprehensive  analysis of 
the situation of biotechnology in Mexico:  training and research activities;  potential 
industrial uses, and described some successful cases. These analyses proposed some 
actions to adopt and diffuse biotechnologies in Mexico (see Table 9.2). 169 
Table 9.2 
Proposed actions to adopt and diffuse biotechnologies in Mexico 
2003  2010 
Human resources  To form and train human 
resources, define new lines 
of  research, and crea  te 
new research centres 
Infrastmcture  To plan and optimize the  To improve the research 
research infrastmcture  infrastructure 
Productive sector  To promote and foster the  To form postgraduates that 
participation in the  can be hired by the private 
development of modem  sec tor 
biotechnology industry 
To reward the creation of 
new process useful for the 
industry 
To develop incubators to 
exploit entrepreneurial 
ideas of young scientists 
To develop topic/sectoral 
clusters 
To create a fund for 
biotechnology activities 
To establish a 
biotechnology association 
Regulatory framework  To develop and advance a  To create a regulatory 
regulatory framework  framework that allow the 
access to GMOs 
Social perception  To discuss and analyze 
issues related to biosecurity, 
bioethics and 
bioprospection. 
Uses of biotechnologies  To solve real problems 
National program  To promote and 
consolidate the adoption of 
biotechnology 
Source: Own elaboratiOn based on Bol! var et al., (2003) and Secretarîa de Economîa (2010). 170 
The  Ministry  of Economy  proposed  also  the  creation  of a  National  ProgJ.·am  of 
Biotechnology (NPB), whose main objectives would be the coordination of the three 
key  actors  in  the  development  of  biotechnologies,  academy,  industry,  and 
governrnent, and to  promote the  development and consolidation of industries using 
these  biotechnologies  (Secretaria  de  Economia,  201 0).  In  addition,  the  authors 
proposed  the  establishment  of critical  support  organizations  and  linkages  for  a 
successful  NPB:  an  association  of biotechnology  enterprises  that  promotes  the 
development  of biotechnology  for  the  industry  and  the  society,  a  fund  to  foster 
productive biotechnology,  and  a  govemment agency  that  coordinated  the  resource 
management (Secretaria de Economfa, 2010). 
Regulatory frameworks 
Since the  mid-2000s, sorne regulatory laws  have been enacted in  order to  promote 
scientific research and industrial use of biotechnologies. They include: 
2005: Bio-safety Law for the use of Genetically Modified Organisms (LBMOGM in 
Spanish).  The  LBMOGM  was  elaborated  by  the  Congress  of the  Union,  after  a 
discussion  among  different  organizations  and  institutions  involved  with  the 
development  of  biotechnology  in  Mexico,  such  as  the  AMC,  UNAM,  UAM, 
CINVESTAV  among  others  and  the  Legislature,  evaluating  scientific  evidence  to 
define  possible  risks  in  order  to  generate  an  adequate  and  balanced  regulatory 
framework for the use of GMOs (Bolivar, 2006: 8). 
2005-2008: Bio-energy Laws. In Mexico there are three laws related with bio-energy: 
•  Law for the sustainable development of the sugar cane, 2005: the objectives of 
this law are to improve 1) the quality of the sugar cane, 2) its industrialization, 
and  3)  the  commercialization  of  the  sugar  cane  products  and  by-products, 
such as ethanol. 171 
•  Law to promote and develop bioenergy, 2008:  its objective is  to promote the 
productions  of  inputs  for  bioenergetics,  based  on  agricultural  activities, 
forestry,  algae, biotechnology and enzymatic processes, without jeopardizing 
the safety and sovereignty of  the country. 
•  Law for  the  exploitation of renewable  energies  and  for  the  funding  of the 
energy transition, 2008. 
In sum, since the  1970s the Mexican government has implemented S&T policies to 
improve  the  scientific  and  technological  capabilities  of the  country,  and  recently 
sorne STI policies have been designed to  encourage technological innovation. In the 
1980s,  the  implementation  of ST  policies  generated  the  basis  of the  country's 
research  capabilities  in  biotechnology.  After  2000,  sorne  regulations  have  been 
enacted to  support  the  development of modern biotechnologies.  In  addition,  sorne 
efforts  have  been  made to  propose  the  guidelines  to  crate  a  National  Program of 
Biotechnology. 
Mexico bas  two  elements that policy makers have to  consider when designing STI 
policies  to  promote  the  adoption  and  diffusion  of biotechnologies:  the  Mexican 
population size and the accumulated experience in industrial activities. The constant 
growth of the  Mexican population poses several challenges related  to  health, food, 
and  environment.  Mexico has  an  important  market  for  biotechnology  and  biology 
products; for instance, the Mexican human health sec  tor represents a market of 1000 
USD  millions.
44  According to  the  International service for  the  acquisitions  of agri-
biotech applications (ISAAA), with data for 2009, Mexico  occupies  the  15th place 
44  Mexic~ is among the eleven largest pharmaceutical markets worldwide, the seventh pharmaceutical 
emerging market, and  the  second market in Latin America, after Brazil (see,  Carolyn  Greton (Sept. 
2011) and Kim Ribbink (Sept.  2011). Infom1ation retrieved from www.pharmavoice.com) (accessed 
on 23  September 2011 ). 172 
among the countries that cultivated OGM (~ 100 000 ha.)
45 
9.6 Characteristics ofbiotechnology agglomerations in emerging countries 
Table 9.3  summarizes the conceptual contributions of this research. Similar to Table 
6.1  (Chapter  VI),  this  table  presents  in  the  column  names  the  stages  of  a 
biotechnology  agglomeration.  In the  case  of an emerging  country  with  a  limited 
govemment  support,  the  'previous  conditions'  are  related  to  the  capabilities 
developed previously to  the  adoption of modem biotechnologies. The  'emergence 
stage' or 'rejuvenation' represents the stage in which enterprises are more active in 
the adoption of biotechnologies and the govemment start to  generate sorne programs 
to support the adoption and diffusion of  biotechnologies. 
The row names represent the  relevant elements for  the  creation of a biotechnology 
agglomeration in an emerging country. At the emergence stage, knowledge-creation 
organizations play an important role to  generate scientific research and train human 
resources.  However,  it  is  not clear that universities  and PRC can  play the role of 
anchor  tenants.  The  Jack  of incentives  to  found  science-based  enterprises  make 
unlikely  that  scientist  working  at  those  universities  can  establish  biotechnology 
enterprises.  In  the  case  of entrepreneurship  and  attraction  of other  firms  to  the 
agglomerations,  it  is  more  likely  to  find  medium  and  large  enterprises  in  mature 
industries willing to adopt biotechnologies to improve their products and processes to 
remain  in  the  market  (i.e.  rejuvenation)  than  new  enterprises  developing  new 
biotechnology  products  to  the  world.  These  enterprises  adopting  biotechnologies 
implement 'imitation' business models. Sorne scientists and non-scientists, however, 
can found small biotechnology enterprises.  Sorne medium and large enterprises can 
establish  format  collaborations  with  other  agents  like  universities  and  other 
45  Information retrieved frowww.agrobiomexico.org.mx/documentos.htm (Accesed on 23  September 
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enterprises. In addition, the funding sources of biotechnology firms  are most of the 
times  family  and  friend;  risk capitals  (like VC and  angels)  are  not present in  the 
agglomeration.  This  situation  is  related  to  govemment  support  or  institutional 
environment.  In the emergence stage,  govemment is  trying  to  create organizations 
and  design  programs  to  encourage  the  adoption  of modern  biotechnologies  and 
support the creation of  new technology-based enterprises. 
Table 9.3 
Characteristics ofbiotechnology agglomerations in emerging countries 
T  -7  1me 
Previous conditions  Emergence 
(Rejuvenation) 
Knowledge-creating  Supp01t to new  Heterogeneity of knowledge 
organizations  research centres  Anchor tenant? 
Entreprenemship and  In sorne sectors S&T  Medium and large firms 
attraction of firms  capabilities  AT? 
-FewR&D SME 
Collaborations  -Informai collaborations 
-Formai collaboration 
Funding  R&D tax credit/subsidies 
Private and farnily funds 
NOVC 
Government support/  RSI 
institutional  1  st steps to improve the 
environment  institutional environment 
-Dep. of  economie development 
-Technology transfer offices and 
technology parks 
Business models  IMITATIVE 
Few potential DBFs CONCLUSIONS 
This chapter presents the theoretical contributions of this  thesis, its  conclusions and 
implications  for  the  STI  policies  for  supporting  the  adoption  and  diffusion  of 
biotechnologies in Mexico. 
Back to the them·y 
Three different bodies of literature -strategie  management, regional agglomerations 
and STI policies- were used to analyze how firms adopt generic technologies, such as 
biotechnologies,  in  institutional  environments  not well-developed  such  as  Mexico. 
The following paragraphs summarize the theoretical value added of  this thesis. 
Business models 
Business models are planning tools that involve the creation and capture of economie 
value  (Magretta,  2002).  Externat  and  internat  elements  affect  the  evolution  and 
adaptation of business models. The extemal elements are related to  the economie and 
institutional  environments  while  the  internai  elements  are  tangible  and  intangible 
resources (Penrose 1959). In the last decade the concept of business  model has been 
used extensively, however little theoretical research has been done to explain how the 
variety of elements influence the way in which the business model is designed (Onetti 
et al.,  2010;  Zott et al.,  2011).  Different authors have underlined the  importance of 
strategy,  financial  structures,  capabilities,  collaborations,  and  location  to  formulate 
business models. 
The resources view literature stresses the importance of internai resources as elements 
that  distinguishes  each  finn  (Penrose,  1959).  The  evolutionary  economies  view 
proposes that resources per se are not enough  to  generate competitive  advantages. 
The repetition (through routines)  and knowledge accumulation (Nelson and Winter, 
1982)  allows  organizations  to  master  specifie  activities,  which  are  defined  as 175 
capabilities (Foss, 1996). According to  these capabilities firms design their strategies 
to  remain in the market (Nelson,  1991).  In industries that rely strongly on scientific 
advances, firms often depend on collaborations with different organizations to obtain 
complementary  capabilities  and  assets  for  creating  and  commercializing  complex 
products and services (Powell et al., 1996). 
Although bioteclmologies can be  applied to  different industries, the  pharmaceutical 
industry bas been one of the most dynamic industry adopting modern biotechnologies 
(Pisano,  2006).  Several  authors  have  analyzed  the  biopharmaceutical  sector  in 
developed countries (Prevezer, 1997; Niosi, 2005; Cockburn and Stern, 2010). These 
studies  have  underlined  that biotechnology firms  in  those  countries  have  followed 
business  models  that  are  closely  related  to  scientific  research  organizations.  The 
founders of those finns are in most of the cases scientists who know the state-of-the-
art of biotechnologies, have contacts with several funding organizations (private and 
state-owned)  that support research  activities  and  assist  in  the  commercialization of 
biotechnology  products. Based on these  organizations  and  relationships,  two  well-
defined business  models have emerged:  1)  classic biotechnology model and 2)  large 
vertical  integrated  model  (McKelvey,  2008).  The  first  business  model  represents 
those biotechnology firms dedicated almost exclusively to  R&D activities, while the 
second business model represents  those firms  that emerge from  the classical model, 
and  have  integrated  all  the  processes  needed  to  create  and  commercialize 
biotechnology products (Pisano, 2006; McKelvey, 2008). 
In this research, I have underlined the importance of three elements in the definition 
of business  models  in  biotechnology  enterprises:  capabilities,  collaborations,  and 
institutional environment. Enterprises adopting bioteclmologies in emerging countries 
face  institutional  obstacles  and  shortage  of resources.  Consequently,  in  emerging 
countries, other types of business models are appearing. For instance, I point out the 
existence of what I caU an "imitative business model''. Given the high risk involved 176 
in the development of new biotechnology products, local enterprises seek at first, to 
adopt  biotechnologies  to  imitate  products  that  are  already  in  the  market.  This 
imitation requires that local enterprises have sorne level of research, managerial and 
commercial capabilities to  ensure the successful adoption of biotechnologies. In this 
sense, in emerging countries, medium and large enterprises with extensive experience 
seem to  play the  role of entrepreneurs. These firms  have accumulated experience 
and resources that allow them to  collaborate with other agents - at the  national and 
international  level.  This  collaboration  is  driven  more  by  the  urgency  of large 
companies  to  remain  in  the  market  rather  than  by  incentives  generated  by  the 
institutional environment. 
Geographical agglomerations 
High technology enterprises tend to  agglomerate in specifie area or regions  (Niosi, 
2005). Biotechnology enterprises are not the  exception, especially those involved in 
the  human  health  sector.  The  reasons  for  these  agglomerations  are  the  positive 
externalities  that  enterprises  can  find  in  the  region:  qualified  human  resources, 
services, and funding (Prevezer, 1998; Niosi, 2005; Cockburn and Stern, 2010). Since 
the 1980s, several scholars have analyzed this phenomenon using different concepts. 
Three agglomeration concepts are relevant for this research: cluster, regional system 
of innovation, and anchor tenant.  The concept of cluster identifies the actors within 
the  agglomeration  (Porter,  2000).  The  concept of RSI  identifies  the  relationships 
between  different  actors  in  the  region  (Cooke  and  Morgan,  1998).  Finally,  the 
concept of anchor tenant identifies which organizations are the main attractors to  the 
agglomeration (Agrawal and Cockburn, 2003; Feldman, 2003). 
In  the  case  of biotechnology,  several  authors  have  underlined  the  presence  of 
different  organizations  and  institutions  that  contribute  to  the  creation  and 
consolidation of biotechnology clusters in developed countries.  These organizations 177 
and  institutions  are:  knowledge-creating  organizations,  DBFs,  large  firms, 
govemment agencies, govemment funds for scientific research, intellectual property 
laws,  incentives  to  encourage  entrepreneurship  and  attract  venture  capitalist,  and 
collaborations  between  different  actors.  These  organizations  and  institutions  are 
different  or  non-existent  in  emerging  countries,  therefore,  the  dynamics  of 
biotechnology agglomerations differ. 
Sorne  authors  have mentioned that regional  agglomerations  follow  a  lifecycle  that 
includes four stages: emergence, growth, sustainment and decline (Braunerhjelm and 
Feldman,  2006).  Agglomerations  following  this  lifecycle  often  rely  only  on  one 
industry or similar industries. On the contrary, dynamics of agglomerations differ in 
the  case  several  industries  converge  in  the  same  geographie  area:  these 
agglomerations  can  rejuvenate  due  to  the  convergence  of several  high-technology 
industries (Menzel and Fomahl, 2009). 
In  the  last  two  decades,  emerging  countries  like  China,  India,  and  Brazil  have 
implemented  policies  to  create  biotechnology  agglomerati.ons.  These  initiatives 
attempt  to  emulate  prevalent  conditions  in  developed  countries  (Prevezer,  2008). 
Therefore,  these  initiatives  seek  to  create  or  attract  all  the  actors  involved  in  the 
creation  and  commercialization of biotechnology products.  Sorne  of the  programs 
include the establishment of scientific and technological parks, and incubators. These 
initiatives require extensive government support, and most of the times the financial 
support  falls  short  to  accomplish  the  objectives.  ln  addition,  the  periods  of 
development  of biotechnology  products  are  long,  especially  in  bio-pharmaceutics 
(12-15  years  ).  Th  en,  successful  biotechnology  agglomerations  require  large 
investments in infrastructure, creation of capabilities, and support for new enterprises 
with new biotechnology products. In this sense, agglomerations in emerging countries 
are not the same as those in developed countries. 178 
I  suggest  that  the  rejuvenation  m  emergmg  countries  1s  possible  by  the  active 
participation not only of the  government but the enterprises  that aim  at improving 
their products and processes to  remain in the market. In this sense, entrepreneurship 
cornes more from large, established enterprises - with products already in the market 
in  sectors  such  as  pharmaceutical,  food  processing,  agriculture- rather  than  from 
biotechnology scientists working at universities and PRC. In addition, biotechnology 
agglomerations prosper in urban geographical areas, which host severa! industries -
high-tech industries among them- and research universities. Often, such agents gather 
in  these  agglomerations  for  historical  reasons  even  if most  of the  times  these 
industries  are  not  related  with  biotechnologies  per  se.  Once  interaction  between 
enterprises  and  knowledge-creating  organizations  begin,  probably  universities  will 
become anchor tenants for the creation of new biotechnology enterprises. In order to 
generate these DBFs, other organizations are needed to assist them. 
However, in emerging countries like Mexico the creation of this kind of organization 
is hindered by the lack of institutional capabilities. In spi te of this situation, medium 
and  large  enterprises  that have  accumulated  research,  managerial  and  commercial 
capabilities  are  able  to  establish  collaboration  agreements  with  national  and 
international agents while SME, with less experience and resources, collaborate with 
national agents, mostly universities and PRC. 
Public policy 
The  evolutionary  economies  approach  suggests  that  the  role  of government  is  to 
create and diffuse technological knowledge, stimulate learning processes, and create 
and maintain a coherent institutional system through public policies (Dalum et  al., 
1992; Niosi and Bellon,  1995;  Carlsson, 2006; Cimoli et al., 2009;  Cockburn and 
Stern,  2010). The  characteristics  that  influence  the  design  and  implementation  of 
public policies are:  the kind ofpolicies (e.g.  science, technology and innovation), the 179 
scope  (  e.g.  horizontal  or  vertical  technology  poli  ci es),  the  relationship  with  the 
environment (  e.g.  top-down and bottom-up  ), and the geographie scope (  e.g.  nation, 
region, sector) (Metcalfe, 1994; Dodgson and Bessant, 1996; Teubal, 1997; Todtling 
and Trippl, 2005). Developed countries have implemented STI policies to  encourage 
the  creation and  commercialization of new high technologies.  Emerging  countries, 
however, struggle to  design and implement STI policies. According to  the  literature 
review,  governments  have  to  establish  priorities  in  order  to  allocate  resources 
effectively. In the case of biotechnologies, a first step is  to  establish the adoption of 
biotechnology as  strategy for economie growth.  Developed and  emerging countries 
have  established  national  programs  of biotechnology  to  define  the  benefits  of 
adopting  biotechnology.  Another  important  element  is  funding;  biotechnologies 
require  large  investments,  therefore,  national  resources  should  be  allocated 
strategically  in  a  few  locations.  Even  in  developed  countries,  there  are  few 
biotechnology agglomerations.  Finally, governments may consider the  attraction or 
creation  of organizations  and  institutions  needed  to  develop  and  commercialized 
biotechnology products. 
Evidence from  other emerging countries, where governments are willing to  support 
the  adoption  of biotechnologies,  shows  that the  process  to  create  capabilities  and 
institutional  frameworks  requires  time  and  resources.  Since  the  1980s,  the 
governments  of the  three  countries  presented  in  Chapter  IX  - China,  India  and 
Singapore- started to  implement STI policies.  However,  in  the  cases of China and 
India the attempts to encourage the creation of organizations like DBF or technology 
parks,  and  new  industries,  for  instance  VC,  have  faced  severa!  obstacles.  Also, 
collaboration between different organizations remains difficult to achieve. 
It seems that a 'biotechnology plan'  is  an important step to  defme biotechnology as 
strategie generic technology for economie growth. However, at first, governments in 
emerging countries have to evaluate the creation of ad hoc institutions that assist the 180 
emergmg  business  models,  and  later,  eventually,  to  create  organizations  and 
institutions to foster radical biotechnology innovations. 
Implications for ST policy for adopting biotechnologies 
Mexico could improve the adoption and diffusion of biotechnologies if the national 
government defines  biotechnology as  a  strategie  technology for  economie  growth, 
and  establishes  a  National  Program  that  sets  the  guidelines  for  the  design  and 
implementation of STI policies.  In this  sense,  it seems crucial that the  government 
evaluates  the  current  situation  of scientific  biotechnology  research  and  its  real 
potential use by the industries that contribute to  economie development.  Once these 
elements are evaluated, govermnent agencies could design programs that complement 
and enforce the lines suggested by the National Program ofBiotechnology. 
Another important element to  be considered in the design of STI policies is  regional 
agglomerations.  The development of high technology agglomerations requires huge 
investments.  Therefore,  the  Mexican government  has  to  evaluate  where  the  most 
salient research institutions already exist, and which kinds of enterprises are adopting 
modern biotechnologies in order to  create appropriate organizations and institutions 
to foster innovation. 
Finally, the collaboration and interaction of different organizations and institutions is 
crucial  for  the  adoption  of modern  biotechnologies.  Therefore  STI  policies  for 
adopting  biotechnologies  have  to  emphasize  the  creation  and  implementation  of 
mechanisms to encourage and facilitate networking. The examples of China and India 
show that establishing relationships  between different organizations  is  not an easy 
task, even with the intervention of powerful and resourceful government agencies. 
General conclusions 
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The general conclusion of this  thesis is that business models appearing in emerging 
countries are different to  those of  developed countries. 
Sorne  emerging  countries  like  Mexico,  offer very few  incentives  to  create  DBF  -
SMEs dedicated mainly to  R&D activities. Moreover, the opportunities for SMEs to 
become large enterprises based on the  biotechnology products they have developed 
are  almost  non-existent  (even  in  advanced  countries  ).  Therefore,  large  enterprises 
with experience, and managerial capabilities are more able to achieve the adoption of 
modern biotechnologies and the commercialization ofbiotechnology products. 
There  are  sorne  signs  that  allow  thinking  about  a  potential  biotechnology 
agglomeration in  the  central region of Mexico  (Mexico  City and  Morelos), which 
hosts  high-level  universities  working  on  biotechnology  research,  and  most  of the 
SMEs and large enterprises that are adopting modern biotechnologies. There are other 
Mexican states that have also  important research laboratories, but they do  not have 
other  organizations  that  can  contribute  for  the  creation  of  a  biotechnology 
agglomeration. After the mid-2000s, SMEs and large enterprises started to  establish 
collaboration agreements with agents, most of the times, located in the same region. 
Particularly,  SMEs  collaborate with national agents  (most of the  times  knowledge 
creating organizations) while  large enterprises  have  established collaborations with 
national and international partners. 
Finally, government intervention seems mandatory to define and support the adoption 
of biotechnologies. The evidence of other emerging countries show that government 
should have a long-term vision that allows to  devote resources to support knowledge 
creation,  funding  and  improvement  of institutional  environments.  However,  the 
design  and  implementation  of STI  to  adopt  biotechnologies  can  be  hindered  by 
underdeveloped institutional  capabilities.  An emerging  countries  like  Mexico,  may 
seek to adopt a strate  gy for assis ting the needs of business models that are appearing, ----------
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to leam and improve institutional capabilities. 
Limitations and further research 
The objective of this thesis was to  analyze the adoption of a generic technology that 
can be applied to different industries, like biotechnology, in emerging countries. The 
main limitation was to  identify biotechnology enterprises. In Mexico there is  not an 
agency in charge of the collection of data of these enterprises and there are different 
sources with different information. As mentioned in Chapter VII, the report presented 
by the Ministry of Economy lists 306 biotechnology enterprises, which I preferred to 
mention them as "potential biotechnology-adopters", because it is not clear if they are 
actually using  biotechnologies, particularly in  the  case  of multinational companies 
(  e.g. pharmaceuticals, grain-traders). 
Another limitation, linked to the above issue, was the number and type of enterprises 
interviewed. Most of the enterprises were Mexican-owned. Thus, further research is 
needed to analyze other kinds of enterprises, for instance multinational corporations. ANNEXES ANNEXA 
EMERGING COUNTRIES 
There is  not a clear definition of emerging countries.  However, sorne  authors have 
grouped emerging countries and coined tenns like, BRIC (Brazil, Russia, India, and 
China),  while  a  variety  of agencies  have  proposed  different  lists  of emerging 
countries  that include:  Argentina,  Brazil, Chile, China, Colombia, Czech Republic, 
Egypt,  Hong Kong, Hungary,  India,  Indonesia, Malaysia,  Mexico,  Morocco,  Peru, 
Philippines,  Poland,  Saudi  Arabia,  Singapore,  South  Africa,  South  Korea, Russia, 
Taiwan,  Thailand,  and Turkey
46
.  The table  A.l  compares  information about GDP, 
GDP per capita, and population of a list of developed countries and those that have 
been considered as emerging countries. 
46 For example, see S&P Global Broad Market Index Fact Sheet (Feb 15, 201 1):  https://www.sp-
indexdata.com/idpNiewPRCMethodologyHome.do?citiMethodology=citiGroupMethodology&indexl 
d=2&prcld=O  (Accessed on 22 June 2011), see FTSE Country classification update (September 2010): 
http://www.ftse.com/Indices/Country  _ Classification/Downloads/Sept%2020 1  0/FTSE  _Country_ Classi  f 
ication_Sept_2010_Update.pdf(Accessed on 22 June 2011) 185 
Table A.1 
Leading and emerging economies 
GDP (PPP)  GDP (PPP) 
Population 
Country  USD billion  per capita 
(2010 est.)  (2010 est.)  (July2011 est.) 
Leading economies 
USA  14,660  47,200  313,232,044 
Japan  4,310  34,000  126,475,664 
German  y  2,920  35,700  81,479,834 
UK  2,173  34,800  62,689,362 
Canada  1,359  39,100  34,030,589 
Emerging economies 
China  10,090  7,600  1,336,718,015 
In  dia  4,060  3,500  1,189,172,906 
Russia  2,223  15,900  138,739,892 
Brazil  2,172  10,800  203,429,773 
Mexico  1,567  13,900  113,724,226 
South Korea  1,459  30,000  48,754,657 
Indonesia  1,030  4,200  245,613,043 
Tm· key  961  12,300  78,785,548 
Taiwan  822  35,700  23,071,779 
Po  land  721  18,800  38,441,588 
Saudi Arabia  622  24,200  26,131,703 
Argen  tina  596  14,700  41,769,726 
Thailand  587  8,700  66,720,153 
South Africa  524  10,700  49,004,031 
Egypt  498  6,200  82,079,636 
Co  lombia  435  9,800  44,725,543 
Malaysia  414  14,700  28,728,607 
Philippines  351  3,500  101,833,938 
HongKong  326  45,900  7,122,508 
Singapore  292  62,100  4,740,737 
Peru  276  9,200  29,248,943 
Czech Republic  261  25,600  10,190,213 
Ch  ile  258  15,400  16,888,760 
Hungary  188  18,800  9,976,062 
Mo  rocco  151  4,800  31,968,361 
Source: Central Intelligence Agency (20 11) ANNEXB 
STRATEGIC MANAGEMENT 
Strategy literature includes concepts and tools helping managers to deal with changes 
in markets (eus tomer needs  ), institutional environments (regulations and policies) and 
technologies  (information and communication technologies).  For example, between 
the 1950's and the 1970's, strategy focus was on planning and managing portfolios of 
market-product to  ensure long-term profitability (Ansoff,  1965; Andrews,  1971).  In 
the  1980's, strategie though was focused on competition, how to  find a competitive 
place in the  market and within an industry to  obtain superior profitability (Porter, 
1980, 1985). Since the mid-1995, strategy authors have underlined the importance to 
react quickly to  environment changes  and maintain a competitive  position (Brown 
and Eisenhardt,  1998).  In the early 21th century,  collaboration and rejuvenation of 
business  models  seem  to  be  key  elements  to  survive  in  a  dynamic  market  place 
(Davenport et al., 2006; Johnson, 2010). 187 
Table B.l 
Technological revolutions and strategie management approaches 
New technologies and  Strategie 
Technological 
new or redefined  management  Dominant focus 
revolution  industries  approach 
......  ··················-······ 
• Mass-produced 
automobiles 
• Cheap oil and oil fuels 
1950's-1960's  • Planning growth . 
From 1908  • Petrochemicals 
Planning:  • Capital and 
Age of oil, the  • Interna! combustion  Business and  operational 
automobile, and  engines  budgetm-y planning  budgeting. 
mass production  • Home electrical  • Financial control. 
appliances 
• Refrigerated and frozen 
food 
• Balancing a 
1970's  portfolio of strategie 
Balancing: 
business 
Optimizing  units/firms/products 
corporate entities 
• Synergy of  re sources  and functions. 
and functions. 
Cheap microelectronics 
........  ······························- ············-······ 
•  1980's  • Choosing industries 
From 1971  • Computers, software 
Positioning:  and markets, and 
Age of  • Telecommunications  Industries, markets  positioning within 
inf01mation and  • Control instrument  and fitms adapting"  them 
telecommunicat  • Computer-aided  and achieving  • Adapting and fitting 
ions  biotechnology and new  unique "fit".  to the environment 
mate  rials 
1990's  • Somces of 
Resources and  competitive 
capabilities:  advantage within the 
Resomce-based  finn. 
view for  • Responding to 
~()l?E~tiY:'~  .................................  )~YP(;:l:~~()!!!P(;:! iti(.)I1 : 
• Innovations from 
• Renewable energy  Early 2ls
1 century  collaborative 
• Energy storage  Organizational  business networks. 
From 2003  technologies  poise:  • Portfolio of 
Age of clean- • Electric vehicles  Value innovation  traditional and new 
tech and biotech 
Nano materials  through multiple  business models  • 
• Synthetic biology  business models.  • Corporate 
-·  -·······-·········- ······-···········  ..  ····-··  ~:~j~y -~ _1!:<1~!(.)~ .:  ......  .  ...................... 
1  . 96  Source: Author, based on Davenport et al (2006. 170) and Jolmson (20  O. ANNEXC 
BIOTECHNOLOGY ENTERPRISES IN MEXICO 
In  Augusts  2010  the  Ministry of Economy (Secretaria  de  Economia)  presented  a 
study  about  the  situation  of biotechnology  in  Mexico.  The  Research  Centre  of 
Applied Biotechnology of the National Polytechnic Institute (CIBA-IPN in Spanish) 
was  in  charge  to  elaborate  this  study.  This  document  list  306  'biotechnology' 
enterprises and includes national enterprises, subsidiaries of MNC, and state-owned 
enterprises.  According to  this  study,  these  enterprises  are  located in  25  states  and 
Mexico City (Figure C.l  ). 
Figure C.l 
Geographie distribution of  potential biotechnology-using enterprises in Mexico 
(percentage) 
othee Me.xican states (22) 
2.5% 
State of  Mexico 
13% 
Mexico City 
46% 
Source: Own elaboration based on data from Secretaria de Economia (20 1  0) 189 
In this list the entities with more,  than 10 enterprises are:  Mexico City (141), State of 
Mexico (40), Jalisco (37), and Puebla (11) (see Figure C.1  and Table C.1). Here it is 
important  to  mention that  the  sorne  enterprises  have  commercial  and  distribution 
offices in Mexico City but their facilities for production and R&D could be located in 
other Mexican states. This fact may affect the number of enterprises. 
Table C.1 
Distribution of  biotechnology firms in Mexico 
State  Number of enterprises 
1  Aguascalientes  1 
2  Baj a California  2 
3  Chiapas  2 
4  Chihuahua  5 
5  Coahuila  6 
6  Durango  3 
7  State of Mexico  40 
8  Guanajuato  7 
9  Hidalgo  2 
10  Jalisco  37 
11  Mexico City  141 
12  Michoacan  5 
13  Morelos  3 
14  Nayarit  2 
15  Nuevo Leon  9 
16  Oaxaca  1 
17  Puebla  11 
18  Querétaro  4 
19  Quintana Roo  1 
20  San Luis Potosi  1 
21  Sinaloa  5 
22  Sonora  3 
23  Tamaulipas  2 
24  Tlaxcala  1 
25  Veracmz  6 
26  Zacatecas  1 
No defined  2 
Total  306 
Source: Own elaboration based on data from Secretaria de Economîa (2010) 190 
These enterprises have activities in a variety of sectors. Table C.2 shows the number 
and percentage of  enterprises according to the sector. 
Table C.2 
Number and percentage of (biotechnology) enterprises in different industries 
Sec  tor  Number  Percentage 
Agriculture  66  22 
Food Processing  36  12 
Environment  16  5 
Fermentation and biology products  23  8 
Livestock  18  6 
Pharmaceutical  119  39 
Services  26  9 
Total  304  100 
Source: Own elaboratiOn based on data from Secretaria de Economia (2010) 
Here it is  important to mention that not all these enterprises carry out biotechnology 
activities. For example, the study (Secretaria de Economfa, 2010) lists  119 enterprises 
in the pharmaceutical sector:  28  multinational companies and 91  local companies. I 
searched on  Internet if those multinational companies have biotechnology  research 
activities.  The results  were  that  in  sorne  cases  the  MNEs  mention  that  they  have 
research  activities,  but  they  do  not  mention  if  these  activities  are  related  to 
biotechnologies.  In  the  case of domestic  enterprises,  only a handful of them  have 
biotechnology research activities. 
Consequently,  I searched for information of each enterprise  on Internet, and when 
possible, obtain information about the products and technologies used. The objective 
of this search was to  verify if the enterprises have scientific activities as we can find 
in  bioteclmology  enterprises  located  111  developed  countries  or  other  emerging 
countries like China and India. ANNEXD 
QUESTIONNAIRE FOR ENTERPRISES AND RESEARCH CENTRES 
(ENGLISH) 
UNIVERSITÉ DU QUÉBEC À MONTRÉAL 
DEPARTMENT OF MANAGEMENT AND TECHNOLOGY 
CANADA RESEARCH CHAIR ON THE MANAGEMENT OF TECHNOLOGY 
RESEARCH TEAM: 
Jorge Niosi, Ph.D. (professor and research director) 
Julieta Flores Amador (Ph.D.  student) 
"QUESTIONNAIRE ABOUT THE ACTIVITIES AND CHARACTERISTICS OF 
ENTERPRISES USING AND DEVELOPING BIOTECHNOLOGIES IN MEXICO" 
Statement of  confidentiality 
AU responses to this questionnaire will be kept confidential and secure. They will be 
made available only to the research team, al of  who will be bound by this statement of 
confidentiality. All reports arising from this research will refer to aggregate statistics 
and will not refer to any company by name, product or people. 
1 agree to abide by the above Statement of  confidentiality ________  _ 
Interviewer signature on behalf  of  the entire research team 
I have read and agree with the above Statement of confidentiality ______  _ 
Res pondent signature on behalf  of  the company 
Note. The interviewer is free ta sign any non-disclosure agreement the respondent finds 
appropriate, and the signature of  the interviewer on such as agreement will bind the entire 
research team to its terms and conditions. Questionnaire 
Name of  person completing the questionnaire and title: 
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Phone (s) ............................. .. .......................................................... . 
E-mail (s) .......................................................... .. .............................  . 
Fax (s) ............................................................................................ . 
Web address .....................................................................................  . 
1  Section 1: Biotechnologies in use (use the table provided) 
This section measures the use of biotechnologies in your firm 
Biotechnologies  Currently  If  currently used, you use them for  #  years 
used  Product/process  Ctment  Environmental  muse 
development  production  pm·poses 
DNA-The coding  Y  es .... 
No .... 
Proteins and  Yes .... 
molecules- The  No  .... 
functional blacks 
Cell and tissue  Y  es .... 
culture and  No  .... 
engineering 
Process  Yes .... 
biotechnologies  No .... 
Sub-cellular  Yes .... 
organisms  No .... 
Other (i.e. bio- Yes .... 
informatics)  No  .... 
Nano- Yes .... 
biotechnologies  No .... 
Environmental  Yes .... 
biotechnology  No .... 
Other (please  Y es .... 
specify)  No .... 
1  Section 2: Human resources in biotechnology 
-· 
1 193 
Number ofbiotechnology employees 
2. a) How many employees did your firm employ in this country in 2008? .................. . 
b) How many employees had biotechnology-related responsibilities in 2008? ......... . 
c) Employees with full time biotechnology responsibilities in this site ................. . 
Position 
Number of full-time  employees  in 
biotechnology 
Scientific Direction/Research 
Technicians 
Regulatory/Clinical Affairs 
Production 
Finance/Marketing/Business Development 
Administrative Management 
Other, please specify 
Total employees with full-time biotechnology 
responsibilities 
d) Employees with part-time biotechnology responsibilities 
For  each  group  listed  below  indicate  how  many  are  employees  with  part-time 
biotechnology responsibilities (less than 50% of their time spent on biotechnology-
related activities)? If an employee fulfills  more  than one duty, report their primary 
responsibility.  Count each person only once. Please report typical employment level 
for 2008 in full-time equivalents (FTE). 
Number of  part-time 
Position  employees 
Scientific Direction/Research 
Technicians 
Regulatory/Clinical Affairs 
Production 
Finance/Marketing/Business Development 
Administrative Management 
Other, please specify 
Total employees with part-time biotechnology 
responsibilities 
e) Total Number ofbiotechnology employees. 
Total employees with full-time and part-time biotechnology-related responsibilities 
Recruiting and Staffing Practices 3. a) Does your finn have unfilled biotechnology-related positions? 
No: Go to question 3 b) 
Y  es: In the table below indicate the number of  unfilled positions by category: 
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Position 
Number ofunfilled positions 
Scientific DirectionJResearch 
Technicians 
Regulatory/Clinical Affairs 
Production 
Finance/Marketing/Business Development 
Administrative Management 
Other, please specify 
b) Does your firm have a formai pro  gram to  train and develop pers mm el for internai 
promotions to senior positions? 
No 
Y  es 
c) Did your firm attempt to recruit any biotechnology employees in 2008 
No ... -+Go to question 4a 
Yes ... -+ Were you successful?  No ... -+ Go to question 3d 
Y  es ... -+  How many did y  ou hire? 
d)  Did you  attempt  to  hire biotechnology staff residing outside of this  country in 
2008? 
No .. . 
Y  es ... -+ In  the  table below indica:te  the  number of biotechnology staff hired from 
each region. 
Region  Repatriation  International hiring  Total 
USA 
Canada 
Europe 
China 
In  dia 
Asia (  other than 
China or India) 
Other (please 
specify) 1 Total employees 
hired abroad 
4. a) Did any biotechnology personnelleave the firmin 2008? 
No ... -+Go to question 5 
Y  es ... -+  How many? 
b) What % ofthose who left in 2008 was your firm's decision? ....................... . 
1  Section 3 - Finn history 
5. a) What year was your company established? ....................... . 
b) What were the motives to establish the company in this location? 
c) what are the specifie advantages that the company has in this location? 
Advantages  YES 
Universities/research centres 
Close to 
Hospitals 
Important suppliers 
Important clients 
Access to specializedlqualified human resources 
Infrastructure (transport, communications) 
Access to financial support 
Government incentives  Policies 
Funds 
Other (please specify) 
6. Is your finn a public finn? 
No ... -+Go to question 8 
Y es ... -+ What year was the Initial public offering (IPO)? 
7. a) Has your finn merged with another firm? 
No ... -+Go to question 8 
Y es ... -+  What year did the mer  ger take place? 
b) What was the reas on for the mer  ger? 
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8. a) Is your firrn a domestically owned company? 
No ... -+Go to question 10 
Yes ... -+ 
b) Does y  ou firrn have branches outside this country? 
No .. . 
Y  es ... -+  Do  es y  our firm conduct R&D outside this country? 
No ... Yes ... 
9.  Is  you  firm  a  spin-off?  (A  spin-off  is  defined  as  a  new  finn  created  to 
commercialize  technology  developed  in  universities,  public  laboratories  or  other 
firrns? 
No ... -+Go to question 10 
Yes ... -+Was your finn a spin-off from: 
•  University/hospital 
•  Another biotechnology company 
•  Non-biotechnology firrn 
•  Government agency or laboratory 
•  Other, please specify 
1  Section 4:  Innovative biotechnology products 
This section measures the development of  new biotechnology products and processes 
by your firm. 
10. a) Do you have products/proéesses on the market that require the use of 
biotechnology? 
Yes...  No  ... 
b) Is your firrn currently developing products that require the use ofbiotechnology? 
Yes...  No ... 
c) Is your firm currently developing processes that require the use of biotechnology? 
Yes...  No ... 
d) Do you consider biotechnology central to your firm's activities or strategies? 
Yes...  No ... 197 
11. a) In the table below, please indicate the number ofbiotechnology products or 
processes your firm currently has for each stage of  development in the Human Health 
Sector. If it is "0" (zero) please indicate "0". 
Biotechnology  Number ofbiotechnology products/processes by development stage 
sec  tor  R&D  Pre- Clinicat  Clinicat  Clinicat  Approved/ 
clinicat  phase 1  phase 2  phase 3  On 
trials  market/ 
Production 
l"~ff~" - "']"'*  '" ?.'tt,  v'iJj Xf~llf~  Ût~Odf~h  ';}"'- ,"]""'  *  ~  >~/}<> 
Diagnostics 
Therapeutics 
Drug delivery 
b) In the table below, for each sector listed please indicate the number of 
biotechnology products or processes your firm currently has for each stage of 
develonmP.nt  If it is "0" (zero) indicate "0". 
Biotechnology sector  }l"umber of hiotP.r.hnology products/proœssP.s  by deve;vpment stage 
R&D  P  re-clini cal  Rcgulatory phase  Approved/ 
trials  Release assessment  On market/ 
Field trials  Final pre-market  Production 
Pre-market  assessment 
.~ghculture  biotec}molo~ 
Plant hiotechnology 
Ammal  biotechnology 
Non food agricultme 
for industrial uses 
Non food agricultme 
for medical uses 
Energy 
Mining 
Forest products 
;J 
Air 
Water 
~ 
Fish health, s:renetics 
Hioi  -"· 
Genomics and 198 
molecular modeling 
Gene therapy 
Food processing 
Bio_processing 
Functional 
food/neutraceuticals 
Other (specify) 
1  Section 5: Biotechnology Products Regulations 
12. a) In 2008, did you have biotechnology products/processes in any stage of  R&D 
but not yet on the market? 
No .. .. -+Go to question 13 
Yes ... -+Go to question 12 b 
b) Of the biotechnology products or processes y  our firm had in research and 
development stages (not yet on market) in 2008, how many require formai regulatory 
evaluation and/or approval by national regulatory authorities? 
Number .. .......  . 
c) In 2005, for your principal biotechnology product, what is the total duration ofits · 
regulatory process to date (in 
months)? ...... ...........................................................  . 
d) What was your last year expenditure in 
R&D? ....................................................... . 
e) What was y  our last year expenditure in 
regulation? ............. ...... ....... ......................  . 
13. Did you experience any problems in the regulatory process, such as: 
Cost  Y es ..... No ....  . 
Speed  Y  es .. ... No ....  . 
Norms Yes ..... No ....  . 
Other  Y es ..... No .. ..  . 
14. a) Did your firm contract out biotechnology related activities in 2008? 
Organization  Number of  contracts 
University/hospital 
Government Lab 
Other biotechnology firm 
Other, please specify 
Total 199 
b) Did your firm pro  vide contract services to other firms or organizations? 
No ... -+Go to question 15 
Y  es ... -+  For each type of contract please provide number and revenues 
Organization  Number of contracts 
Other biotechnology firm 
Pharmaceutical firm 
Form other than biotechnology or pharmaceutical 
Govemment Lab 
University/hospital 
Other, please specify 
Total 
Collaborative arrangements 
Cooperative  and  collaborative  arrangements  involve  the  active  part1c1pation  in 
projects  between your  company and other companies  or organizations  in  order  to 
develop  and/or  continue  work  on  new  or  significantly  improved  biotechnology 
processes,  products  and/or  services.  Pure  contracting-out  work  is  not regarded  as 
collaboration. 
15.  a)  Was  your  firm  involved  in  biotechnology-related  cooperative/collaborative 
arrangements with other companies or organizations in 2005?  (Please include bath 
those inside and outside the country) 
No  ... -+Go to question 16 
Y es ... -+Pro  vide the number of  arrangements by purpose and partner type 
Arrangement  Number of  arrangements by partner type 
purpose  Bio  tech  Pharma  Firm other than  Academie  Govemment 
firm  firm  biotech or  institution/  lab or 
pharmaceutical  hospital  agency 
To conduct 
R&D 
Regulatory 
aff  airs 
Access to 
others' patents 
Production/ 
Manufacturing 
Access 
markets 
Access 
Capital 200 
Access 
intellectual 
property 
Access  others' 
knowledge/ 
skills 
Lower 
exp ens es 
Other,  please 
specify 
b) In 2005, was your firm involved in biotechnology related cooperative/collaborative 
arrangements with other foreign companies or organizations (located outside of  the 
country)? 
No ... -+Go to question 16 
Y  es ... -+ In the table below, check collaboration/cooperation arrangements by each 
type and their 
geographie location: 
Partner type  USA  Europe  Canada  China  In dia  Other 
Biotechnology firm 
Pharmaceutical firm 
Form other than biotechnology 
or pharmaceutical 
Government Lab 
University/hospital 
Other, please specify 
c) Rate the following purposes in your decision to form collaborative/cooperative 
arrangements with a foreign partner (located abroad). Rank the three most important 
Arrangement purpose  Rank 
To conduct R&D 
Regulatory affairs 
Access to others' patents 
Production/ Manufacturing 
Access markets 
Access Capital 
Access intellectual property 
Access others' knowledge/ skills 201 
Intellectual property 
16 a) Does your finn have biotechnology related patents or pending patents? 
No ... -+Go to question 16 d 
Y es ... -+  How many? Indicate the distribution of biotechnology related patents and 
pending patents your firm has by Patent Office: 
Domestic  USPTO  European 
Existing 
patents 
Pending 
patents 
Expired 
patents 
16 b) Does your finn have biotechnology related trademarks? 
No...  -+Go to question 17 
Y es ... -+How many? 
Other 
17. a) Did your firm assign or license biotechnology related intellectual property (IP) 
rights to another finn? 
No ...  -+Go to question 17 b 
Y es ... -+For each type of IP instrument listed below, please indicate the number of 
IP rights granted by country. 
IP instrument  Number  Number  Number  Number 
do mes tic  US firms  European  other 
Firms  firms  firms 
Licensing agreement 
Patent assignment 
Technology transfer agreement 
Other, please specify 
17 b) Did your finn acquire biotechnology related intellectual property rights from 
another firm? 
No ...  -+Go to question 18 
Y es ...  -+For each type of  IP instrument listed below, please indicate the number of 
IP rights obtained by country. 202 
IP instrument  Number  Number  Number  Number 
domestic  US firms  European  other 
Firms  firms  firms 
Licensing agreement 
Patent assignment 
Technology transfer agreement 
Other, please specify 
1  Section 6- Firm characteristics and financial profile 
18. Please complete the following table. If information is not available please provide 
a carefully considered estimate in US$. 
2007  2008  2009 forecast 
Total firm revenues 
(  all sources) 
% revenues from 
biotechnology 
Total R&D spending 
% of  R&D spending 
on biotechnology 
Financing activities 
19. a) Did y  our firm attempt to rai se capital for biotechnology related purposes in 
2008? 
No-+Why 
not? ................................................................................................................................. . 
Go to question 19e 
Y  es -+  Why did you attempt to raise capital? (Please check all responses that apply) 
R&D Purposes 
Production 
Commercialize products 
Clinical regulatory expenses 
19 b) Were you successful in raising capital? 
0 No-+ Go to question 19d Y  es-+ How much capital did you raise in 2008? 
19 c) Did you reach your target? 
No-+ Go to question 19 d 
Yes-+ Go to question 19 e 
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19 d) What reasons did the lender/provider give in limiting the funds or refusing your 
request for capital? 
19 e) What sources provided fun ding in the past? 
Source  % 
Domestic venture capital 
US venture capital 
European venture capital 
Venture capital from other countries 
Debt capital (i.e. banks) 
Angel investors/ family 
Govemment 
Private placement 
Initial private offering (IPO) 
Alliances 
Total 
20. Did your finn apply for tax credits for R&D? 
No-+ Why not? 
Y es 
21. Did your firm export biotechnology products in 2008? 
No-+ Go to question 22 
Y  es-+ Please check if exports to 
us 
Europe 
Latin America 
Japan 
China 
Other (please specify) 
22. a) Did your finn import biotechnology products in 2008? No-+ Go to question 23 
Y es-+ Please check if imports from 
us 
Europe 
Latin America 
Japan 
China 
Other (please specify) 
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b) In 2008, what were the main intended end-uses of the bio tech products imported 
by your firm? (Please indicate "yes" or "no") 
End use 
Resale as final product 
Use as intennediary product or raw material in 
Seeding and planting 
Feed/food use 
Veterinary biologies 
Drug/  pharmaceutical 
Other please specify 
1  Section 7:  Strategies used in 2008 
23. Please indicate the significance of each of the following firm's strategies in the 
firm performance in 2008, by "yes" or "no". 
Knowledge development strategies 
Captured and used knowledge obtained from other industry 
sources such as industry associations, competitors, clients 
and suppliers 
Captured and used knowledge obtained from public research 
Institutions including universities and govemment laboratories 
Developed new knowledge through collaborative agreements 
With other firms or organizations 
Used and updated databases of  scientific information 
Developed firm policies and practices for IP protection 
Yes  No 
DO 
DO 
DO 
DO 
DO Developed or encouraged staff education /upgrading 
Conducted an IP audit to ensure protection of  products and processes 
at all stages of development 
Used IP to signal competency 
Business strategies 
Increased firm size through acquisition, merger or joint venture 
Downsized operations of the firm 
Provided products or services to other firms based on interim 
or incrementai R&D discoveries to generate revenue flow 
Entered product trials/adapted products or processes for 
increased market penetration 
Began new research & development project 
Expanded into foreign markets 
Other, please specify  ....... ........................ ...................... ....  . 
24. What are the plans for the company in the next five years? 
Thankyou 
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DO 
DO 
DO 
DO 
DO 
DO 
DO 
DO 
DD ANNEXE 
QUESTIONNAIRE FOR ENTERPRISES AND RESEARCH CENTRES 
(SPANISH) 
UNIVERSITÉ DU QUÉBEC À MONTRÉAL 
DEPARTMENT OF MANAGEMENT AND TECHNOLOGY 
CANADA RESEARCH CHAIR ON MANAGEMENT OF TECHNOLOGY 
RESEARCH TEAM: 
Jorge Niosi, Ph.D. (professor and research director) 
Julieta Flores Amador (Ph.D. student) 
"CUESTIONARIO ACERCA DE LAS ACTIVIDADES Y CARACTERÎSTICAS 
DE LAS EMPRESAS QUE UTILIZAN Y DESARROLLAN BIOTECNOLOGÎAS 
EN MÉXICO" 
Clausula de Confidencialidad 
Todas las  respuestas de este cuestionation setan manejadas de  forma confidencial y 
segura  s6lo  el  quipo  de  investigaci6n  tendra  acceso  a  ellas,  y  se  compromete  a 
respetar esta clausula de confidencialidad. Todos los reportes surgidos de este trabajo 
de  investigaci6n  mostraran  estadisticas  agregadas  y no  haran  referencia a ninguna 
empresa por su nombre, productos o personas. 
Me comprometo a respetar esta clausula de confidencialidad  -----------------
Firma del entrevistador en nombre de toda el equipa de investigaciôn 
He leido la clausula de confidencialidad y estoy de acuerdo con ella ------------
Firma del entrevistado en nombre de su empresa 
Nota. El entrevistador tiene la facultad de firmar cualquier acuerdo de confidencialidad 
que el entrevistado juzgue pertinente, y la jirma del entrevistador compromete a toda el 
equipa de investigaciôn a respetar los términos y condiciones de dicho acuerdo. 207 
Nombre de la persona que completa el cuestionario y su puesto 
Teléfono(s) ____________________  _ 
Correo(s) electr6nico(s  ) ________ _ _______  _ 
Fax  --------------------------------------------------------
Sitio web ------------------------------------------------------
1  Secci6n 1: Biotecnologias en uso (use la siguiente tabla) 
1. Esta secci6n mide el uso de biotecnologias en la empresa 
Usadas 
Si las usa actualmente, éstas son usadas para  Numero 
Biotecnologias 
actualmente  Desarrollo de  Producci6n  Prop6sitos  de afios 
Producto/proceso  ac tuai  ambientales  en uso 
ADN- Codificaci6n  Si .... 
No .... 
Proteinas y  Si .... 
moléculas- Los  No .... 
bloques funcionales 
Cultivo celular 1  Si .... 
Cultivo e ingenieria  No .... 
de tejidos 
Biotecnologias de  Si .. .. 
procesos  No  .... 
Organismos  Si .... 
Sub-celulares  No  .... 
Otros  Si .. .. 
(  ej .bio-informatica)  No  .... 
Nanobiotecnologias  Si .... 
No .... 
Biotecnologia  Si .... 
ambiental  No  .... 
Otro (por favor  Si .. .. 
especifique)  No .... 208 
1  Secci6n 2: Recursos humanos en biotecnologia 
2. Numero de empleados en biotecnologia 
a)  z,Cuantos empleados laboraron en la empresa en el pais en 2008? ......................... . 
b)  l, Cuantos  empleados  tuvieron responsabilidades  relacionadas  con biotecnologîa 
en 2008? ................................. . 
c)  Empleados dedicados  tiempo  completa a responsabilidades en biotecnologia en 
esta planta ..........................  . 
Puesto 
Numero de empleados 
dedicados exclusivamente a 
actividades de biotecnologîa 
Direcci6n cientifica/Investigaci6n 
Técnicos 
Asuntos de regulaci6n/clinicos 
Producci6n 
Finanzas/Mercadotecnia/Desarrollo de negocias 
Gestion Administra  ti va 
Otro, por favor especifique 
Total de empleados dedicados exclusivamente a 
responsabilidades de biotecnologia 
d) Empleados dedicados tiempo parcial a responsabilidades en biotecnologîa 
Para  cada  grupo  enlistado  abajo  indique  z,cuantos  empleados  dedicados  tiempo 
parcial tienen responsabilidades relacionadas con biotecnologia (es decir, menos del 
50% de su  tiempo es  dedicado a actividades relacionadas con biotecnologia)? Si un 
empleado cubre méts de un deber,  reporte su responsabilidad principal.  Cuente cada 
persona solamente una vez. 209 
Numero  de  empleados 
Puesto  dedicados  tiempo  pm·cial  a 
actividades de biotecnologia 
Direccion cientifica/Investigacion 
Técnicos 
Asuntos de regulacionlclinicos 
Produccion 
Finanzas/Mercadotecnia/Desarrollo de negocios 
Gestion Administrativa 
Otro, por favor especifique 
Total  de  empleados  dedicados  parcialmente  a 
responsabilidades en biotecnologia 
e) Numero total de empleados en biotecnologia. 
Total  de  empleados  de  tierp.po  completo  y  tiempo  parcial  con  responsabilidades 
relacionadas con biotecnologia 
3. Reclutamiento y prâcticas de seleccion 
a) z,La empresa tiene vacante alglin puesto relacionado con biotecnologia? 
No .... -+Pase a la pregunta 3b) 
Si ...... -+  En  la  siguiente tabla indique el  numero de puestos  libres de acuerdo a su 
categoria: 
Puesto  Numero de puestos vacantes 
Direccion cientifica/Investigacion 
Técnicos 
Asuntos de regulacionlclinicos 
Produccion 
Finanzas/Mercadotecnia/Desarrollo de negocios 
Gestion Administrativa 
Otro, por favor especifique 
Total de puestos vacantes 
b) z,La empresa tiene un programa formai para capacitar y desarrollar al persona! para 
promociones intemas hacia altos puestos (senior)? 
No .. . 
Si ...  . c)  . 
No 
0Su empresa intenté reclutar algun empledo en biotecnologfa en 2008? 
.  .  . -+ Pase a la pregunta 4a) 
Si .. ... -+  ~Tuvo  éxito?  No  ... -+ Pase a la pregunta  3d) 
Si ..... -+ ~Cuantas personas 
contrat6? ......................... . 
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d)  .  0Intent6 contratar personal de biotecnologia residiendo fuera de este pais en 2008? 
No 
Si .. ...  -+  En la  tabla  siguiente  indique  el  numero  de  empleados  en  biotecnologfa 
ntratados por cada region  co 
Region 
Est  ados Unidos 
nada  Ca 
Repatriaci6n 
Contrataci6n 
internacional 
Total 
----------------------~----------~-----------1------~ 
Eu ropa ______________________  ~----------~-----------1------~ 
Ch ma 
Ind la 
As·  ta (otro ademas de China o India) 
ro (por favor especifique)  Ot 
To  tal de empleados contratados del 
en  or  ext 
----------------------~----------~----------~------~ 
4. a)  ~Alguien de su personal  de biotccnologia dej6 la empresa en 2008? 
... -+ Pase a la pregunta 5  No 
Si .. ...  -+ ~  Cuantos? ......................... .. . 
b)  ~Qué porcentaje de  aquellos  que se  fueron  en  2008  se debi6 a  la  decision de  la 
em presa? ............  . 
1  Secci6n 3 - Historia de la empresa 
S.a)  ~En  qué aiio fue establecida la compaiiia? ............................. . 
b)  ~Cu  ales  fueron  los  mo ti vos  para  establecerse  en  esta 
localidad? ...................................... ................ .. ............ .....................  . 
c)  ~Cu  ales  son  las  venta  jas  especfficas  que  tiene  la  empresa  al  ubicarse  en  esta 
localidad? 211 
Ventajas  SI  NO 
Universidad/centros de investigaci6n 
Cercania con 
Hospitales 
Importantes proveedores 
Importantes clientes 
Acceso a persona! especilizado/calificado 
Infraestructura fisica (transporte, comunicaciones) 
V entaj as financieras 
Incentivos gubernamentales  Politicas 
Fondos 
Otros (por fa v or especifigue) 
6. (,La empresa es una empresa publica? 
No  ... -+  Pase a la pregunta 8a) 
Si ...... -+ (,En gué afio fue la Oferta Pub  li  ca de Venta (OPV)?  ....................... . 
7. a) (,SU empresa se ha fusionado con alguna otra empresa? 
No  ...  -+Pase a la pregunta 8a) 
Si  ..... -+  (,En gué afio tom6 lugar la fusion? .................. . 
b) L, Cu  ales fueron las razones de la fusion? ............................................................ . 
8. a) (,Es la empresa una compafiia de capital nacional? 
No  ... -+Pase a la pregunta lûa) 
Si ..... -+ 
b) (,La empresa tiene sucursales fuera del pais? 
No  .. . 
Si  .... -+  (,La empresa realiza actividades de I+D fuera del pais? 
No  ... Si ... 
9.  L,La  empresa es un spin-off (desprendimiento)? (Un spin-off  es definido como una 
nueva empresa creada para comercializar tecnologia desarrollada en universidades, 
laboratorios publicos u otras empresas) 
No  ... -+Pase a la pregunta lûa) 
Si ..... -+  La empresa fue un spin-off de: 
•  Universidad/Hospital 
•  Otra compafiia de biotecnologia 
•  Empresa no biotecnol6gica 
•  Agencia o Laboratorio gubernamental ~------ ----- ------
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•  Otro, por favor especifique 
1 Seccion 4: Productos biotecnologicos innovadores 
Esta secci6n mide el desarrollo de nuevos productos y procesos biotecnol6gicos de la 
empresa. 
10. a) L,La empresa tiene productos/procesos en el mercado que requieren el uso de 
biotecnologias? 
Si.....  No  ... 
b) (,Actualmente la empresa esta desanollando productos que requieren el uso de 
biotecnologias? 
Si... ..  No ... 
c) L,Actualmente la empresa esta desarrollando procesos que requieren el uso de 
biotecnologias? 
Si. .....  No  ... 
d) (,Considera usted que la biotecnologia es central para las actividades y estrategias 
de la empresa? 
Si.....  No  ... 
11. a) En la tabla siguiente, por favor indique el numero de productos o procesos que 
la empresa actualmente tiene para cada etapa de desarrollo en el sector de Salud 
Humana. Si éste es "0" (  cero) por favor indique "0". 
Numero de productos/procesos biotecnol6gicos por etapa de 
desarrollo 
Sector de  Aprobado/ 
Biotecnologia  Ensayos  Fase  Fa se  Fase  En 
I+D  Pre- clinica 1  clinica 2  clinica 3  mercado/  clinicos  Producci6n 
Ill 
Diagn6sticos 
Terapéuticos 
Administraci6n de 
fam1acos 
b) En la tabla siguiente, para cada sec  tor enlistado, por favor indique el numero de 
productos o procesos que la empresa actualmente tiene para cada etapa de desanollo. 213 
Si éste es "0" (  cero) por favor indique "0". 
Numero de productos/procesos biotecnol6gicos por etapa 
de desarrollo 
Ensayos Pre- Fase reguladora/  Aprobado/ 
Sector de Biotecnologia  clinicos/  Evaluaci6n de  En 
I+D  Ensayos de  lanzamiento/  mercado/ 
campo/  Evaluaci6n final  Producci6n 
Pre-mercado  de pre-mercado 
~~i9t"'"'1olo'fHa  A\grtèol~ 
Biotecnologia de plantas 
Biotecnologia animal 
Agricultura para uso 
industrial, no para 
alimento 
Agricultura para usos 
médicos, no para 
alimento 
~ 
Minerfa 
Productos forestales 
~ 
A  gua 
1 miêrmmnl 
Salud de peces, genética 
iR l•  .  ,; ~:; l mati  c~ 
Gen6mica y 
modelizaci6n molecular 
Terap1a génica 
Procesamiento de ::~1 mlfmto ~ 
Bwprocesos 
Alimentos funcionales/ 
nutracéuticos 
Otro (  c:s11c:cifique) 
1  Secci6n 5: Regulaciones de productos biotecnol6gicos 214 
12. a) En 2008, (,la empresa tuvo productos/procesos biotecnol6gicos en alguna etapa 
de I+D, pero no aun en el mercado? 
No .... -+  Pase a la pregunta 13 
Si ...... -+Pase a la pregunta 12b) 
b) De los productos o procesos  de biotecnologia que la empresa tuvo en la etapa de 
I+D (no alin en el mercado) en 2008, (,CUântos requerian la evaluaci6n y/o la 
aprobaci6n formai de autoridades reguladoras nacionales? Nùmero ....... .. . 
c) En 2005, para su principal producto biotecnol6gico, (,Cual es la duraci6n total de su 
proceso regulador hasta la fecha (en meses)? 
d) (,Cual fue el gasto de I+D en el afio pasado? 
e) (,Cuâl fue el gasto en regulaciones del afio pasado? 
13. La empresa ha experimentado alglin problema en el proceso de regulaci6n, tal 
co  mo 
Costo 
Tiempo 
Normas 
Otro 
Si ..... No .... . 
Si ..... No ....  . 
Si ..... No .. .. . 
Si ..... No ....  . 
14. a) (,La empresa contrat6 actividades relacionadas con biotecnologia en 2008? 
No ....  -+Pase a la pregunta 14b) 
Si ..... . 
Organizaci6n  Numero de contratos 
Universidad/Hospital 
Laboratorio gubemamental 
Otra empresa de biotecnologia 
Otro, por favor especifique 
Total 
b) (,La empresa fue contratada por otras empresas u organizaciones para proveer 
algùn sevicio biotecnol6gico en 2008? 
No ... -+Pasealapregunta 15a) 
Si .... -+  Para cada ti po de contrato, por favor mencione el numero e ingresos --- --~----------------------------------
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Organizaci6n  Numero de contratos  Ingresos 
Otra empresa biotecnol6gica 
Empresa farmacéutica 
Otra empresa, no biotecnol6gica o farmacéutica 
Laboratorio gubernamental 
U  niversidad/hospital 
Otro, por favor especifique 
Total 
Acuerdos de colaboraci6n 
Acuerdos  de  Cooperaci6n  y  Colaboraci6n  incluyen  la  participaci6n  activa  en 
proyectos entre esta empresa y  otras empresas u organzaciones para  desarrollar 
y/o  continuar  trabajando  sobre  nuevos,  o  significativas  mejoras  a,  procesos, 
productos  o  servicios  biotecnol6gicos.  Contratos  que  no  incluyen  el  trabajo 
conjunto no son vistos como colaboraci6n. 
15.  a)  L,La  empresa  tuvo  acuerdos  de  cooperaci6n/colaboraci6n  relacionados  con 
biotecnologia  con otras compafiias u organizaciones en 2005? (Por favor mencione 
am bos,  dentro y fuera del pais) 
No ...  -+Pase a la pregunta 16a) 
Si ..... -+  Mencione el numero de acuerdos por prop6sito y ti po de socio 216 
Numero de acuerdos por tipo de socio 
Prop6sito del  Empresa 
Otra empresa, 
Instituci6n 
Laboratorio 
acuerdo  biotecno-
Empresa  no 
académica/ 
o agencJa 
16gica 
farmacéutica  biotecnol6gica 
hospital 
gu berna-
o farmacéutica  mental 
Para realizar 
I+D 
Asuntos 
regulatorios 
Acceso a las 
patentes de 
otros 
Producci6n/ 
Manufactura 
Acceso a 
mercados 
Acceso a 
capital 
Acceso a 
propiedad 
intelectual 
Acceso a 
conocimiento/ 
habilidades de 
otros 
Disminuir 
costos 
Otro, por 
fa v  or 
especifique 217 
b) En 2005, la empresa tuvo acuerdos de cooperaci6n/colaboracci6n relacionados con 
biotecnologia con otras compafiias u organizaciones extranjeras (Localizadas fuera 
del pais)? 
No ... -+  Pase a la pregunta  16a) 
Y es ... -+  En la tabla siguiente, marque los acuerdos de cooperaci6n/colaboraci6n por 
cada ti po y su localizaci6n geografica: 
Tipo de socio  E.U.  Euro  pa  Canada  China  In  dia  Otro 
Empresa de Biotecnologia 
Empresa Fmmacéutica 
Otra Empresa, no biotecnol6gica 
o farmacéutica 
Laboratorio gubemamental 
Universidadlhospital 
Otro, por favor especifique 
d)  Ordene los siguientes prop6sitos que influyeron su decision para establecer 
acuerdos de cooperaci6n/colaboraci6n con socios extranjeros (localizados en el 
extranjero). Ordene los tres mas importantes 
Prop6sitos del acuerdo  Orden 
Para realizar l+D 
Asuntos regulatorios 
Acceso a patentes de otros 
Producci6n/ Manufactura 
Acceso a mercados 
Acceso a capital 
Acceso a propiedad intelectual 
Acceso al conocimiento/habilidades de otros 
Propiedad Intelectual 
16. a) Su empresa tiene patentes o patentes pendientes relacionadas con 
biotecnologia? 
No  ... -+Pase a la pregunta 16b) 
Si ..... -+  ~Cuantas? ............... . 
Indique la distribuci6n de patentes o patentes pendientes relacionadas con 
biotecnologia que su empresa tiene por Oficina de Patentes Nacional  USPTO  Europa  Otra 
(IMPI) 
Patentes 
existentes 
Patentes 
pendientes 
Patentes 
expiradas 
16. b) La empresa tiene marcas registradas relacionadas con biotecnologia? 
No...  -+  Pase a la pregunta 17a) 
Si ...... -+  ~Cua.ntas?  ..................... . 
17. a) La empresa asign6 o licenci6 derechos de propiedad intellectual (PI) a otra 
empresa? 
No...  -+  Pase a la pregunta 17b) 
Si ...... -+Para cada ti  po de instrumenta de PI listado abajo, por fa v  or indique el 
numero de derechos de PI otorgados/asigandos por pais. 
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Numero de  Numero de  Numero de  Numero 
Instrumenta de PI  empresas  empresas en  empresas en  de otras 
nacionales  E.U.  Euro  pa  empresas 
Acuerdo de licenciamiento 
Cesi6n de patente 
Acuerdo de transferencia de 
tecnologia 
Otro, por favor especifique 
17 b) La empresa adquiri6 derechos de PI de biotecnolgia de otra empresa? 
No ...  -+Pase a la pregunta 18 
Si ...... -+Para cada ti po de instrumenta de PI listado abajo, por fa v  or indique el 
numero de derechos de PI obtenidos por pais. 
Numero de  Numero  Numero  Nùmero 
Instrumenta de IP 
empresas  de  de  de otras 
nacionales  empresas  empresas  empresas 
en E.U.  en Europa 
Acuerdo de licenciamiento 
Cesi6n de patente 
Acuerdo de transferencia de 
tecnologia 
Otro, por favor especifique 219 
1  Secci6n 6 - Caracteristicas de la empresa y perfil de financiamiento 
18. Por favor complete la siguiente tabla. Si la informaci6n no esta disponible 
mencione un estimado considerado cuidadosamerite en d6lares americanos (USD). 
2007  2008  2009 pron6stico 
Ingresos totales de la 
empresa (todas las 
fuentes) 
% de ingresos de 
biotecnologia 
Gasto total en I+D 
% de gasto de I+D en 
biotecnologia 
Actividades financieras 
19. a)  ~La  empresa intent6 obtener capital para prop6sitos relacionados con 
biotecnologia en 2008? 
No-+  ~Por qué 
no? ........................................................................................................................ . 
Pase a la pregunta 19e) 
Si -+  ~Por qué intent6 obtener el capital? (Por favor marque todas las opciones que 
apliquen) 
•  Prop6sitos de I+D 
•  Producci6n 
•  Comercializaci6n de productos 
•  Gastos en regulaciones clinicas 
•  Otro 
19 b)  ~Logr6 obtener el capital? 
No .. -+ Pase a la pregunta 19d) 
Si ...  -+ ~Cuanto capital obtuvo en 2008? ..................................... . 
19 c)  ~Se alcanz6 el objetivo? 
No  .. -+ Pasealapregunta  19d) 
Si ...  -+ Pase a la pregunta  19 e) 
19 d)  ~Qué  razones tuvo el prestamista/proveedor para limitar los fondos o rechazar 
la solicitud de capital? -----------
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19 e) (,Cmiles fueron sus fuentes de financiamiento en el pasado? 
Fu  ente  % 
Capital de riesgo nacional 
Capital de riesgo de E.U. 
Capital de riesgo de Europa 
Capital de riesgo de otros paises 
Capital de deuda (i.e. bancos) 
Inversionistas Angel/Familial  Amigos 
Gobiemo 
Colocacion privada 
Oferta Publica de Venta (OPV) 
Alianzas 
Total 
20. (,La empresa postulo para la obtencion de créditos fiscales para I+D? 
No  ... ~  Porqué 
no? ...........................................................................................................................  . 
Si .. . 
21. (,La empresa exporto productos biotecnologicos en 2008? 
No  ... ~  Pase a la pregunta  22a) 
Si .... ~  Por fa v  or marque si las exportaciones son dirigidas a 
•  E.U. 
•  Euro  pa 
•  América Latina 
•  Japon 
•  China 
•  Otro (por fa v  or especifique) 
22. a) La empresa importo productos biotecnologicos en 2008? 
No  ...  ~  Pase a la pregunta 23 
Si .... -+ Por fa v  or marque si las importaciones provienen de 
•  E.U. 
•  Europa 
•  América Latina 
•  Japon 
•  China 
•  Otro (por fa v  or especifique) 
b) En 2008, (,CUâles fueron los principales usos finales de los productos 221 
biotecnol6gicos que importé la empresa? (Por favor indique "si" o "no") 
Uso Final  SI  NO 
Reventa como producto final 
Uso como producto intermediario o material prima en 
Semillas y plantas 
Uso en alimentos/comida 
Veterinarios biol6gicos 
Medicinas/farmacéutica 
Otro, por favor especifique 
1  Secci6n 7: Estrategias usadas en 2008 
23. Por favor indique la importancia de cada una de las siguientes estrategias en el 
desempefio de la empresa en 2008, diga "si" o "no". 
Estrategias de desan-ollo de conocimiento 
Utiliz6 conocimiento obtenido de otras fuentes industriales tales 
como asociaciones industriales, competidores, clientes y proveedores. 
Utiliz6 conocimiento obtenido de  instituciones publicas de 
investigaci6n incluyendo universidades y laboratorios gubernamentales. 
Desarro116 nuevo conocimiento a través de acuerdos de colaboraci6n 
con otras empresas u organizaciones. 
Us6 y actualiz6 bases de datos de informaci6n cientifica. 
Desarro116 politicas y practicas para la protecci6n de la PI. 
Desarro116 o incentiv6 la educaci6n/actualizaci6n de los empleados. 
Condujo una auditoria de PI para asegurar la protecci6n de productos y 
procesos en todas las etapas de desarrollo. 
Us6 PI para mostrarse competente/crear una imagen competitiva 
Si  No 
DO 
DO 
DO 
DO 
DO 
DO 
DO 
DO --- - ---·---- --
222 
Estrategias de negocio 
Incrementa el tamafio de la empresa a través de adquisiciones, fusiones,  D  D 
o joint ventures (alianza) 
Contrajo operaciones de la empresa  0  D 
Provey6 productos o servicios a otras empresas, los cuales estaban  D  D 
basados en descubrimientos incrementales de I+D, para generar 
flujo de ingresos 
Introdujo ensayos de productos/ Adapt6 productos o procesos  D  D 
para incrementar la penetraci6n del mercado 
Comenz6 nuevos proyectos de I+D  D  D 
Expansion hacia mercados extranjeros  D  D 
Otro, por fa v  or especifique ......... ... .................. ................ ..... ......  . 
24. i,Cuales son los planes de la compafifa para los pr6ximos cinco afios? ANNEXF 
QUESTIONNAIRE FOR TECHNOLOGY TRANSFER AND LIAISON 
OFFICES (ENGLISH) 
UNIVERSITÉ DU QUÉBEC À MONTRÉAL 
DEPARTMENT OF MANAGEMENT AND TECHNOLOGY 
CANADA RESEARCH CHAIR ON THE MANAGEMENT OF TECHNOLOGY 
RESEARCH TEAM: 
Jorge Niosi, Ph.D. (professor and research director) 
Julieta Flores Amador (Ph.D. student) 
"QUESTIONNAIRE ABOUT TECHNOLOGY TRANSFER AND LIAISON 
OFFICES RELATED TO BIOTECHNOLOGY PRODUCTS AND PROCESSES" 
Statement of confidentiality 
All responses to this questionnaire will be kept confidential and secure. They will be 
made available only to the research team, al of who will be bound by this statement of 
confidentiality. All reports arising from this research will refer to  aggregate statistics 
and will not refer to any company by name, product or people. 
I agree to abide by the above Statement of confidentiality ________  _ 
Interviewer signature on behalf  of  the entire research team 
I have read and agree with the above Statement of confidentiality ______  _ 
Respondent signature on behalf  of the company 
Note. The interviewer isfree to sign any non-disclosure agreement the respondentfinds 
appropria  te,  and the signature of  the interviewer on such as agreement will bind the entire 
research team to its terms and conditions. 224 
Name of the person completing the questionnaire and title 
Phone (s) _____________________  _ 
E-mail (s) ____________________  _ 
Fax(s) ________________ _____  ___ 
Web address -------------------------------------------
1  Section 1: His tory of the centre and hu man resources 
1. What year was this centre established?  ................... . 
2.  What were the motives to establish this centre? 
3. What were the reas  ons to establish the centre in this location? ........................... . 
4. Is this centre public or private? 
•  Private 
•  Public 
Depending on: 
•  University 
•  Hospital 
•  Other organization (please specify) 
5. In general, does the centre have agreements with other national and/or intemational 
centres of linkage or technology transfer? 
No  .. . 
Yes ... . 
In the case ofbiotechnologies, are there agreements with other centres? Types? 
Where? 
National  North  Centre  South 
Academy 
Technology 
trans  fer 225 
1 Incubation 
International  U.S.A  Canada  Europe  China  In dia  Other 
Academy 
Technology 
trans fer 
Incubation 
6.  Is this centre collaborating with the following institutions? What is the impact of 
these collaborations in the performance of the centre? 
•  Mexican institute for the industrial property 
•  National council for science and technology (CONACYT in Spanish) 
•  Ministry of Economy 
•  Industrial associations 
•  Other (please specify) 
Human resources 
7. How many employees did the centre employ in 2008? .................  . 
8. How many employees were dedicated full time to support services related to 
biotechnology?  ..........  . 
9. How many employees were dedicated partial time to support services related to 
biotechnology? ............ . 
1  Section 2: Support and services 
1  O.  Types of services that support enterprises using biotechnologies 
SERVICES  YES  NO 
Academy linkages (for basic research) 
Human resources formation (  continuing education) 
Use of  specialized equipment (for trials) 
Up-grading 
Incubation of  enterprises 
Advice for launching new products 
Advice for regulatory/clinic affaires 
Advice for intellectual property 
Advice forget funding (public and private) 
Advice for the management of collaborations (e.g. alliances) 
with other enterprises or institutions 
Other (please specify) 226 
11. Please complete the following table. Mention the type and number of enterprises 
sectors that have been  this c  and the  !location. 
Biotechnology sectors 
Plant biotechnology  Y es ...  No  ... 
Animal biotechnology  Yes ...  No ... 
Non food agriculture for industrial  Yes .. .  No .. . 
uses 
Non food agriculture for medical  Yes ...  No ... 
uses 
Energy  Yes ...  No  ... 
Yes ...  No  ... 
Functional 
Others (please specify)  Yes ...  No ... 
12. Which means use this centre to make public its services (university-industry 
linkages or technology transfer)? How many times a year? 
•  None 227 
•  Information sessions 
•  Linkages congresses 
•  Persona! invitation to potential enterprises 
•  Other (please specify) 
13. Does the centre have a formai program to follow up the links that the centre has 
helped to make or companies that have been incubated? 
No  .. . 
Y es .. . 
How it works? 
1  Section 3: Results 
14. Results related to biotechnology in 2008 
a) Number of publications (peer-review) ........ ........  . 
%publications ofbiotechnology in peer-review journals  ................ . 
b) Number of patents (or other intellectual property) given or filed ........... . 
Number of  patents registered by this centre and th en licensed, in what 
biotechnology sector? .............. . 
How many patents are in the process to be licensed? in what biotechnology sector? 
c) Number of  demands solved by this centre. 
Type of  demand  Demands  Solved  Sec  tor 
To evaluate products 
To improve processes 
Other (please specify) 
d) Incubation of enterprises 228 
How many enterprises were in incubation and in what biotechnology sector? 
How many enterprises are in process of  incubation and in wh at biotechnology sec tor? 
e) Spin-off 
Have this centre helped to the process of spin-offs? 
No .. . 
Y es .. . 
What biotechnology sector? 
f) Economie results 
Please complete the following table. If  information is not available please provide a 
carefully considered estimate in USD. 
2007  2008  2009forecast 
Licensing patents 
Assignment of 
patents 
Technology 
trans fer 
Contracts 
Other  (please 
specify) 
Total 
15. What are the plans for the centre in the next five years? ............................. . ANNEXG 
QUESTIONNAIRE FOR TECHNOLOGY TRANSFER AND LIAISON 
OFFICES (SPANISH) 
UNIVERSITÉ DU QUÉBEC À MONTRÉAL 
DEPARTMENT OF MANAGEMENT AND TECHNOLOGY 
CANADA RESEARCH CHAIR ON MANAGEMENT OF TECHNOLOGY 
RESEARCH TEAM: 
Jorge Niosi, Ph.D. (professor and research director) 
Julieta Flores Amador (Ph.D. student) 
"CUESTIONARIO ACERCA DE LOS VÎNCULOS UNIVERSIDAD-EMPRESA Y 
OFICINAS DE TRANSFERENCIA TECNOLÔGICA RELACIONADOS CON 
PRODUCTOS Y PROCESOS BIOTECNOLÔGICOS" 
Clausula de Confidencialidad 
Todas  las  respuestas de este cuestionation setan manejadas de  forma confidencial y 
segura  solo  el  quipo  de  investigaci6n  tendra  acceso  a  elias,  y  se  compromete  a 
respetar esta clausula de confidencialidad. Todos los reportes surgidos de este trabajo 
de  investigaci6n  mostraran estadisticas  agregadas  y  no  haran  referencia a ninguna 
empresa por su nombre, productos o personas. 
Me comprometo a respetar esta clâusula de confidencialidad. ________  _ 
Firma del entrevistador en nombre de toda el equipa de investigaci6n 
He leido la clausula de confidencialidad y estoy de acuerdo con ella. _____  _ 
Firma del entrevistado en nombre de su empresa 
Nota. El entrevistador tiene lafacultad defirmar cualquier acuerdo de conjidencialidad 
que el entrevistado juzgue pertinente, y la firma del entrevistador compromete a toda el 
equipa de investigaci6n a respetar los términos y condiciones de dicho acuerdo. 230 
Nombre de la persona que completa el cuestionario y su puesto 
Teléfono(s)  _ _______ _______________  _ 
Coneo(s) electr6nico(s  ) _____________________  _ 
Fax (s) _______________________ _  _ 
Sitio web ------ - -----------------------
1  Secci6n 1: Historia del centro y recursos humanos 
1. (,En qué afio fue establecido este centro de vinculaci6n?  ...................  . 
2. (,Cuales fueron los motivos para la :fundaci6n del centro? 
3. (,Cuales fueron las razones para el establecimiento del centro en esta localidad?  .. 
4.  (,Este centro es publico o privado? 
•  Privado 
•  Publico 
Depende de: 
•  Universidad 
•  Hospital 
•  Otra instituci6n (por favor especifique) 
5. En general, (,el centro tiene acuerdos con otros centros de vinculaci6n/transferencia 
tecnol6gica nacionales y/o extranjeros? 
No  .. . 
Si ... . 
· En el caso de biotecnologias, z,existen acuerdos de vinculaci6n con otros centros? z,de 
1  'fi  ?  que tl  po y  ugar geogra tco. 
Nacionales  Norte  Centro  Sur 
Académico 
Transferencia 
tecnol6gica 
Incubaci6n 231 
Extranjeros  E.U.  Canada  Europa  China  ln  dia  Otro 
Académico 
Transferencia 
tecnol6gica 
Incubaci6n 
6. z,Este centro mantiene cercanas relaciones con las siguientes instituciones? z,Cual 
es el impacto de esta cercania en el desempefio del centro? 
•  Instituto Mexicano de Propiedad Industrial (IMPI) 
•  Consejo Nacional de Ciencia y Tecnologia (CONACYT) 
•  Secretaria de Economia (SE) 
•  Camaras industriales/empresas lideres 
•  Otras (por fa v  or especifique) 
Recursos Humanos 
7. z,Cuantas personas laboraron en el centro en 2008? ................. . 
8. z,Cuantas personas estuvieron dedicadas tiempo completo a labores de servicios y 
apoyos relacionados con biotecnologias? ............ . 
9. z,Cuantas personas estuvieron dedicadas tiempo parcial a labores de servicios y 
apoyos relacionados con biotecnologias?  ............ . 
1  Secci6n 2: Tipos de apoyos o servicios 
10. z,Cuciles son los servicios con loque cuenta este centro y que estan relacionados 
1  b" t  1  '  ?  con e  apoyo a empresas que usan  10 ecno ogras. 
SERVI  CI  OS  SI  NO 
Vinculaci6n académica (para investigaci6n basica) 
Formaci6n de recursos humanos (actualizaci6n de personal) 
Uso de equipo especializado (pruebas o ensayos) 
Escalamiento 
Incubadora 
Asesoria para introducir productos en el mercado 
Asesoria en asuntos de regulaci6n/clinicos 
Asesoria en el manejo de propiedad intelectual 
Asesoria para conseguir fondos publicos o privados 
Asesoria para gestion de colaboraci6n (alianzas) con otras 
empresas o instituciones 1 
1 
1 
232 
1 Otro (por favor especifique) 
11. En la tabla siguiente mencione el tipo y numero de empresas por sector 
biotecnol6gico que son apoyadas por este centro, y estado en el que estan establecidas 
Sector de Biotecnologia 
Biotecnologia animal 
Agricultura para uso industrial, no 
alimento 
Agricultura para usos médicos, no 
alimento 
Alimentos funcionales/ 
nutracéuticos 
Otro (por favor especifique) 
Localidad 
Si ...  No ... 
Si ...  No ... 
Si ...  No ... 
Si ...  No ... 
Si ...  No ... 
No ... 
Si .. .  No ... 
Si .. .  No .. . 12.  (, Qué medios utiliza este centro para promover sus servicios (de vinculaci6n 
universidad-empresa o transferencia tecnol6gica)? (,Cuantas veces al afio? 
•  Ninguna 
•  Sesiones informativas 
•  Congresos de vinculaci6n 
•  Invitaci6n personalizada a potenciales empresas 
•  Otra (por fa  v or especifique) 
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13. (,El centro tiene un programa formai de seguimiento a los vinculos que el centro 
ha ayudado a realizar o de las empresas que han sido incubadas? 
No  .. . 
Si .. . 
(,C6mo funciona? 
1  Secci6n 3: Resultados del centro 
14. (,Cuales  fueron los resultados obtenidos en el2008 relacionado con 
biotecnologia? 
a) Numero de  publicaciones con arbitraje (peer-review) ..... ........... . 
(,Qué porcentaje representan las publicaciones del area de biotecnologia en revistas 
arbitradas? ................. . 
b) Numero de patentes (u otra propiedad intelectual) otorgadas o en 
espera ........... . 
(,Cuantas patentes registra el instituto/universidad/centro de investigaci6n y fueron 
licenciadas por este centro y en qué sec  tor de biotecnologia?  ..............  . 
(,Cuantas patentes estan en tramite de ser licenciadas y en qué sector de 
biotecnologia? ..... 
c) Numero de solicitudes recibidas por empresas y resueltas por este centro. (,En qué 
sector de biotecnologia? 
Tipo de solicitud  Recibidas  Resueltas  Sec  tor 234 
Para evaluar productos 
Para mejorar procesos 
Otro (por fa  v or especifique) 
d) Empresas en incubaci6n 
~Cuantas empresas estuvieron en incubaci6n y en qué sector de biotecnologia? 
~Cuantas empresas siguen en proceso de incubaci6n y en qué sector de 
biotecnologia? ............................ ....................................................... . 
e) Spin-off 
~Se  ha establecido alguna empresa (spin-off) basada en el conocimiento generado por 
la universidad/centro de investigaci6n relacionado con este centro? 
No  .. . 
Si .. . 
~En  qué sector de biotecnologia? 
f) Resultados econ6micos 
Por favor llene la siguiente tabla. En caso de no terrer el dato exacto por favor 
considere un estimado en d6lares americanos (USD). 
Fuente de ingresos  2007  2008  2009pron6stico 
Licencia de 
patentes 
Cesi6n de patente 
Transferencia de 
tecnologia 
Contratos 
Otro (por favor 
especifique) 
Total 
15.  ~Cuales son los planes para los pr6ximos cinco anos de este centro? ............ . ANNEXH 
STATISTICAL TESTS 
In order to test the correlations between different variables I used two nonparametric 
tests:  Spearman  correlation  coefficient  and  biserial  correlation  coefficient.  The 
Spearman correlation coefficient is  a procedure to  measure the relationship between 
two rank-order variables, while  "the biserial correlation is a procedure to measure the 
relationship  between  a  continuous  dichotomous  variable  and  an  interval  scale 
variable",  both procedures  can be applied  to  small  samples  (Corder  and  Foremar, 
2009: 134).
47 
The formula to calculate the Spearman rank-order correlation coefficient with ties is: 
r  ==  . (n
3 
~n)-? .~Dt .-C!·:+"~, ~~  .. ~  ....... . 
s  ~(n
3 -n)
2
- (T, + TY )(n
3
- n)+  T,TY 
where n is the number of  rank pairs and Di is the difference between a ranked pair. 
Also, 
T,  = !  (tf' - t;) 
i• l 
TY = !(t(  ~ t; ) 
i=l 
where gis the number of ties groups in that variable and ti is the number of ties values 
in a tie group. 
Corner and Foreman (2009) suggest to calculate the biserial correlation coefficient to 
47 These procedmes are explained in detail in Corner and F01·eman (2009) Chapter 7. ----------- - - -----------
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measure the relationship between a dichotomous continue variable and a rank order 
variable. The formula to calculate the biserial correlation coefficients is: 
where 
rpb is the Spearman correlation coefficient with ties, and 
where e is the naturallog base and z is  the z-score at the point dividing the proportion 
of the  interval  variable  values  associated  with  the  dichotomous  variable's  first 
category  (Pp)  and  the  interval  variable  values  associated  with  the  dichotomous 
variable's second category (Pq). 
In order to  analyze the relationships between different variables, I ranked the values 
of the ordinal variables and dichotomous variables (see Table H.l) and calculated the 
coefficients (see Table H.2). T
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